TYROSINE PHOSPHATASE PROTEIN INHIBITORS AND THEIR METHODS OF USE

Abstract

This document provides useful compounds, compositions, and methods for inhibiting protein tyrosine phosphatase, for example, non-receptor protein tyrosine phosphatase type 2 (PTPN2) and / or non-receptor protein tyrosine phosphatase type 1 (PTPN1), and for treating diseases, disorders, and related conditions that respond favorably to treatment with PTPN1 or PTPN2 inhibitors, for example, cancer or metabolic disease.

Description

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND THEIR METHODS OF USE n i cnon / zznz / q / υιλι BACKGROUND OF THE INVENTION Cancer immunotherapy regimens targeting immune evasion mechanisms that include checkpoint blockade (e.g., PD-1 / PD-L1 and CTLA-4 blocking antibodies) have been shown to be effective in treatment of a variety of cancers, dramatically improving outcomes in some populations refractory to conventional therapies. However, incomplete clinical responses and the development of intrinsic or acquired resistance will continue to limit patient populations that could benefit from checkpoint blockade. Nonreceptor protein tyrosine phosphatase type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is an intracellular member of the class 1 subfamily of phosphotyrosine-specific phosphatases that control multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates. PTPN2 is ubiquitously expressed, but expression is highest in hematopoietic and placental cells (Mosinger, B. Jr. et al., Proc Nati Acad Sel usa 89:499-503; 1992). In humans, the expression Ref. 335081 of PTPN2 is controlled post-translationally by the existence of two splice variants: a 45 kDa form containing a nuclear localization signal at the C-terminus upstream of the splice junction, and a 48 kDa canonical form which has an ER retention motif at the C-terminus (Tillmann U. et al., Mol Cell Biol 14:3030-3 04 0; 1994). The 45 kDa isoform can be passively transfused into the cytosol under certain cellular stress conditions. Both isoforms share an N-terminal phospho-tyrosine phosphatase catalytic domain. PTPN2 negatively regulates signaling by non-receptor tyrosine kinases (e.g., JAK1, JAK3), receptor tyrosine kinases (e.g., INSR, EGFR, CSF1R, PDGFR), transcription factors (e.g., STAT1, STAT3, STAT5a / b) and Src family kinases (e.g. Fyn, Lck). As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. The catalytic domain of PTPN2 shares 74% sequence homology with PTPN1 (also called PTP1B), and shares similar enzyme kinetics (Romsicki Y. et al., Arch Biochem Biophys 414:40-50; 2003). Data from loss-of-function in vivo genetic screening using CRISPR / Cas9 genome editing in a B16F10 mouse transplant tumor model show that deletion of the Ptpn2 gene in tumor cells improved the response to the immunotherapy regimen of a GM-CSF-secreting vaccine (GVAX) plus DP-1 checkpoint blockade (Manguso RT et al., Nature 547: 413-418; 2017). Loss of Ptpn2-sensitized tumors to immunotherapy by increasing IFNy-mediated effects on antigen presentation and growth suppression. The same screening also revealed that genes known to be involved in immune evasion, including PD-L1 and CD47, were also depleted under the pressure of selective immunotherapy, while genes involved in the IFNy signaling pathway, including IFNGR , JAK1 and STAT1, were enriched. These observations point to a putative role for therapeutic strategies that enhance IFNγ sensing and signaling to improve the efficacy of cancer immunotherapy regimens. Nonreceptor protein tyrosine phosphatase type 1 (PTPN1), also known as protein tyrosine phosphatase-IB (PTP1B), has been shown to play a key role in insulin and leptin and is a primary mechanism for downregulating both leptin and insulin receptor signaling pathways (Kenner KA et al., J Biol Chem 271: 19810-19816, 1996). PTP1B-deficient animals have better regulation of glucose and lipid profiles and are resistant to weight gain when treated with a high-fat diet (Elchebly M. et al., Science 283: 15441548, 1999). Therefore, PTP1B inhibitors are expected to be useful for the treatment of type 2 diabetes, obesity, and metabolic syndrome. SUMMARY OF THE INVENTION The present description relates, at least in part, to compounds, compositions and methods for the inhibition of protein tyrosine phosphatase, for example, non-receptor protein tyrosine phosphatase type 2 (PTPN2) and / or non-receptor protein tyrosine phosphatase type 1 ((PTPN1), also known as protein tyrosine phosphatase-ΙΒ (PTP1B)). In some embodiments, an inhibitor of protein tyrosine phosphatase, ex vivo, PTPN2 and / or PTP1B, is described herein, comprising a compound described herein, ex vivo, a compound of formula (I), formula ( lia), formula (Ilb), formula (III), formula (IV) or formula (V). In other embodiments, methods of treating a disease or disorder are described herein, for example, cancer, type 2 diabetes, obesity, a metabolic disease or any other disease, disorder or condition that responds favorably to treatment with inhibitor. PTPN2 or PTP1B, comprising administering an effective amount of a compound described herein, for example, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV ), or Formula (V). n t cnon / zznz / q / υιλι For example, described herein is a compound represented by formula (I): EITHER R1F °'SNH R / Ñ ° lí jCr6 r7 R3γγOH R4R5(i) ; or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of hydrogen, halogen, Ci-e alkyl, C3-6 cycloalkyl, -O-Ci-g alkyl, N(Ra)-Ci-g alkyl and 5-6 -Ci-g alkylene-heterocyclyl members; where Ci-g alkyl, C3-6 cycloalkyl, -O-alkyl C1-6, -N(Ra)-C1-6 alkyl and -Ci-6 alkylene-5-6 membered heterocyclyl may be optionally substituted on one or more carbons available with one, two, three or more substituents each selected, independently, from Rg; and wherein n t cnon / zznz / q / υιλι if the 5-6 membered Ci-s-heterocyclyl -alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; R2 is selected from the group consisting of hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -CFR-O-Ci-e alkyl, -CH2-N (Ra)-C1-6 alkyl, C2-6 alkyl, C2-6 alkenyl, -O-C1-6 alkyl, -N (Ra)-Ci-6 alkyl, -S (O) «-C1-6 alkyl, -C (O)-N (Re C1-6 alkyl, -N (Ra) —0 (O) -C1-6 alkyl, -0-0 (O) -N (Ra) -Ci6 alkyl 6, -N (Ra) —C (O) -O-Ci-6alkyl, -C3-6cycloalkyl, -0C3-6cycloalkyl, Ci-6alkylene_C3-6cycloalkyl, -Ci-6alkenylene-C3-6cycloalkyl , -O-alkylene Ci-g-C3-6 cycloalkyl, 5-6-membered heteroaryl, 4-6-membered heterocyclyl, O-alkylene Ci-6-5-6-membered heteroaryl, -O-4-6-heterocyclyl members, -N(Ra)-4-6-membered heterocyclyl, 4-6-membered alkylene Ci-g-heterocyclyl and -O-4-6-membered Ci6-alkylene-heterocyclyl; where -CH^-O-Ci-6 alkyl, -CHp-N (Ra)-Ci-g alkyl, C2-6 alkyl, C2-6 alkenyl, -O-C1-6 alkyl, -N (Ra) - Ci6 alkyl, -S (O)w-Ci-6 alkyl, -C (0)-N (Ra)-Ci-6 alkyl, -N(Ra)-C(O)C1-6 alkyl, -0-0 (O)-N(Ra)-Ci-g alkyl, -N(Ra)-C(O)-O-Οι-e alkyl, -C3-6 cycloalkyl, -O-C3-6 cycloalkyl, -Ci-alkylene C3-6 ecycloalkyl, -C3-6 alkenylene-C3-6 cycloalkyl, -0C3-6 alkylene-cycloalkyl, 5-6 membered heteroaryl, O-5-6 membered Ci-e-heteroaryl alkylene, 4-6-membered, -O-4-6-membered heterocyclyl, -N(Ra)4-6-membered heterocyclyl, -4-6-membered -Ci-e-alkyleneheterocyclyl and -O-Ci-6~alkyleneheterocyclyl 4-6 members may be optionally substituted on one or more available carbons with one, two, three or more substituents each independently selected from R9; and wherein if 5-6 membered heteroaryl, 4-6 membered heterocyclyl, N(Ra)-4-6 membered heterocyclyl, -C1-6 alkylene4-6 membered heterocyclyl or -O-Ci-6 alkylene 4-6 membered heterocyclyl n t cnon / zznz / q / υιλι contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; or R1 and R2, taken together with the atoms to which they are attached, form 5-6 aryl or heteroaryl members; wherein aryl or heteroaryl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, Ci-g alkyl and Ci-s alkoxy; wherein Ci-e alkyl and Ci-6 alkoxy may be optionally substituted with one, two, three or more substituents each independently selected from Rp; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, -NH2, -C1-6alkyl, -O-C1-6alkylene, -0Ci-g-cycloalkylene, -O-C1-6alkylene (Ra)-C(O)-0C1-6alkyl, -N(Ra)-C1-6alkyl, -N(Ra)-C1-6alkylene©C3-6cycloalkyl, -S(O)w-Ci-alkyl e, -C(O)-N(Ra)-Ci-s-alkyl, -N(Ra)-C(0)-C1-6-alkyl and -Ci-6-alkylene-4-6-membered heterocyclyl; where -C1-6alkyl, -O-C1-6alkyl, -O-Ci-6alkylene-C3-6cycloalkyl, -O-C1-6alkylene-N(Ra)-C(0)-O-alkyl Ci6, -N(Ra)-C1-6alkyl, -N(Ra)-alkylene Ci-g-C3-6cycloalkyl, S(0)w-C1-6alkyl, -C(0)-N(Ra) -C1-6 alkyl, -N (Ra)-C (0)-C1-6 alkyl and -4-6 membered Ch-6 alkylene-heterocyclyl may be optionally substituted on one or more available carbons n t cnon / zznz / q / υιλι by one, two, three or more substituents each independently selected from Rg; and wherein if -alkylene© 4-6 membered Ci-6heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by Rh; R4 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl and -C1-6 alkylene 4-6 membered heterocyclyl; wherein Ci-e alkyl, C3-6 cycloalkyl and -Ci-g-alkylene-4-6 membered heterocyclyl may be optionally substituted on one or more available carbons with one, two, three or more substituents each independently selected , from Rg; and wherein if 4-6 membered Ci-g-heterocyclyl alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; where at least one of R1, R2, R3 and R4 is not hydrogen; R5 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl and 4-6 membered Ci-eheterocyclyl-alkylene; wherein C1-6 alkyl, C3-6 cycloalkyl and -Ci-6 alkylene-4-6 membered heterocyclyl may be optionally substituted on one or more carbons available with one, two, three or more substituents each independently selected , from Rg; and wherein if 4-6 membered Ci-g-heterocyclyl alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom n t cnon / zznz / q / υιλι may be optionally substituted with Rh; R6 is hydrogen; R7 is hydrogen; R9 is selected, independently, for each occurrence of the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, RaRbN-, RaRbN-C(O)-, RaRbN-SOw- , RaRbN-C (O)-N (Ra)-, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, Ci-ecycloalkylene C3-6, -O-Ci-alkylene e-C3-6 cycloalkyl, -(CO)(NRa) -Ci-6 alkylene-C3-6 cycloalkyl, C1-6 alkoxy, C36 alkenyl-oxy, C3-6 alkynyl-OXY, C3-6 cycloalkoxy, Ci-alkyl e-C(O)-, C1-6-O-C alkyl (O) -, C1-6-C alkyl (O)-O-, Ci-6-S(O)w-alkyl, C1-6-N alkyl (Ra )-, Ci-g-N alkyl (Ra)-C (O)-, C1-6 alkyl-C (O) N(Ra), Ci-6 alkyl-N (Ra)-C (O)-N (Ra) -, Ci-6-N alkyl (Ra)-SOW-, C3-6-N cycloalkyl (Ra)-SO«-, Ci-6-SOw-N alkyl (Ra) -, C3-6-N cycloalkyl-SOw-N (Ra)-, 4-6 membered heterocyclyl-SOwN(Ra)-, C1-6 alkoxy-C (O)-N (Ra)-, Ci-g-C alkyl (O) -N (Ra) -C1 alkyl- 6-, C1-6 alkyl-N (Ra)-C (O)-C1-6 alkyl-, -P (O) (01-3 alkyl)2 and Ci-6 alkoxy-C1-6 alkyl-; wherein C1-6 alkyl, C2e alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, C1-6 alkylene C3-6 cycloalkylene, -O-Ci-6 alkylene-C3-6 cycloalkyl, - (CO) (NRa) -C3-6 alkylene-cycloalkyl, C1-6 alkoxy, C36 alkenyl-oxy, C3-6 alkynyl-OXY, C3-6 cycloalkoxy, Ci-g-C(O)-alkyl, Ci-e-O-C alkyl (O)- , C1-6-C alkyl (O)-O-, Ci-5-S(O)w- alkyl, C1-6-N alkyl (Ra)-, Ci-g-N alkyl (Ra)-C (O)- , alkyl Ci-g-C (O) n t cnon / zznz / q / υιλι N(Ra)-, Ci-6-N(Ra)-C(O)-N(Ra)-alkyl, Ci-6-N(Ra)-alkyl-SOW-, C3-6-N(Ra)-SOW cycloalkyl -, Ci-6-SOw-N alkyl (Ra) -, C3-6-cycloalkyl-SOw-N (Ra)-, 4-6-membered heterocyclyl-SOwN(Ra)-, Ci-g-C alkoxy (O) -N (Ra)Ci-g-alkyl (O) -N (Ra) -C1-6 alkyl-, C1-6 alkyl-N (Ra)-C (O)-C1-6 alkyl-, -P (O) (alkyl Ci-3)2 and Ci-e-C1-6 alkoxy may be optionally substituted with one, two, three or more substituents each independently selected from Rp; or 2 R9 on adjacent atoms, together with the atoms to which they are attached, form a 5-6-membered aryl or heteroaryl; Rhse is selected, independently, for each occurrence from the group consisting of Ci-e alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, -Ci-6 alkyl-C36 cycloalkyl, Ci-e-S alkyl(O )2-, C3-6-cycloalkyl-S(O)2-, 4-6-membered heterocyclyl-S(O) 2-, 4-6-membered heterocyclyl-Ci-6-alkyl-S(O)2-, heteroaryl 5-6 membered-S(O)2-, phenyl-S(O)2-, phenyl-Ci-6-alkyl-S(O)2-, Ci-6-alkyl-C(O)-, Ci-cycloalkyl eC(O)-, alkoxy Ci-6-C(O)-, RaRbN-C(O)-, RaRbN-SO2- and -P(O) (01-3 alkyl)2; where Ci-e alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, -Ci-g-C3-6 alkyl, C1-6S alkyl (O) 2-, C3-e-S(O) cycloalkyl 2-, 4-6-membered heterocyclylS(O)2-, 4-6-membered heterocyclyl-Ci-6-alkyl-S(O)2-, 5-6-membered heteroaryl-S(O)2-, phenyl- S (O)2-, phenyl-alkyl Ci-6-S(O)2-, alkyl Ci-e-C(O)-, cycloalkyl C1-6-C (O)-, alkoxy n t cnon / zznz / q / υιλι Ci-6-C(O)-, RaRbN-C(O)-, RaRbN-SO2- and -P(O) (€1-3 alkyl)2 may be optionally substituted with one, two, three or more substituents each one selected, independently, from Rp; Rpse is selected, independently, for each occurrence of the group consisting of halogen, hydroxyl, cyano, Ci-e alkyl, C1-6 alkoxy, C3-6 cycloalkyl, 46-membered heterocyclyl, RaRbN-, RaRbN-carbonyl-, RaRbN -SC>2- and RaRbN-carbonylN(Ra) Ray Rbse are independently selected, for each occurrence, from the group consisting of hydrogen, C1-6 alkyl and C3-6 cycloalkyl; wherein C1-6 alkyl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, hydroxyl and Ci-s alkoxy (optionally substituted with one, two or three atoms of fluorine); o Ray Rb together with the nitrogen to which they are attached form a 4-6 membered heterocyclyl, wherein the heterocyclyl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, cyano, oxo and hydroxyl; and w is 0, 1 or 2. Also described herein is a compound represented by the formula (Ha): n t cnon / zznz / q / υιλι EITHER n t cnon / zznz / q / υιλι or a pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of -O- and -N(Ra)-; L is linear or branched Ci-s alkylene, wherein the Ci-8 alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R2-íias is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N cycloalkyl (Ra) -, C1-6 alkyl-SO2-N (Ra)-, phenyl, heteroaryl 5-6 membered, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein C1-2 alkoxy, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each selected, so independent, from the group consisting of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl or one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence of the group consisting of hydrogen and Ci-3 alkyl (optionally substituted with one or more halogens, cyano or C1-2 alkoxy). Also described herein is a compound represented by the formula (Ilb): n t cnon / zznz / q / υιλι O p NHR 2<b / X NLXXX Xr7Y OH R5(Ilb) or a pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of -O- and -N(Ra)-; L is linear or branched Ci-g alkylene; R2-iibs is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N cycloalkyl (Ra)-, C1-6 alkyl-SO2-N (Ra)-, phenyl, heteroaryl 5-6 membered, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consists of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substituted ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Ci-a alkyl; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. Also described herein is a compound represented by formula (III): n t cnon / zznz / q / υιλι or a pharmaceutically acceptable salt thereof, wherein: X111 Select from the group consisting of a link, -ch2-, -nra-, -o-, -o-ch2- and -ch2-ch2m e s 1, 2 or 3; nesl, 2 or 3; R1-111 is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens ); R2-111 is selected from the group consisting of hydrogen, C1-4 alkyl, -C (O)-C1-4 alkyl, -C (O)-O-C1-4 alkyl, -C (O)N (Ra)- C1-4 alkyl, -S (O) 2-C1-4 alkyl and -S (O) 2-C36 cycloalkyl, where C1-4 alkyl, -C (O)-C1-4 alkyl, -C (O) -O-Ci4 alkyl, —C (O) -N (Ra) -C1-4 alkyl, -S (O) 2-C1-4 alkyl and -S(O)2~ C3-6 cycloalkyl may be optionally substituted with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally replaced with one, two or three halogens); R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; y n t cnon / zznz / q / υιλι Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. Also described herein is a compound represented by formula (IV): n t cnon / zznz / q / υιλι O p NH L»l í 2Γ d” R“R?pj3-nT^ X'^^ Y ^OH R5(iv) or a pharmaceutically acceptable salt thereof, wherein: X111is selected from the group consisting of -O- and N(Ra) L111 is linear or branched Ci-g alkylene, wherein the Ci-s alkylene is optionally substituted with hydroxyl or fluoro; R3-111 is selected from the group consisting of hydrogen, -NRaRb, -N(Ra)—C(O)-O-Ci-g alkyl, hydroxyl, fluoro, Ci2 alkoxy, 4-6 membered heterocyclyl and C3-6 cycloalkyl ; wherein 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; either Liii-r3-ihehydrogen; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. Also described herein is a compound represented by formula (V): n 1 cnon / zznz / q / υιλι or a pharmaceutically acceptable salt thereof, wherein: Xv is selected from the group consisting of -O- and N(Ra) Lves a linear or branched C1-8 alkylene or bond, wherein the Ci-s alkylene is optionally substituted with one or more hydroxyl or fluoro; R2-v is selected from the group consisting of hydrogen, halogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N cycloalkyl (Ra), C1-6 alkyl-SO2-N (Ra) -, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consists of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl or one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. n t cnon / zznz / q / υιλι Also described herein is a compound selected from the group consisting of: 5-{l-fluoro-3-hydroxy-7-[2-(moriolin-4yl)ethoxy]naphthalen-2-yl} -1λ6, 2, 5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-i1]1Á6,2,5-thiadiazolidin-l,1,3-trione; 8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl propan-2-ylcarbamate; 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[2-(azetidin-l-yl)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-methoxy (4-2H)naphthalen-2-yl] (4,42H2) — 1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7[2-(piperidin-4-yl)ethoxy]naphthalen-2-yl}-lÁ6,2,5thiadiazolidin-1,1,3-trione; 5-(l-fluoro-7-{[3-fluoro-l-(propan-2-yl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1Λ6, 2,5-1iadiazolidin1,1, 3-trione; 5-{l-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; n t cnon / zznz / q / υιλι 5-{[8-fluoro-6-hydrοχ1-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile; 5-{l-fluoro-3-hydroxy-7-[2-(piperidin-1yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5—{7—[1—(cyclopropanesulfonyl)-2,5-dihydro-lH-pyrrole-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3- trione; 5-{1-finoro-3-hydroxy-7-[(piperidin-4yl)methoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3dimethylpentanenitrile; 5-{7-[(3,3-dimethylbutyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[ (2H3)methyloxy]naphthalen-2-yl}1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2dimethylbutanenitrile; 5-{7-[2-(3-aminobicyclo[1,1,1]pentan-l-yl)ethoxy]-1fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1 ,3 n t cnon / zznz / q / υιλι trione; 5-(7-{[2-(dimethylamino)ethyl]amino}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4-2H2)1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-finoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; N-(2-{[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2yl]amino}ethyl)cyclopropanesulfonamide; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]amino}naphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; N-(2-{[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)cyclopropanesulfonamide; 5 - (1-fluoro-3-hydroxy-7{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)1Λ6,2,5-thiadiazolidin-l,1,3-trione; 4-{[8-finoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy¡butanenitrile; [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}methyl)cyclopropyl]acetonitrile; 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropylmethyl)-lH-pyrazol-4-yl]-1-fluoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l ,1,3-trlone; 5-{1-finoro-3-hydroxy-7-[(lH-pyrazol-4yl)methoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-f luoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl] 1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2yl]-IX6, 2,5-thiadiazolidin-l,1,3-trione; N-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo1λ6,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide; 5-[l-fluoro-3-hydroxy-7-(2-{[2(trifluoromethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl)amino]ethoxy}naphthalen-2-yl)-lÁe,2,5-thiadiazolidin1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen2-yl}-lX6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(cyclopropylamino)ethoxy]-1-fInoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l, 1,3-trione; n t cnon / zznz / q / υιλι 5-{7-[2-(ethylamino)ethoxy]-1-finoro-3-hydroxynaphthalen-2yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2yl)amino]ethoxy}naphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3trione; 5-{7-[3-(diethylphostoryl)propoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l,4-difluoro-3-hydroxy-7-[(3methylbutyl)amino]naphthalen-2-yl}-1Á6,2,5-thiadiazolidin-l,1,3trione; 5-{1-fInoro-3-hydroxy-7-[ (3R)-3-hydroxybutoxy ]naphthalen2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen2-yl}-lX6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4methylpentyl)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-l,1,3trione; n t cnon / zznz / q / υιλι 5-{l-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; N-[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide; 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen2-yl]-1Á6, 2,5-thiadiazolidin-l, 1,3-trione; 1- (2 — {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropan-1carbonitrile; 5-(1-fluoro-3-hydroxy-7-{2-[1(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1Λ6, 2,5thiadiazolidin-1,1,3-trione; 5-(7-{[(cyclopropylmethyl)amino]methyl}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(2,2-difluoropropyl)amino]-1-fInoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[ (4,4,4n t cnon / zznz / q / υιλι trifluorobutyl)amino]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1,1,3 -trione; 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(dimethylthostoryl)-2,5-dihydro-lH-pyrrol-3-yl]-lfluoro-3-hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1, 3triona; 5-{1-fInoro-3-hydroxy-7-[(3,3,3trifluoropropyl)amino]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3methylbutoxy)naphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-1,1,3trione; 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-({2-[(propan-2yl)oxy]ethyl]amino)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]methoxy}naphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5tradiazolidin-2-yl)naphthalen-2-yl]amino}butanenitrile; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-[7-(4-amino-3,3-dimethylbutoxy)-1-finoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3 -triona; 5-(7-{[2-(azetidin-l-yl)ethyl]amino}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-{1-fInoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2yl} -1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-(3,3,3trifluoropropoxy)naphthalen-2-yl]-1Λ6,2,5-thiadiazolidin-l,1,3trione; 1-({[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropan-1carbonitrile; 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[3-(IH-pyrazol-lyl)propoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-{1-[(4-aminophenyl)methanesulfonyl]-2,5-dihydro-1Hpyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1 ,1,3-trione; 5-[l-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fInoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1, 3-trlona; 5-{7-[1-(cyclopropancarbonyl)pyrrolidin-2-yl]-1-fInoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[2-(IH-pyrazol-lyl)ethoxy]naphthalen-2-yl}-lλ6,2,5-thiadiazolidin-l,!,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fInoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fInoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(1methylcyclopropyl)ethoxy]naphthalen-2-yl}-lÁÉ,2,5-thiadiazolidin1,1,3-trione; 5- ( 7-{1- [ (3-aminophenyl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fInoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1 ,1,3-trione; 5- ( 7-{1- [ (2-aminophenyl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fInoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1 ,1,3-trione; 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-finoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalenn t cnon / zznz / q / υιλι 2-11]-1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 1-({[8-fInoro-6-hydroxy-7- (1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy]methyl)cyclopropan-1carbonitrile; 5-{1-fInoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(cyclopropylmethyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; {[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrile; 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropancarbonyl)azetidin-3-yl]-1-fInoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile; n t cnon / zznz / q / υιλι 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2 11]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(2,2-difluorocyclopropyl)methoxy]-1-fInoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-{7-[2-(cyclopropylmethoxy)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy Jnaphthalen2-yl} -1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fInoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2yl)oxy]ethoxy}naphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; — (7 — {[rac-(lR,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-l-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(l-chloro-3-hydroxypropan-2-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; n t cnon / zznz / q / υιλι 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; —{7 —[(2-cyclopropylethyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1—fluoro-3-hydroxy- 7-(4-methyl-lH-imidazol-2yl)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile; 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(3-methyloxetan-3yl)methoxyJnaphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-lHpyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5thiadiazolidin-1, 1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-{1-fluoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalenn j cnon / zznz / q / υιλι 2-11}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-(8-chloro-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(3,3-difluorocyclobutyl)methoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-cyclopropyl-l-fluoro-3-hydroxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropancarbonyl)-2,5-dihydro-lH-pyrrole-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3- trione; 5-(4-chloro-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidin-l,1,3-trione; —{7 — [ (E)-2-cyclopropylethenyl]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(1E)-4-methylpent-l-en-lyl]naphthalen-2-yl}-lÁ5,2,5-thiadiazolidin-l,1,3-trione ; 5-{l-fluoro-3-hydroxy-7-[1(pentamethylphenyl)ethenyl]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin1,1,3-trione; 5-{7 -[1-(cyclopropylmethyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1 ,3trione; 5-(4-bromo-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)n t cnon / zznz / q / υιλι 1λ6, 2,5-thiadiazolidin-l,1,3-phryone; 5-{7-[1-(2-cyclopropylethyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l ,1,3trione; 5-{l-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-l-en-lyl]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione ; 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(1,l-dioxo-lA6-thian-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(cyclopropylmethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]—1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-(l-fluoro-3-hydroxy-7-{[1-(2,2,2trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-lA6,2,5thiadiazolidin-1,1,3 -triona; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1A6, 2,5thiadiazolidin-1,1,3 -triona; 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2methylpropyl)amino]ethoxy}naphthalen-2-yl)-lA6,2,5-thiadiazolidin n t cnon / zznz / q / υιλι 1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-lfluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-(7-{[1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-[l-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[l-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-lfluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[(pyrrolidin-3yl)methyl]naphthalen-2-yl}-lX6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3,6-dihydro-2H-pyran-4-yl)-l-fluoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l ,1,3-trione; 5-[7-(2,5-dihydro-lH-pyrrol-3-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-finoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; —{7 —[ (azetidin-3-yl)methyl]-1-finoro-3-hydroxynaphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; N-(2-cyclopropylethyl)-2-{[8-fInoro-6-hydroxy-7-(1,1,4trioxo-ΐλ6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]amino}acetamide; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-methylbutanamide; N-ethyl-77' - (2 - {[ 8-fInoro-6-hydroxy-7- (1,1,4-trioxo1λ6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl )urea; 5-{l-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2yl} — 1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(l-chloro-3-hydroxypropan-2-yl)oxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[l-(2,2,2-trifluoroethyl)1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; n t cnon / zznz / q / υιλι 5-(l-fluoro-3,7-dihydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λδ, 2, 5thiadiazolidin-1,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; {[8-Fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino¡acetic acid; N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-ΐλ6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy}acetamide; N, 2V-diethyl-2- {[ 8-f luoro-6-hydroxy-7- (1,1,4-trioxo1λ6, 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxyacetamide; 5-{l-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4yl]oxy}naphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l, 1,3-trione; 5-{1-finoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁg,2,5-thiadiazolidin1 ,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁÉ,2,5-thiadiazolidin1,1 ,3-trione; n t cnon / zznz / q / υιλι 5-{l-fluoro-3-hydroxy-7-[l-(3,3,3-trifluoropropan-1sulfonyl)-2,5-dihydro-lH-pyrrole-3-yl]naphthalen-2-yl}-1λ6 , 2,5thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxl-7-[1-(3,3,3-trifluoropropan-1sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6 ,2,5thiadiazolidin-1,1,3-trione; 5- (1-finoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]2,5-dihydro-lH-pyrrol-3-yl}naphthalen-2-i1)-1λ6, 2 ,5thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutan-1sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6 ,2,5thiadiazolidin-1,1,3-trione; 5-{7-[1-(bufan-1-sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin -1,1,3trione; 5— (7 — {1— [ (1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1Λ6 , 2,5 thiadiazolidin-1,1,3-trione; 5-{3-[8-fluoro-6-hydrox1-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-lH- pyrrol-lsulfonyl}pentanenitrile; 5-{l-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1 ,1,3-trione; 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-1 n t cnon / zznz / q / υιλι fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2 ,5-thiadiazolidin-l ,1,3trione; 5-{l-fluoro-3-hydroxl-7-[1-(propan-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin1 ,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3- trione; N- (2 — {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3sulfonamide; 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(2-methylpropan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; 5-(7-ethoxy-l-fluoro-3-hydroxynaphthalen-2-yl)-1Λ6, 2,5thiadiazolidin-1,1,3-trione; 5-[7-(2,2-difluoroethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-lH-pyrazol-4-yl]-1-fluoro3-hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[(3R)-1(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ6,2,5thiadiazolidin-1,1,3- trione; n t cnon / zznz / q / υιλι 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4yl]amino}naphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5- (7 — {[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1fluoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3trione; 5-(l-fluoro-7-{[3-fluoro-l-(methanesulfonyl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidin1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(propan-2sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-lÁ6,2,5thiadiazolidin-1,1,3-trione; 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(1,3-dimethyl-lH-pyrazol-4-sulfonyl)-2,5-dihydrolH-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}- 1λ6, 2,5thiadiazolidin-1,1,3-trione; N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide; 5-{1-fluoro-7 -[l-(furan-3-sulfon11)-2,5-dihydro-lHpyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin1, 1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(3-methylbutan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2.5 n t cnon / zznz / q / υιλι dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lXÉ,2,5-thiadiazolidin1,1,3-trione; 5—{7—[1—(heneensulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl} -IX6, 2,5-thiadiazolidin-l,1, 3trione; 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-lH-pyrrol-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-IX6, 2,5-thiadiazolidin1,1,3- trione; methyl (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-lX6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy Jbutanoate; 5-{7-[(3,5-dimethyl-lH-pyrazol-4-yl)methoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-IX6, 2,5-thiadiazolidin-l,1,3-trione ; 5-[7-(3,5-dimethyl-lH-pyrazol-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-IX6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-IX6, 2,5-thiadiazolidin-l,1,3-trione; 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1X6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]-lH-imidazole-4-carbonitrile; 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-1,3-dioxolan4-yl)ethoxy]naphthalen-2-yl}-lX6,2,5-thiadiazolidine- l,1,3trione; 5-[7-(3,4-dihydroxy-3-methylbutoxy)-l-fluoro-3hydroxynaphthalen-2-yl]-IX6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7 -[ (4,4-difluorobutyl)amino]-1-fluoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3- trione; 5-(7-{[rae-{2R, 4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-l,1,3-trione ; 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-pyrazol-lyl)ethoxy]naphthalen-2-yl}-lλ6,2,5-thiadiazolidin-l,!,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-3,6-dihydroxynaphthalen-2-yl)-1Λ6, 2,5thiadiazolidin-1,1,3-trione; 5-(6-amino-l-fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{6-[(cyclopropylmethyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3methylbutyl)amino]naphthalen-2-yl}-1Á6,2,5-thiadiazolidin-l,1,3trione; 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; n i cnon / zznz / q / υιλι tert-butyl (2-{[5-fluoro-7-hydroxy-6-(1,1, 4-trioxo1Á6,2,5-thiadiazolidin-2-yl)naphthalen-2-11 ]oxy}ethyl)carbamate; 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[6-(cyclopropylmethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3dimethylbutoxy)naphthalen-2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3trione; 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[l-(3-hydroxy-2,2dimethylpropane-l-sulfonyl)-2,5-dihydro-lH-pyrrole-3yl]naphthalen-2-yl} -1Á6 , 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(3-aminopropane-l-sulfonyl)-2,5-dihydro-lHpyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl} -1λ6, 2,5thiadiazolidin- 1,1,3-trione; (3R)-5-{[8-fluoro-6-hydroxy-7 - (1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy- 3 n j cnon / zznz / q / υιλι methylpentanenitrile; (35)-5-{[8-fluoro-6-hydroxy-7 - (1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy- 3methylpentanenitrile; 5—{7 —[(5-amino-3,3-dimethylpentyl)oxy)-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2yl)amino]propyl}naphthalen-2-yl)-1Á6,2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-l-fluoro-3-hydroxynaphthalen-2yl]—1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclobutylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2(trifluoromethoxy)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 5-[7-(2-cyclopropylethoxy)-l-fluoro-3,6 n t cnon / zznz / q / υιλι dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-ethyl-l-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidine-1,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-l-fluoro-3,6-dihydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3,6-dihydroxy-7-[2-(oxolan-2yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(2-cyclobutylethoxy)-l-fluoro-3,6-dihydroxynaphthalen2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-butoxy-l-fluoro-3,6-dihydroxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-cyclopentylethoxy)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(4,4-difluorobutoxy)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1Á6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}—2,2—dimethylbutanenitrile; 5-{l-fluoro-3,6-dihydroxy-7-[2-(oxolan-3yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; n t cnon / zznz / q / υιλι 5-{l-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-lsulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-1λ6, 2,5thiadiazolidine -1,1,3-trione; 5-(7-bromo-l-finoro-3,6-dihydroxynaphthalen-2-yl)-1Λ6, 2,5thiadiazolidine-1,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2yl]-IX6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxy]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[1(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1Λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-(7 — {2 —[3-(aminomethyl)bicyclo[1,1,1]pentan-l-yl]ethoxy}1-fluoro-3-hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidin -l,1,3trione; 5-(1-fluoro-3-hydroxy-7-{[3-(2hydroxyethyl)bicyclo[1,1,1]pentan-l-yl]methoxy}naphthalen-2-yl)1Λ6, 2,5-thiadiazolidine- l,1,3-trione; 5—{7—[2 — (bicyclofl,1,l]pentan-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione ; 5-(7 — {2 —[1-(aminomethyl)cyclobutyl]ethoxy}-l-fluoro-3 n t cnon / zznz / q / υιλι hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-l,1 ,3-trione; 5-{1-fluoro-3-hydroxy-7-[2 - (3-hydroxy-3-methylazetidin-lyl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidine-l,1,3- trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2(trifluoromethyl)pyrrolidin-l-yl]ethoxy]naphthalen-2-yl)-lÁ6,2,5thiadiazolidine-1,1, 3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-1Λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[2-(3,3-difluoropyrrolidin-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3 -triona; 5-{7-[2-(3,3-difluoroazetidin-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-{l-fluoro-3,6-dihydroxy-7-[2-(1methylcyclopropyl)ethoxy]naphthalen-2-yl}-lXg,2,5-thiadiazolidin1,1,3-trione; 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3,6dihydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-(7 — {2 —[ethyl(methyl)amino]ethoxy}-l-fluoro-3hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidine-l,1,3-trione; 3- [ (2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)(methyl)amino] propanenitrile; n t cnon / zznz / q / υιλι 5-(l-fluoro-3-hydroxy-7-{2-[ (2,2,2trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-trione; and a pharmaceutically acceptable salt thereof. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (Ha), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is formulated as a pharmaceutically acceptable composition comprising a described compound and a pharmaceutically acceptable carrier. Also described herein is a method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, ex vivo, a compound of Formula (I), Formula ( lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-Ll antibody, and an anti-CTLA-4 antibody. For example, described herein is a method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, ex vivo, a n j cnon / zznz / q / υιλι composed of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). Further provided herein is a method of treating type 2 diabetes in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V). Described herein, for example, is a method of treating and / or controlling obesity in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V). For example, described herein is a method of inhibiting further weight gain in an overweight or obese patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). Also described herein is a method of treating a metabolic disease in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein n j cnon / zznz / q / υιλι document, ex vivo, a compound of Formula (I), Formula (Ha), Formula (Ilb), Formula (III), Formula (IV) or Formula (V). In some embodiments, the method comprises treating cancer. In some embodiments, the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, or a cancer of the secretory cells. In some embodiments, the method comprises treating a metabolic disease. In some embodiments, the metabolic disease comprises nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, type 2 diabetes, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy or disease by Kearns-Sayre. Also described herein is a composition for use in the treatment of cancer in a patient in need thereof, wherein the composition comprises a compound described herein, for example, a compound of formula (I), formula ( lia), formula (Ilb) or formula (III), formula (IV) or formula (V) in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-Ll antibody, and an anti-CTLA-4 n j cnon / zznz / q / υιλι antibody. For example, described herein is a composition for use in treating cancer in a patient in need thereof, wherein the composition comprises a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). Also provided herein is a composition for use in the treatment of type 2 diabetes in a patient in need thereof, wherein the composition comprises a compound described herein, ex vivo, a compound of formula (I) , formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). Described herein is, for example, a composition for use in the treatment and / or control of obesity in a patient in need thereof, wherein the composition comprises a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). For example, described herein is a composition for use in inhibiting further weight gain in an overweight or obese patient in need thereof, wherein the composition comprises a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V). n j cnon / zznz / q / υιλι Also described herein is a composition for use in the treatment of a metabolic disease in a patient in need thereof, wherein the composition comprises a compound described herein, ex vivo, a compound of formula (I), formula (Ha), formula (Ilb), formula (III), formula (IV) or formula (V). In some embodiments, the cancer comprises pancreatic cancer, breast cancer, multiple myeloma, or a cancer of the secretory cells. In some embodiments, the metabolic disease comprises nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), liver fibrosis, obesity, type 2 diabetes, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy or disease by Kearns-Sayre. DETAILED DESCRIPTION OF THE INVENTION The present description relates, at least in part, to compounds, compositions and methods for the inhibition of protein tyrosine phosphatase, for example, non-receptor protein tyrosine phosphatase type 2 (PTPN2) and / or non-receptor protein tyrosine phosphatase type 1 ((PTPN1), also known as protein tyrosine phosphatase-ΙΒ (PTP1B)). Definitions Chemical definitions Definitions of specific functional groups and chemical terms are described in more detail below. n j cnon / zznz / q / υιλι Chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd., Inside cover, and specific functional groups are generally defined as described therein. In addition, the general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd edition, Cambridge University Press, Cambridge, 1987. The abbreviations used herein have their conventional meaning within chemical and biological techniques. The chemical structures and formulas set forth herein are constructed in accordance with the standard rules of chemical valence known in the chemical arts. The compounds described herein may comprise one or more asymmetric centers, and therefore may exist in various isomeric forms, for example, as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of an individual enantiomer, diastereomer, or geometric isomer, or may be in the form of a mixture of stereoisomers, which includes racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or, it is possible to prepare the isomers by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972) . The description further comprises compounds described herein as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. As used herein, a pure enantiomeric compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, an S form of the compound is substantially free of the R form of the compound and is therefore in an enantiomeric excess of the R form. The terms enantiomerically pure or enantiomerically pure indicate that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5 % by weight, or more than 99.9% by weight, of the enantiomer. In certain embodiments, the weights are based on the total weight of all enantiomers or stereoisomers of the compound. In the compositions provided herein, an enantiomerically pure compound may be present along with other ingredients, active or inactive. For example, a pharmaceutical composition comprising an enantiomerically pure compound R may comprise, for example, about 90% excipient and about 10% enantiomerically pure compound R. In certain embodiments, the enantiomerically pure compound R present in such compositions may comprise, for example, at least about 95% by weight of compound R and at most about 5% by weight of compound S, based on the total weight of the compound. For example, a pharmaceutical composition comprising an enantiomerically pure compound S may comprise, for example, about 90% excipient and about 10% enantiomerically pure compound S. In certain embodiments, the enantiomerically pure compound S in such compositions may comprise, for example, at least about 95% by weight of compound S and at most about 5% by weight of compound R, referred to the total weight of the compound. In certain embodiments, the active ingredient may be formulated with little or no excipient or carrier. Isotopically enriched variant, as used herein, refers to a described compound having one or more isotopic substitutions, wherein one or more atoms are replaced by an atom having an atomic mass or mass number different from that. atomic mass or the mass number generally found in nature. Examples of isotopes that may be incorporated into the compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2H,3H,13C,14C,15N,18O,17O,31P,32P ,35S,18F and 36C1, respectively. For example, hydrogen (H) can be in any isotopic form, including 3H, 2H (D or deuterium), and 3H (T or tritium); carbon (C) can be in any isotopic form, including 12C, 13C, and 14C; oxygen (O) can be in any isotopic form, including 16O and 18O; and the like. For example, an isotope-enriched variant as described herein may have one or more hydrogen atoms replaced with deuterium. In the present document, the articles un and una can be used to refer to a (i.e., to at least one) n t cnon / zznz / q / υιλι of the grammatical objects of the article. By way of example, an analogue means one analogue or more than one analogue. When a range of values ​​is listed, it is intended to encompass each value and subrange within the range. For example, Ci-Cg alkyl is intended to encompass Ci, C2, C3, C4, C5, Ce, Ci-Ce, C1-C5, C1-C4, C1-C3, C1-C2, C2_Ce, C2_Cs, C2_C4, C2- C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5 and C5-C6. The following terms are intended to have the meanings presented below and are helpful in understanding the description and intended scope of this description. Alkyl refers to a radical of a straight or branched chain saturated hydrocarbon group having 1 to 20 carbon atoms (C1-C20 alkyl or C1-C20 alkyl). In some embodiments, an alkyl group has 1 to 12 atoms. carbon (C1-12 alkyl or C1-C12 alkyl). In some embodiments, an alkyl group has 1 to 8 carbon atoms (Ci-g alkyl or Ci-Cg alkyl). In some embodiments, an alkyl group has 1 to 6 carbon atoms (Ci-e alkyl or Ci-Ce alkyl). In some embodiments, an alkyl group has 1 to 5 carbon atoms (C1-5 alkyl or CiC5 alkyl). In some embodiments, an alkyl group has 1 to 4 carbon atoms (C1-4 alkyl or C1-C4 alkyl). In some embodiments, an alkyl group has 1 to 3 carbon atoms (C1-3 alkyl or C1-C3 alkyl). In some embodiments, an alkyl group has 1 to 2 carbon atoms (C1-2 alkyl n t cnon / zznz / q / υιλι or C1-C2 alkyl). In some embodiments, an alkyl group has 1 carbon atom (Ci alkyl). In some embodiments, an alkyl group has 2 to 6 carbon atoms (C2-Cg alkyl). Examples of Ci-Ce alkyl groups include methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), nbutyl (C4), tere-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5) and n- hexyl (Ce). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs), and the like. Each instance of an alkyl group may be, independently, optionally substituted, that is, unsubstituted (an unsubstituted alkyl) or substituted (a substituted alkyl) with one or more substituents; for example, 1 to 5 substituents, 1 to 3 substituents or 1 substituent. In certain embodiments, the alkyl group is unsubstituted C1-10 alkyl (e.g., CH3). In certain embodiments, the alkyl group is substituted C1-6 alkyl. Common alkyl abbreviations include Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3) or i-Bu(-CH2CH(CH3 ) 2) . The term alkylene, by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited to, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have 1 to 24 n t cnon / zznz / q / υιλι carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present description. The term alkenylene, by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. An alkylene group may be described as, for example, an alkylene of Ci-Ce members, where the term members refers to the non-hydrogen atoms within the moiety. Alkenyl refers to a radical of a straight-chain or branched hydrocarbon group that has 2 to 20 carbon atoms, one or more carbon-carbon double bonds and no triple bonds (C2-20 alkenyl or C2-C20 alkenyl). In some embodiments, an alkenyl group has 2 to 10 carbon atoms (C2-10 alkenyl or C2-Cio alkenyl). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (€2-3 alkenyl or Ce-Ce alkenyl). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (C2-g alkenyl or C2-Ce alkenyl). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (C2-5 alkenyl or C2-C5 / z alkenyl). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (€2-4 alkenyl or C2-C¿ alkenyl). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (€2-3 alkenyl or C2-Cs alkenyl). In some embodiments, an alkenyl group has 2 carbon atoms (C2 alkenyl). The one or more n t cnon / zznz / q / υιλι carbon-carbon double bonds may be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups, as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cg), octatrienyl (Cg), and the like. Each instance of an alkenyl group may be, independently, optionally substituted, e.g., unsubstituted (an unsubstituted alkenyl) or substituted (a substituted alkenyl) with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents or 1 substituent. In certain embodiments, the alkenyl group is unsubstituted C2-10 alkenyl. In certain embodiments, the alkenyl group is substituted C2-6 alkenyl. Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (ex vivo, having 6, 10, or 14 shared π electrons in a cyclic arrangement) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (Ce-Cu aryl). In some embodiments, an aryl group has six carbon atoms of the n j cnon / zznz / q / υιλι ring (aryl Ce; for example, phenyl). In some embodiments, an aryl group has ten ring carbon atoms (Cio aryl; for example, naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (aryl Cu; e.g., anthracyl). An aryl group can be described as, for example, an aryl Ce-Cio member, where the term member refers to the non-hydrogen ring atoms within the moiety. Aryl groups include, but are not limited to, phenyl, naphthyl, indenyl and tetrahydronaphthyl. Each instance of an aryl group may be, independently, optionally substituted, for example, unsubstituted (an unsubstituted aryl) or substituted (a substituted aryl) with one or more substituents. In certain embodiments, the aryl group is unsubstituted Ce-Ci4 aryl. In certain embodiments, the aryl group is substituted Ce-Cu aryl. In certain embodiments, an aryl group is substituted with one or more of groups selected from halo, Ci-Cs alkyl, halo-Ci-Cs alkyl, haloxy-Ci-Cs alkyl, cyano, hydroxy, Ci-Cg alkoxy-alkyl and amino. . Examples of representative substituted aryls include the following n t cnon / zznz / q / υιλι wherein one of R56and R57may be hydrogen and at least one of R56and R57is each independently selected from Ci-Cs alkyl, Ci-Cs haloalkyl, 4-10 membered heterocyclyl , alkanoyl, alkoxy-alkyl Ci-Cs, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR58COR59, NR58SOR59NR58SO2R59, C (O) Oalkyl, C(0)0aryl, CONR58R59, CONR58OR59, NR58R59, SO2NR58R59, S-alkyl, S (O) -alkyl, S(O)2-alkyl, Saryl, S(O)-aryl, S(O2)-aryl; or R56 and R57 can be joined to form a cyclic ring (saturated or unsaturated) of 5 to 8 atoms, optionally containing one or more heteroatomic groups selected from the group N, O, S, S(O) or S(O)2. Other representative aryl groups having a fused heterocyclyl group include the following: ...W'·.. ..... W .. „ n t cnon / zznz / q / υιλι where each W' is selected from C(R66)2, NR66, O and S; and each Y' is selected from carbonyl, NR66, O and S; and R66 is, independently, hydrogen, Ci-Cg alkyl, C3C10 cycloalkyl, 4-10 membered heterocyclyl, Ce-Cio aryl and 5-10 membered heteroaryl. An arylene and a heteroarylene, alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. Non-limiting examples of heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl, benzodioxanyl, thianaphtanyl, pyrrolopyridinyl, indazolyl, quinolinyl, quinoxalinyl, pyridopyrazinyl, quinazolinonyl, benzoisoxazolyl, imidazopyridinyl, nzofuranyl, benzothienyl, benzothiophenyl, phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furylthienyl, pyridyl, pyrimidyl, benzothiazolyl, purinyl, benzimidazolyl, isoquinolyl, thiadiazolyl, oxadiazolyl, pyrrolyl, diazolyl, triazolyl, tetrazolyl, , isothiazolyl, pyrazolopyrimidinyl, pyrrolopyrimidinyl, benzotriazolyl, benzoxazolyl or quinolyl. The above examples may be substituted or unsubstituted and the divalent radicals of each heteroaryl example above are non-limiting examples of heteroarylene. Halo or halogen, independently or as part of another substituent, means, unless otherwise stated, an atom of fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). The term halide by itself or as part of another substituent refers to a fluoride, chloride, bromide or iodide atom. In certain embodiments, the halo group is fluorine or chlorine. Additionally, terms such as haloalkyl include monohaloalkyl and polyhaloalkyl. For example, the term Ci-Ce halo-alkyl includes, but is not limited to, n t cnon / zznz / q / υιλι fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. The term heteroalkyl, by itself or in combination with another term, means, unless otherwise stated, a stable non-cyclic or branched linear chain or combinations thereof, including at least one carbon atom and at least one heteroatom. selected from the group consisting of O, N, P, Si and S and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The O, N, P, S, and Si heteroatoms can be located at any interior position of the heteroalkyl group or at the position where the alkyl group is bonded to the rest of the molecule. Examples of heteroalkyl groups include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N (CH3)-CH3, CH2-S-CH2-CH3, -S (O) -CH3, -S (O) 2-CH3, -CH2-CH2-S (O) 2-CH3, -CH=CHO-CH3, -Yes(CH3)3, -CH2-CH=N -OCH3, -CH=CH-N (CH3)-CH3, -O-CH3y O-CH2-CH3. Up to two or three heteroatoms may be consecutive such as, for example, -CH2-NH-OCH3 and -CH2-O-YES(CH3) 3. When heteroalkyl is mentioned, followed by citations of specific heteroalkyl groups, such as -CH2O- CH3, -NRBRCo or similar, it is understood that the terms heteroalkyl and -CH2OCH3 or -NRBRC are not redundant or mutually exclusive. Rather, specific heteroalkyl groups are mentioned to add clarity. Thus, the term heteroalkyl not n t cnon / zznz / q / υιλι is to be interpreted herein as excluding specific heteroalkyl groups, such as -CH2O-CH3, NRBRCo like. Similarly, the term heteroalkylene, by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited to, by CH2O- and -CH2CH2O- . A heteroalkylene group can be described as, for example, a 2-7 membered heteroalkylene, where the term members refers to the non-hydrogen atoms within the moiety. For heteroalkylene groups, heteroatoms can also occupy either one or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamine, and the like). Furthermore, for alkylene and heteroalkylene linker groups, an orientation of the linker group is not implied by the direction in which the linker group formula is written. For example, the formula -C(O)2R'- can represent both -C (O)2R' and -R'C (O)2-. Heteroaryl refers to a radical of a 5-10 membered 4n+2 monocyclic or bicyclic aromatic ring system (e.g., having 6 or 10 π electrons compared to a cyclic arrangement) having ring carbon atoms and 1 -4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is n t cnon / zznz / q / υιλι independently selected from nitrogen, oxygen and sulfur (5-10 membered heteroaryl). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valency permits. Bicyclic heteroaryl ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes ring systems where the heteroaryl ring, as defined above, is fused with one or more aryl groups where the point of attachment is on the aryl or heteroaryl ring and, in such instances, the number of members of the ring designates the number of ring members in the fused ring system (aryl / heteroaryl). Bicyclic heteroaryl groups where a ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment may be on a ring, i.e., the ring bearing a heteroatom (e.g., 2- indolyl) or the ring that does not contain a heteroatom (for example, 5-indolyl). A heteroaryl group can be described as, for example, a 6-10 membered heteroaryl, where the term members refers to the non-hydrogen ring atoms within the moiety. In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided n t cnon / zznz / q / υιλι in the aromatic ring system, wherein Each heteroatom is independently selected from nitrogen, oxygen and sulfur (5-10 membered heteroaryl). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected. , of nitrogen, oxygen and sulfur (5-8 membered heteroaryl). In some embodiments, a heteroaryl group is a 56-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen and sulfur (5-6 membered heteroaryl). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen and sulfur. Each instance of a heteroaryl group may be, independently, optionally substituted, that is, unsubstituted (an unsubstituted heteroaryl) or substituted (a substituted heteroaryl) with one or more substituents. In certain embodiments, the heteroaryl group is 5-14 membered unsubstituted heteroaryl. In certain embodiments, the heteroaryl group is 5-14 membered substituted heteroaryl. Exemplary 5-membered heteroaryl groups containing a heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing a heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing a heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, n t cnon / zznz / q / υιλι benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl and quinazolinyl. Examples of representative heteroaryls include the following formulas: n j cnon / zznz / q / υιλι wherein each Y is selected from carbonyl, N, NR65, O and S; and R65 is, independently, hydrogen, Ci-Cs alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Ce~C10 aryl and 5-10 membered heteroaryl. Cycloalkyl refers to a radical of a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms (C3-C10 cycloalkyl) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (Cg-Cg cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (C3-C6 cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (C3-C6 cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (C5-C10 cycloalkyl). A cycloalkyl group can be described as, for example, a C4-C7-membered cycloalkyl, where the term members refers to the non-hydrogen ring atoms within the moiety. Exemplary C3-C6 cycloalkyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C¿), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce), and the like. Exemplary C3-C8 cycloalkyl groups include, without limitation, C3-C6 cycloalkyl groups, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (Cs), cyclooctenyl ( Cs), cubanyl (Cg), bicyclo[1,1,1]pentanyl (C5), bicyclo[2,2,2]octanyl (Cs), bicyclo[2,1,1]hexanyl (Ce), bicyclo[3 ,1,1]heptanyl (C7), and the like. Exemplary C3-C10 cycloalkyl groups include, without limitation, the aforementioned n t cnon / zznz / q / υιλι C3-C8 cycloalkyl groups, as well as cyclononyl (Cg), cyclononenyl (Cg), cyclodecyl (Cío), cyclodecenyl (Cío ), octahydro-lH-indenyl (C9), decahydronaph talenyl (Cio), spiro[4,5] decanyl (Cio), and the like. As the above examples illustrate, in certain embodiments, the cycloalkyl group is monocyclic (monocyclic cycloalkyl) or contains a fused, bridged or spiro ring system such as a bicyclic system (bicyclic cycloalkyl) and may be saturated or partially unsaturated. Cycloalkyl also includes ring systems where the cycloalkyl ring, as defined above, is fused with one or more aryl groups where the point of attachment is on the cycloalkyl ring and in such instances, the number of carbons continues to designate the amount of carbons in the cycloalkyl ring system. Each instance of a cycloalkyl group may be, independently, optionally substituted, that is, unsubstituted (an unsubstituted cycloalkyl) or substituted (a substituted cycloalkyl) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3-C10 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-C10 cycloalkyl. In some embodiments, cycloalkyl is a monocyclic saturated cycloalkyl group having 3 to 10 ring carbon atoms (C3-C10 cycloalkyl). In some n t cnon / zznz / q / υιλι embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (Cj-Cs cycloalkyl). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (Cs-Cs cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (Cs-Ce cycloalkyl). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (C5-C10 cycloalkyl). Examples of Cs-Cs cycloalkyl groups include cyclopentyl (C5) and n j cnon / zznz / q / υιλι cyclohexyl (C5). Examples of C3-C6 cycloalkyl groups include the aforementioned C5-C6 cycloalkyl groups, as well as cyclopropyl (C3) and cyclobutyl (C4) Examples of C3-C8 cycloalkyl groups include the aforementioned CsCe cycloalkyl groups, as well as cycloheptyl ( C?) and cyclooctyl (Cs). Unless otherwise specified, each instance of a cycloalkyl group is, independently, unsubstituted (an unsubstituted cycloalkyl) or substituted (a substituted cycloalkyl) with one or more substituents. In certain embodiments, the cycloalkyl group is unsubstituted C3-C10 cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C3-C10 cycloalkyl. Heterocyclyl or heterocyclic refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatomic groups, where each heteroatomic group is independently selected from nitrogen. , oxygen, sulfur and oxidized forms of sulfur (e.g. 8, S (O) and 8(0)2), boron, phosphorus and silicon (3-10 membered heterocyclyl). In heterocyclyl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valency permits. A heterocyclyl group may be monocyclic (monocyclic heterocyclyl) or a fused, bridged or spiro ring system such as a bicyclic system (bicyclic heterocyclyl) and may be saturated or may be partially unsaturated. Bicyclic heterocyclyl ring systems may include one or more heteroatoms in one or both rings. Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is on the cycloalkyl ring or heterocyclyl ring or ring systems, wherein the heterocyclyl ring , as defined above, fuses with one or more aryl or heteroaryl groups, where the point of attachment is on the heterocyclyl ring and in such instances, the number of ring members continues to designate the number of ring members in the heterocyclyl ring system. A heterocyclyl group can be described as, for example, a 3-7 membered heterocyclyl, where the term members refers to the non-hydrogen ring atoms, i.e., n t cnon / zznz / q / υιλι carbon, nitrogen, oxygen , sulfur and oxidized forms of sulfur (e.g., S, S(O) and S(O), boron, phosphorus and silicon within the remainder. Each instance of heterocyclyl may be, independently, optionally substituted, e.g., no substituted (an unsubstituted heterocyclyl) or substituted (a substituted heterocyclyl) with one or more substituents. In certain embodiments, the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. substituted member. In certain embodiments, the heterocyclyl group is substituted 4-6 membered heterocyclyl. In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g. S, S(O) and S(O)2), boron, phosphorus and silicon (5-10 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g. S, S(O) and 8(0)2) (5-8 membered heterocyclyl). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic n j cnon / zznz / q / υιλι ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is selected, from independently, of nitrogen, oxygen, sulfur and oxidized forms of sulfur (for example, S, S(O) and S(O)2) (5-6 membered heterocyclyl). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g., S, S(O) and S(O)2). In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g., S, S(O) and S(O)2). In embodiments, the 5-6 membered heterocyclyl has a ring heteroatom selected from nitrogen, oxygen, sulfur and oxidized forms of sulfur (e.g., S, S(O) and S(O)2). Exemplary 3-membered heterocyclyl groups containing a heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl containing a heteroatom include, without limitation, azetidinyl, oxetanyl and titanyl. Exemplary 5-membered heterocyclyl groups containing a heteroatom include, without limitation, tetrahydrofuranoyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two n t cnon / zznz / q / υιλι heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing a heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl and tianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Heterocyclyl groups containing 6 members, for example two heteroatoms, include, without limitation, triazinanyl. Exemplary 7-membered heterocyclyl groups containing a heteroatom include, without limitation, azepanyl, oxepanyl and tiepanyl. Exemplary 8-membered heterocyclyl groups containing a heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. 5-membered heterocyclyl groups fused to an exemplary Ce aryl ring (also referred to herein as a 5,6-bicyclic heterocyclic ring) include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like. 6-membered heterocyclyl groups fused to an exemplary aryl ring (also referred to herein as a 6,6-bicyclic heterocyclic ring) include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like. Particular examples of heterocyclyl groups are shown in the following illustrative examples: n t cnon / zznz / q / υιλι where each W is selected from CR67, C(R67)2, NR67, 0 and S; and each Y is selected from NR67, O and S; and R67 is, independently, hydrogen, Ci-Ce alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, Cg-Cio aryl and 5-10 membered heteroaryl. These heterocyclyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (e.g., amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl , aryloxy, azido, carboxyl, cyano, cycloalkyl, halogen, hydroxy, keto, nitro, thiol, -S-alkyl, -S-aryl, -S(O)-alkyl, -S(O)-aryl, —S ( O)2-alkyl and -S (O)2-aryl. Substituent groups include carbonyl or thiocarbonyl providing, for example, lactam and urea derivatives. Nitrogen-containing heterocyclyl group means a 4- to 7-membered non-aromatic cyclic group containing at least one nitrogen atom, for example, but not limited to, morpholine, piperidine (for example, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (ex vivo, 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine and N-alkylpiperazines such as N-methylpiperazine. Particular examples include azetidine, piperidone and piperazone. Amino refers to the radical -NR70R71, where R70 and R71 are each, independently, hydrogen, Ci-Cg alkyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl, CgC10 aryl and 5-10 membered heteroaryl. In some embodiments, amino refers to NH2. Glano refers to the radical -CN. Hydroxy or hydroxyl refers to the -OH radical. In some embodiments, one or more of the nitrogen atoms of a described compound if present are oxidized to the corresponding N-oxides. Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups, as defined herein, are optionally substituted (e.g., substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl, alkynyl n j cnon / zznz / q / υιλι substituted or unsubstituted, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl). In general, the term substituted, whether preceded by the term optionally or not, means that at least one hydrogen present in a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which, after substitution, results in a stable compound, for example, a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination or other reaction. Unless otherwise indicated, a substituted group has a substituent at one or more substitutable positions in the group and when more than one position in any given structure is substituted, the substituents are the same or different at each position. The term substituted is intended to include a substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound. The present description contemplates each and every one of such combinations, in order to reach a stable compound. For the purposes of this description, heteroatoms such as nitrogen may have hydrogen substituents and / or any appropriate n t cnon / zznz / q / υιλι substituents as described herein, where they satisfy the valences of the heteroatoms and give as resulting in the formation of a stable residue. Two or more substituents may optionally be attached to form aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups. These so-called ring-forming substituents are usually, but not necessarily, attached to a cyclic backbone. In one embodiment, the ring-forming substituents are attached to adjacent members of the backbone. For example, two ring-forming substituents attached to adjacent members of a cyclic backbone create a fused ring structure. In another embodiment, the ring-forming substituents are linked to a single member of the backbone. For example, two ring-forming substituents attached to a single member of a cyclic backbone create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the backbone. A counterion or anionic counterion is a negatively charged group associated with a cationic quaternary amino group to maintain electronic neutrality. Exemplary counterions include halide ions (ex vivo, F~, Cl~, Br_, I“), NOa, CIO4·, OH-, H2PO4·, HSO4·, sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate , n j cnon / zznz / q / υιλι benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-l-sulfonic acid 5sulfonate, ethane-l-sulfonic acid 2-sulfonate, and the like) and carboxylate ions (e.g. , acetate, ethanoate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, and the like). The term "pharmaceutically acceptable salts" is intended to include salts of the active compounds that are prepared with relatively non-toxic acids or bases, depending on the particular substituents found in the compounds described herein. When the compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either in pure form or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts, or a similar salt. When the compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either in pure form or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as n t cnon / zznz / q / υιλι hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic or phosphorous acids. , and the like, as well as salts derived from relatively non-toxic organic acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, italic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate, and the like, and salts of organic acids such as glucuronic or galactunoric acids and the like (see, for example, Berge et al, Journal of Pharmaceutical Science 66: 1-19 (1977)). . Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted to base or acid addition salts. Other pharmaceutically acceptable carriers known to those skilled in the art are suitable for the present description. Salts tend to be more soluble in aqueous or other proton solvents than the corresponding free base forms. In other cases, the preparation may be a powder lyophilized in a first buffer, for example, in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol in a pH range of 4.5 to 5.5, which is combined with a second shock absorber before use. Therefore, the compounds of the present disclosure may exist in the form of salts, such as with pharmaceutically acceptable acids. This description includes salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+) tartrates, (-)-tartrates or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid. These salts can be prepared by methods known to those skilled in the art. The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as its solubility in polar solvents. In addition to the salt forms, the present disclosure provides compounds, which are in prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present description. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Certain compounds of the present disclosure may exist in unsolvated forms as well as solvated forms, which includes hydrated forms. In general, solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by this description and are intended to fall within the scope of this description. As used herein, the term "salt" refers to acid or base salts of the compounds used in the methods of the present description. Illustrative examples of acceptable salts include mineral acids (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like), salts of organic acids (acetic acid, propionic acid, glutamic acid, citric acid, and the like), quaternary ammonium salts (methyl iodide, ethyl iodide, and the like). Certain compounds of the present description have n j cnon / zznz / q / υιλι asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R) - or (S) - or, as (D) - or (L) - for amino acids , and individual isomers, are encompassed within the scope of the present description. The compounds of the present description do not include those known in the art to be too unstable to synthesize and / or isolate. The present description is intended to include compounds in racemic and optimally pure forms. The optically active (R)- and (S)-, or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved by conventional techniques. Where the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless otherwise specified, the compounds are intended to include both E and Z geometric isomers. As used herein, the term isomers refers to compounds that have the same number and type of atoms, and therefore the same molecular weight, but that differ in the structural arrangement or configuration of the atoms. The term tautomer, as used here, refers to one of two or more structural isomers that exist in n t cnon / zznz / q / υιλι equilibrium and are easily converted from one isomeric form to another. It will be apparent to a skilled person that certain compounds of this description may exist in tautomeric forms, and that all such tautomeric forms of the compounds are within the scope of the description. Other Definitions Treat or treatment includes preventing or eliminating the onset of symptoms, complications or biochemical signs of a disease, alleviating or improving symptoms, or stopping or inhibiting the advanced development of the disease, condition or disorder. Treat or treatment includes any effect, for example, diminution, reduction, modulation or elimination, which results in improvement of the condition, disease, disorder and effect. For example, certain methods herein treat cancer by slowing or reducing or preventing the occurrence, growth, metastasis or progression of cancer or by decreasing a symptom of cancer. The term treat and its conjugations include the prevention of an injury, pathology, condition or disease (for example, the prevention of the development of one or more symptoms of a disease, disorder, or condition described herein) An effective amount is an amount sufficient to achieve a stated purpose (for example, to achieve the effect for which it is administered, to treat a disease, to reduce an enzyme activity, to increase an enzyme activity, or reduce one or more symptoms of a disease or condition). An example of an effective amount is an amount sufficient to contribute to the treatment, prevention, or reduction of one or more symptoms of a disease, which could also be referred to as a therapeutically effective amount. A prophylactically effective amount of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, for example, preventing or delaying the onset (or recurrence) of an injury, disease, pathology or condition. reduce the probability of the appearance (or reappearance) of an injury, disease, pathology or condition or its symptoms. The complete prophylactic effect does not necessarily occur upon administration of one dose, and may occur only after administration of a series of doses. Therefore, it is possible that a prophylactically effective amount may be administered in one or more administrations. The exact amounts will depend on the purpose of the treatment and will be determinable by one skilled in the art using known techniques (see, ex vivo, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Edition, 2003, Gennaro, Ed., Lippincott, Williams and Wilkins). A reduction of one or more symptoms (and grammatical equivalents of this expression) means the decrease in the severity or frequency of the symptom(s) or elimination of the symptom(s). The terms control or control experiment are used according to their usual meanings and refer to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for the omission of a procedure, reagent or variable from the experiment. . In some cases, the control is used as a comparison standard to evaluate experimental effects. The term bringing into contact is used according to its usual meaning and refers to the process of allowing at least two distinct species (e.g., chemical compounds including biomolecules or cells) to become sufficiently proximal to each other to react, interact, or touch. physically. However, it should be kept in mind that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate compound of one or more of the added reagents that can be produced in the reaction mixture. The term "bring into contact" may include allowing two species to react, interact, or physically touch each other, wherein the two species may be a compound described herein and a protein or enzyme, e.g. a protein tyrosine phosphatase, for example, nonreceptor protein tyrosine phosphatase type 2 (PTPN2) or nonreceptor protein tyrosine phosphatase type 1 (PTP1B). As defined herein, the terms inhibition, inhibits, inhibiting and the like in reference to an inhibitory protein interaction (e.g., antagonist) mean to negatively affect (e.g., decrease) the activity or function of the protein relative to to the activity or function of the protein in the absence of the inhibitor. In some embodiments, inhibition refers to the reduction of a disease or symptoms of the disease. In some embodiments, inhibition refers to a reduction in the activity of a signal transduction pathway or signaling pathway. Therefore, inhibition includes, at least in part, the partial or complete blockage of stimulation, decrease, prevention or delay of activation, or deactivation, desensitization or downregulation of signal transduction or enzyme activity or the amount of a protein. In some embodiments, inhibition refers to a reduction in the activity of a protein tyrosine phosphatase, for example, non-receptor protein tyrosine phosphatase type 2 (PTPN2) or non-receptor protein tyrosine phosphatase type 2. 1 (PTP1B) . Thus, inhibition may include, at least in part, partially or completely reducing stimulation, decreasing or reducing activation or inactivation, desensitization or downregulation of signal transduction or enzyme activity or the amount of a protein tyrosine phosphatase, for example, nonreceptor protein tyrosine phosphatase type 2 (PTPN2) or nonreceptor protein tyrosine phosphatase type 1 (PTP1B). The terms patient or subject in need refer to a living organism that suffers from or is prone to a disease or condition that can be treated by the administration of a compound or pharmaceutical composition provided herein. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, monkeys, goats, sheep, cows, deer and other non-mammalian animals. In some embodiments, a patient is a human being. In some embodiments, a patient is a domesticated animal. In some embodiments, a patient is a dog. In some embodiments, a patient is a parrot. In some embodiments, a patient is a livestock animal. In some embodiments, a patient is a mammal. In some embodiments, a patient is a cat. In some embodiments, a patient is a horse. In some embodiments, a patient is a bovine. In some embodiments, a patient is a canine. In some embodiments, a patient is a feline. In some n t cnon / zznz / q / υιλι modalities, a patient is an ape. In some embodiments, a patient is a monkey. In some embodiments, a patient is a mouse. In some embodiments, a patient is an experimental animal. In some embodiments, a patient is a rat. In some embodiments, a patient is a hamster. In some embodiments, a patient is a test animal. In some embodiments, a patient is a newborn animal. In some embodiments, a patient is a newborn human being. In some embodiments, a patient is a newborn mammal. In some embodiments, a patient is an elderly animal. In some embodiments, a patient is an elderly human being. In some embodiments, a patient is an elderly mammal. In some embodiments, a patient is a geriatric patient. The terms disease, disorder or condition refer to a state of health or health condition of a patient or subject or capable of being treated with a compound, pharmaceutical composition or method provided herein. In some embodiments, the compounds and methods described herein comprise the reduction or elimination of one or more symptoms of the disease, disorder or condition, for example, by administering a compound described herein one of its salts. pharmaceutically acceptable or a pharmaceutical composition comprising a compound described herein or one of its pharmaceutically acceptable salts and a pharmaceutically acceptable carrier. The term "signaling pathway" as used herein refers to a series of interactions between cellular components and optionally extracellular components (e.g., proteins, nucleic acids, small molecules, ions, lipids) that convey a change in a component. to one or more other components, which in turn can transmit a change to additional components, which optionally propagates to other components of the signaling pathway. The terms pharmaceutically acceptable excipient and pharmaceutically acceptable vehicle refer to a substance that assists in the administration of an active agent and its absorption by a subject and that can be included in the compositions of the present description without causing a significant adverse toxicological effect on the subject. patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrating agents, lubricants, coatings, sweeteners, flavorings, saline solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose starch esters of fatty acids, n t cnon / zznz / q / υιλι hydroxymethylcellulose, polyvinylpyrrolidine, and dyes, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants and / or aromatic substances and the like that do not react in any way. unfavorably with the compounds of the description. One skilled in the art will recognize that other pharmaceutical excipients are useful in the present description. The term preparation is intended to include the formulation of the active compound with encapsulating material as a support that provides a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus associated with it. Similarly, stamps and pads are included. Tablets, powders, capsules, pills, tablets and lozenges may be used as solid dosage forms suitable for oral administration. As used herein, the term administration encompasses oral administration, suppository administration, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration or implantation of a slow release device, for example, a miniosmotic pump, to a subject n t cnon / zznz / q / υιλι. Administration is carried out by any route, including parenteral and transmucosal routes (for example, buccal, sublingual, palatal, gingival, nasal, vaginal, rectal or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular and intracranial administration. Other modes of administration include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. Coadminister means that a compound or composition described herein is administered at the same time, just before or just after the administration of one or more additional therapies (ex vivo, anticancer agent, chemotherapeutic or immunotherapeutic agent). The compounds or compositions described herein may be administered alone or may be co-administered to the patient. Coadministration is intended to include the simultaneous or sequential administration of the compound or composition individually or in combination (more than one compound or agent). Therefore, the preparations can also be combined, if desired, with other active substances (e.g. to reduce metabolic degradation). The term PTPN2 as used herein refers to non-receptor protein tyrosine phosphatase type 2. The term PTPN1 refers to non-receptor protein tyrosine phosphatase type 1 (PTPN1), also known as as protein tyrosine phosphatase-ΙΒ (PTP1B), n t cnon / zznz / q / υιλι Compounds Described herein, for example, is a compound of Formula (I): EITHER R1F °'SNH Rl^L / L / Ñ Ϊ jC JCr6 r7r3oh R4R5(D; or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from the group consisting of hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, -O-C1-6 alkyl, N(Ra)-Ci-g alkyl and -Ci-g-heterocyclyl 5-6 membered alkylene; wherein Ci-e alkyl, C3-6 cycloalkyl, -O-C1-6 alkyl, -N(Ra)-Ci-s alkyl and -Ci-g alkylene-5-6 membered heterocyclyl may be optionally substituted on one or more carbons available with one, two, three or more substituents each independently selected from Rg; and wherein if the 5-6 membered -Ci-6-alkylene heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; R2 is selected from the group consisting of hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -CH2-0-Ci-6 alkyl, -CH2-N (Ra) -Ci-6 alkyl, C2-6 alkyl, C2-6 alkenyl, -O-C1-6 alkyl, -N (Ra) -Ci-6 alkyl, -S (O)«-alkyl Ci-6, -C(O)-N(Ra)C1-6alkyl, -N(Ra)-C(O)-C1-6alkyl, -O-C(O)-N(Ra)-Ci6alkyl, - N(Ra)—C(O)-O-Ci-ealkyl, -C3-6cycloalkyl, -0C3-6cycloalkyl, Ci-6alkylene-C3-6cycloalkyl, -Ci-6alkenylene-C3-6cycloalkyl, -O-alkylene Ci-e-C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, O-alkylene Ci-6-5-6 membered heteroaryl, -O-4-6 membered heterocyclyl , -N(Ra)-4-6-membered heterocyclyl, 4-6-membered Ci-g-heterocyclyl alkylene and -O-4-6-membered Cie-heterocyclyl alkylene; where -CH2-0-C1-6 alkyl, -CH2-N (Ra)-C1-6 alkyl, C2-6 alkyl, C2-6 alkenyl, -O-Ci-e alkyl, -N (Ra)-alkyl Ci6, -S (O) «-C1-6 alkyl, -C (0)-N (Ra)-C1-6 alkyl, -N (Ra)-C (0) Ci-e alkyl, -O-C (O) -N(Ra)-Ci-g alkyl, -N(Ra)-C(O)-O-C1-6 alkyl, -C3-6 cycloalkyl, -O-C3-6 cycloalkyl, -C3-gcycloalkylene-alkylene 6, -Ci-6alkenylene-C3-6cycloalkyl, -0Ci-6alkylene-C3-6cycloalkyl, 5-6 membered heteroaryl, O-Ci-6alkylene~5-6 membered heteroaryl, 4-6 heterocyclyl -0-4-6-membered heterocyclyl, -N(Ra) 4-6-membered heterocyclyl, -4-6-membered Ci-g-alkylene heterocyclyl and -O-4-6-membered Ci-g-heterocyclyl alkylene members may be optionally substituted on one or more available carbons with one, two, three or more substituents each independently selected from RC and wherein if the n t cnon / zznz / q / υιλι 5-6 membered heteroaryl, 4-6-membered heterocyclyl, N(Ra)-4-6-membered heterocyclyl, -alkylene 4-6-membered heterocyclyl or -O-alkylene 4-6-membered Ci-g-heterocyclyl contains one nitrogen atom of the substitutable ring, that ring nitrogen atom may be optionally substituted with Rh; or R1 and R2, taken together with the atoms to which they are attached, form 5-6 aryl or heteroaryl members; wherein aryl or heteroaryl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, Ci-6 alkyl and Ci-g alkoxy; wherein Ci-6 alkyl and Ci-6 alkoxy may be optionally substituted with one, two, three or more substituents each independently selected from Rp; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, -NH2, -Ci-g alkyl, -O-Ci-g alkylene, -0Ci-6 alkylene, C3-6 cycloalkylene, -O-C1-6-N alkylene (Ra)-C(O)-0C1-6alkyl, -N(Ra)-C1-6alkyl, -N(Ra)-C1-6alkyleneC3-6cycloalkyl, -S(O)«-Ci-ealkyl , -C(O)-N(Ra)-C1-6alkyl, -N(Ra)—C(0)-C1-6alkyl and -4-6-membered Ci-g-heterocyclyl alkylene; where -C1-6alkyl, -O-C1-6alkyl, -0-Ci-6alkylene-C3-6cycloalkyl, -O-C1-6alkylene-N(Ra)-C(0)-O-alkyl Ci6, -N (Ra)-C1-6 alkyl, -N (Ra)-alkylene Ci-e-C3-6 cycloalkyl,_n t cnon / zznz / q / υιλι S (O) w-Ci-6 alkyl, -C (O)-N (Ra)-Ci-6 alkyl, -N (Ra)-C (O)-Ci-6 alkyl and -Ci-6 alkylene_heterocyclyl of 4 -6 members may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from Rg; and wherein if -4-6 membered Ci-6heterocyclyl alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by Rh; R4 is selected from the group consisting of hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl and 4-6 membered -C1-6 alkyleneheterocyclyl; wherein C1-6 alkyl, C3-6 cycloalkyl and -Ci-6 alkylene-4-6 membered heterocyclyl may be optionally substituted on one or more carbons available with one, two, three or more substituents each independently selected , from Rc; and wherein if 4-6 membered Ci-g-heterocyclyl alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; where at least one of R1, R2, R3 and R4 is not hydrogen; R5 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl and -C1-6 alkylene 4-6 membered heterocyclyl; wherein Ci-e alkyl, C3-6 cycloalkyl and -Ci-6 alkylene-4-6 membered heterocyclyl may be optionally substituted on one or more carbons available with one, two, three or more substituents each n t cnon / zznz / q / υιλι selected, independently, from R,a; and wherein if 4-6 membered Ci-6-heterocyclyl alkylene contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; R6 is hydrogen; R7 is hydrogen; R9 is selected, independently, for each occurrence of the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, RaRbN-, RaRbN-C(O)-, RaRbN-SOw- , RaRbN-C (O)-N (Ra)-, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, C1-6 alkylene C3-6 cycloalkylene, -O-Ci-alkylene 6-C3-6cycloalkyl, -(CO)(NRa)-Ci-6alkylene-C3-6cycloalkyl, C1-6alkoxy, C36alkenyloxy, C3-6alkynyl-OXY, C3-6cycloalkoxy, Ci-alkyl 6-C(O)-, Ci-e-O-C alkyl (O) -, C1-6-C alkyl (O)-O-, Ci-6-S(O)w- alkyl, C1-6-N alkyl (Ra )-, Ci-g-N (Ra)-C (O)- alkyl, Ci-g-C (O)N (Ra) alkyl, Ci-g-N (Ra)-C (O)-N (Ra)-alkyl, Ci alkyl -6-N (Ra) -SO„-, C3-6-N cycloalkyl (Ra)-SOW-, Ci-6-SOw-N alkyl (Ra) -, C3-6-N cycloalkyl-SOw-N (Ra)- , 4-6 membered heterocyclyl-SOwN(Ra)-, C1-6 alkoxy-C (O)-N (Ra)-, Ci-e-C alkyl (O)-N (Ra)-C1-6 alkyl-, alkyl Ci-g-N (Ra) -C (O) -Ci-g-alkyl, -P (O) (01-3 alkyl)2 and Ci-g-C1-6 alkyl-; where Ci-e alkyl, C26 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, C1-6 alkylene C3-6 cycloalkylene, -O-Ci-6 alkylene-C3-6 cycloalkyl, - (CO) (NRa) -Ci-6 alkylene-C3-6 cycloalkyl, C1-6 alkoxy, C3 alkenyl n t cnon / zznz / q / υιλι 6-oxy, C3-6-alkynyl-OXY, C3-6 cycloalkoxy, Ci-g-C(O)-alkyl, C1-&-O-C(O)-alkyl, C1-6-C(O)-O-alkyl, alkyl C1-&-S (O)w-, Ci-g-N (Ra)- alkyl, Ci-g-N (Ra)-C (O)- alkyl, Ci-g-C (O)N(Ra) alkyl, Ci-6 alkyl -N (Ra)-C (O)-N (Ra) -, Ci-6-N (Ra)-SOW-alkyl, C3-6-N (Ra)-SO«-cycloalkyl, Ci-6-SOw alkyl -N(Ra)-, C3-6_SOW-N(Ra)-cycloalkyl, 4-6-membered heterocyclyl-SOwN(Ra)-, Ci-g-C(O)-alkoxy-N(Ra)Ci-g-C(O)alkyl -N (Ra)-alkyl Ci-g-, alkyl Ci-e-N (Ra) -C (O) -alkyl Ci-g-, -P (O) (alkyl €1-3)2 and alkoxy Ci-g- Ci-6-alkyl may be optionally substituted with one, two, three or more substituents each independently selected from Rp; or 2 R9 on adjacent atoms, together with the atoms to which they are attached, form a 5-6-membered aryl or heteroaryl; Rhse is selected, independently, for each occurrence from the group consisting of C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, -Ci-g-alkyl-C3e cycloalkyl, Ci-6-S alkyl (O)2-, C3-6 cycloalkyl-S(O)2-, 4-6 membered heterocyclyl-S(O) 2-, 4-6 membered heterocyclyl-Ci-6“alkylS(O)2- , 5-6 membered heteroaryl-S (O) 2-, phenyl-S (O) 2-, phenyl-alkyl Ci-6-S(O)2-, alkyl Ci-6-C(O)-, cycloalkyl C1-6C(O)-, Ci-6-C(O)-alkoxy, RaRbN-C(O)-, RaRbN-SO2- and -P(O) (Ci-3)2 alkyl; where C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, -C3-6 alkyl-C3-6 cycloalkyl, C1-6 alkylS(O)2-, C3-6_S(O) cycloalkyl 2-, 4-6 membered heterocyclyl n t cnon / zznz / q / υιλι S(O)2-, 4-6-membered heterocyclyl-Ci-6-alkyl-S(O)2-, 5-6-membered heteroaryl-S (O)2-, phenyl-S (O)2~, phenyl -alkyl Ci-6-S(O)2-, alkyl Ci-g-C(O)-, cycloalkyl 01-6-0(0)-, alkoxy 01-6-0(0)-, RaRbN-C(O) -, RaRbN-S02- and -P(0) (Ci-3 alkyl)2 may be optionally substituted with one, two, three or more substituents each independently selected from Rp; Rp is selected, independently, for each occurrence of the group consisting of halogen, hydroxyl, cyano, Ci-6 alkyl, Ci-6 alkoxy, C3-6 cycloalkyl, 46-membered heterocyclyl, RaRbN-, RaRbN-carbonyl-, RaRbN-SC>2- and RaRbN-carbonylN(Ra)-; Ray Rbse are independently selected, for each occurrence, from the group consisting of hydrogen, C1-6 alkyl and C3-6 cycloalkyl; wherein Ci-e alkyl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, cyano, oxo, hydroxyl and C1-6 alkoxy (optionally substituted with one, two or three atoms of fluorine); o Ray Rb together with the nitrogen to which they are attached form a 4-6 membered heterocyclyl, wherein the heterocyclyl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, cyano, oxo and hydroxyl; y n t cnon / zznz / q / υιλι 100 In some embodiments, one, two, three or more hydrogen atoms of the compound or a pharmaceutically acceptable salt thereof may optionally be deuterium atoms; and where all other atoms of the compound are present in their natural isotopic abundance. For example, in some embodiments, one, two, three or more hydrogen atoms may optionally be deuterium atoms with one, two, three or more groups each independently selected from R1, R2, R4, R5, R6 , R7 and R9. In some embodiments, R1 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting, ex vivo, of hydrogen, deuterium, chlorine and fluorine. In some embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is 4-6 membered heterocyclyl; wherein R2 may be optionally substituted on one or more available carbons by one, two or three substituents each independently selected from R9, wherein if 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent selected from Rh. For example, in some embodiments R2 of the compound or a pharmaceutical salt thereof is 4-6 membered heterocyclyl; wherein R2 may be optionally substituted on one or more available carbons with one, two or three substituents each selected, so n j cnon / zznz / q / υιλι 101 independent, from the group consisting of hydrogen and Cie alkyl; and wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of hydrogen, Ci-g alkyl (optionally substituted with one, two or three fluorine atoms ), -Cig-C3-6 cycloalkyl, Ci-e-C(O)-cycloalkyl, Ci-g-S(O)2 alkyl (optionally substituted with cyano, methoxy, hydroxyl, -RaRbN or one, two or three fluorine atoms) , C3-s-cycloalkyl-S(O)2-, 4-6-membered heterocyclyl-S (O)2-, 4-6-membered heterocyclyl-Ci-6_S(O)2-alkyl, 5-6-membered heteroaryl-S (O)2, phenyl-S (O) 2-, phenyl-C1-6 alkyl-S (O) 2- (optionally substituted with RaRbN-) and -P (O) (62-3 alkyl)2. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n j cnon / zznz / q / υιλι 102 n t cnon / zznz / q / υιλι n t cnon / zznz / q / υιλι In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is 5-6 membered heteroaryl; wherein R2 may be optionally substituted on one or more available carbons by one, two or three substituents each independently selected from R9, and wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent selected from Rh. For example, in some embodiments R2 of the compound or a 104 pharmaceutically acceptable salt of this is 5-6 membered heteroaryl; wherein R2 may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consisting of hydrogen, cyano, Ci-g alkyl, Ci-6 alkoxy and -P(O ) (alkyl 01-3)2; and wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of hydrogen, Ci-6alkyl-C3-6cycloalkyl and C3-6~S cycloalkyl. (O)2-. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n j cnon / zznz / q / υιλι In further embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-C1-6 alkylene 4-6 membered heterocyclyl, wherein R2 may be optionally substituted on one or more available carbons by one, two or three substituents each selected from mode 105 independent of Rd (optionally 2 R$ on adjacent atoms, together with the atoms to which they are attached, form a 5-6 membered aryl or heteroaryl), and where if R2 contains a substitutable ring nitrogen atom, that atom The ring nitrogen may be optionally substituted by a substituent selected from Rh. For example, in some embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-alkylene Ci-6-heterocyclyl 4-6 members, wherein R2 may be optionally substituted on one or more available carbons by one, two or three substituents each independently selected from the group consisting of hydrogen, halogen, hydroxyl and Οι-e alkyl (optionally substituted by one, two or three fluorine atoms), optionally wherein the heterocycle of R2 may be substituted on two adjacent atoms, and the two substituents, together with the atoms to which they are attached, form a fused phenyl, and wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent selected from the group consisting of hydrogen, Ci-6 alkyl and Ci-g-S(O)2- alkyl. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n j cnon / zznz / q / υιλι 106 n j cnon / zznz / q / υιλι In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is 5-6 membered -O-Cy-6heteroaryl alkylene. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: In additional modalities R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -C2-6 alkyl, C2-6 alkenyl and C3-6 cycloalkyl; 107 wherein R2 may be optionally substituted with one, two, three or more substituents each selected independently of R9. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -C2-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, -Ci-e-C3-6 cycloalkylene and alkenylene Ci-g-C3-6 cycloalkyl; wherein R2 may be optionally substituted with one, two, three or more substituents each independently selected from the group consisting of cyano, chloro, fluorine, hydroxyl, C1-6 alkoxy, phenyl and RaRbN-. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n t cnon / zznz / q / υιλι In other embodiments, R2 of the compound or a salt 108 pharmaceutically acceptable of this is -O-alkyl Ci-6,' where R2 may optionally be substituted with one, two, three or more substituents each selected independently of Rg. For example, in some embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-Ci-e alkyl; wherein R2 may be optionally substituted with one, two, three or more substituents each independently selected from the group consisting of cyano, deuterium, chloro, fluorine, hydroxyl, oxo, alkoxy Ci-g (optionally n t cnon / zznz / q / υιλι substituted with one, two, three fluorine atoms), C3e cycloalkoxy, -O-Ci-6alkylene-C3-6cycloalkyl, -(CO)-(NRa)-Cig-alkylene-C3-6cycloalkyl, C1-6alkyl- O-C(O)-, RaRbN- (where Rb is optionally substituted with -OCH3 or -OCF3), Ci-eN alkyl (Ra)- (where C1-6 alkyl is optionally substituted with fluoro, cyano or -OCH3), RaRbN -C(O)-, -P(O) (01-3 alkyl)2, C1-6-N alkyl (Ra)-0 (O)-, C1-6-N alkyl (Ra)-0 (O) -N (Ra) -, alkyl C1-6-SO2-N (Ra) -, C3-6-SO2-N cycloalkyl (Ra) - and 4-6-membered heterocycloalkyl-S02-N (Ra) -. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: -OCH3, -OCD3, -OCF3, -OCHF2, -OCH2CH3, ^0- 109 n t cnon / zznz / q / υιλι 110 In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-C3-6 cycloalkyl or 4-6 membered O-heterocyclyl; wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by a substituent selected from Rh. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is -O-C3-6 cycloalkyl or -O-4-6 membered heterocyclyl; wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent 111 selected from the group consisting of C1-6-SO2-N alkyl (Ra) - and C3-6-SO2-N cycloalkyl (Ra) -. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n j cnon / zznz / q / υιλι In still other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -N(Ra)-C1-6 alkyl, wherein R2 may be optionally substituted with one, two or three substituents each independently selected from R9. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is -N(Ra)-C1-6 alkyl, wherein R2 may be optionally substituted with one, two or three substituents each independently selected from the group consisting of fluoro, -C(O)OH, cyano, oxo, RaRbN-, Ci-g alkoxy, phenyl, -C3-6 cycloalkyl, C3-6 cycloalkyl-SO2-N (Ra) - and - (CO) - (NRa)-C1-6alkyleneC3-6cycloalkylene. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: 112 n t cnon / zznz / q / υιλι In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-C3-6Cy-6cycloalkylene, wherein R2 may be optionally substituted by one, two or three substituents, each independently selected from Rg. For example, in some embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-Cy-6alkylene-C3-6alkylene, wherein R2 may be optionally substituted with one, two or three substituents each selected independently of the group that consists of fluoro, hydroxyl, RaRbN-, cyano and C1-3 alkyl; wherein C1-3 alkyl may be optionally substituted with a substituent selected from the group consisting of hydroxyl, RaRbN-, cyano and C1-3 alkoxy. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex 113 n j cnon / zznz / q / υιλι In some embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -O-C(O)-N(Ra)-alkyl. Ci-6. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is represented, by I HEARD A A ArO N example: H In further embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -N(Ra)-4-6 membered heterocyclyl, wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent 114 selected from Rh. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is N(Ra)-4-6 membered heterocyclyl, wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted. by a substituent selected from the group consisting of C1-6-SO2-N alkyl (Ra) - and C3-6-SO2-N cycloalkyl (Ra) -. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: n j cnon / zznz / q / υιλι In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is -C1-6 alkylene 4-6 membered heterocyclyl, wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted by a substituent selected from Rh. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is 4-6-membered Ci-6-alkylene heterocyclyl, wherein if R2 contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted with a substituent 115 selected from the group consisting of Ci-6 alkyl, Ci6-SO2-N alkyl (Ra) - and C3-6-SO2-N cycloalkyl (Ra) -, where Ci6 alkyl may be optionally substituted with one, two or three n j cnon / zznz / q / υιλι fluorine atoms. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: In some embodiments, R2 is the compound or a pharmaceutically acceptable salt thereof that is selected from the group consisting of, for example, HA -CHF2, -CH2OH, -CH2OCH3, -CH2CN, -OH, and In other embodiments, R2 of the compound or a pharmaceutically acceptable salt thereof is halogen. For example, in some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of, ex vivo: fluorine, chlorine and bromine. For example in 116 some embodiments R2 of the compound or a pharmaceutically acceptable salt thereof is bromine. n t cnon / zznz / q / υιλι In some embodiments, R1 and R2 of the compound or a pharmaceutically acceptable salt thereof taken together with the atoms to which they are attached form a 5-membered heteroaryl. For example, in some embodiments R1 and R2 taken together with the atoms to which they are attached form, for example, furanyl. For example, in some embodiments the compound of Formula (I) is represented by: In some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is hydrogen. In some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of OH and NH2. In some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is -N(Ra)-Ci-6 alkyl, wherein -N(Ra)-Ci-e alkyl may optionally be substituted by one, two or three substituents which are selected each independently of the group consisting of fluoro and hydroxyl. For example, in some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of: 117 n t cnon / zznz / q / υιλι In other embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is -N(Ra)-C3-6Cy-ecycloalkylene, wherein -N(Ra)-Ci-6alkylene-C3-6cycloalkylene may be optionally substituted by one, two or three substituents, each independently selected from the group consisting of fluoro and hydroxyl. For example, in some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is represented by: In some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is -O-Ci-e alkyl; wherein -O-Ci-e alkyl may be optionally substituted with one, two, three or more substituents each independently selected from the group consisting of fluorine, hydroxyl and RaRbN. For example, in some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of: In some embodiments, R3 of the compound or a salt 118 pharmaceutically acceptable of this is -O-alkylene Ci-6C3-6cycloalkyl, wherein -O-alkyleneCi-6-C3-6cycloalkyl n t cnon / zznz / q / υιλι may be optionally substituted by one, two or three substituents , each independently selected from the group consisting of fluoro and hydroxyl. For example, in some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is In other embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is -O-C1-6-alkylene-N(Ra) O (O)-O-Ci-e alkylene. For example, in some embodiments, R3 of the compound or a pharmaceutically acceptable salt thereof is O1 In other embodiments, R4 of the compound or a pharmaceutically acceptable salt thereof is hydrogen. In further embodiments, R5 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen, deuterium, bromine, chlorine and fluorine. In other embodiments, R6 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen and deuterium. In further embodiments, R7 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen and deuterium. In In some embodiments, all atoms of the compound of Formula (I) of the compound or a pharmaceutically acceptable salt thereof are present in their naturally occurring isotopic abundance. Also described herein is a compound represented by the formula (Ha): EITHER F Oi?g—NH R2¿ Y X \ / ÑLla ar°r7 R5(lia) or a pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of -O- and -N(Ra)-; L is linear or branched Ci-s alkylene, wherein the Ci-s alkylene is optionally substituted with one or more hydroxyl or one or more fluoro; R2-TTase is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-cycloalkyl-SO2-N (Ra)-, C1-6 alkyl-SO2-N (Ra)-, phenyl, heteroaryl 5-6 membered, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein C1-2 alkoxy, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each selected, so independent, from the group consisting of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl one, two three halogens) and C1-2 alkoxy n t cnon / zznz / q / υιλι 120 (optionally replaced with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence of the group consisting of hydrogen and C1-3 alkyl (optionally substituted with one or more halogens, cyano or C1-2 alkoxy). In some embodiments, X of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -O-, -N(H)- and -N(CH3)-. In other embodiments, L is of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of n t cnon / zznz / q / υιλι 121 n t cnon / zznz / q / υιλι where * and # represent the covalent attachment points to R2-11 and X, respectively. In further embodiments, R2-11 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen, cyano, -NH2, -N(CH3)2, N(H)CH2CF3, -N (CH3) (CH2CH3) , -N (CH3) (CH2CH2OCH3) , N(CH3)(CH2CH2CN) , -OCH3, -OCF3, Pharmaceutically acceptable this is selected from the group consisting of hydrogen, deuterium and fluorine. 122 Also described herein is a compound represented by the formula (Ilb): o F O-g-NH R2; jxX ,N. L' XXXr7vY OH R5(Ilb) or a pharmaceutically acceptable salt thereof, wherein: X is selected from the group consisting of -O- and -N(Ra) ; L is linear or branched Ci-6 alkylene; R2-iibs is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N cycloalkyl (Ra)-, C1-6 alkyl-SO2-N (Ra)-, phenyl, heteroaryl 5-6 membered, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consists of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; R5 is selected from the group consisting of hydrogen, n t cnon / zznz / q / υιλι deuterium and halogen; 123 R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. In some embodiments, X of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of -O-, -N(H)- and -N(CH3)~. In other embodiments, L is of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of covalent attachment points to R2-11 and X, respectively. n t cnon / zznz / q / υιλι In additional embodiments, R2--1of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of: hydrogen, cyano, -NH2, -N(CH3)2, -OCH3,Λ 124 n t cnon / zznz / q / υιλι In some embodiments, R5 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen, deuterium and fluorine. Also described herein is a compound represented by formula (III): or a pharmaceutically acceptable salt thereof, wherein: X111 is selected from the group consisting of a bond, -CH2-, -NRa-, -O-, -O-CH2- and -OCH2-CH2mes 1, 2 or 3; n e s 1, 2 or 3; ri-iiis is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens) ; R2-111 is selected from the group consisting of hydrogen, C1-4 alkyl, -C(O)-C1-4 alkyl, -C(O)-O-C1-4 alkyl, -C(O)N (Ra)- C1-4 alkyl, -S(O)2-C1-4 alkyl and -S(O)2-C3e cycloalkyl; where C1-4 alkyl, -C(O)-C1-4 alkyl, -C(O)-O-Ci125 alkyl 4, —C(O)-N(Ra)-C1-4alkyl, -S(O)2-C1-4alkyl and -S(O)2C3-6cycloalkyl may be optionally substituted with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. In some embodiments, X111 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of a bond, -CH2-, -O-, -NH- and -O-CH2-. In other embodiments, R2-111 of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen, isopropyl, -CH2CF3, -S(O)2-CH3 and S(O)2-cyclopropyl. In still more embodiments, R5 of the compound or a pharmaceutically acceptable salt thereof is selected from the group n t cnon / zznz / q / υιλι € > ΠK 126 c IX N C σ c u consisting of hydrogen, deuterium and fluorine. £ Also described herein is a compound represented by formula (IV): or a pharmaceutically acceptable salt thereof, wherein: X111is selected from the group consisting of -O- and N(Ra) L111 is linear or branched Ci-6 alkylene, wherein the Ci-g alkylene is optionally substituted with hydroxyl or fluoro; R3-111 is selected from the group consisting of hydrogen, -NRaRb, -N(Ra)-C(O)-O-Ci-6 alkyl, hydroxyl, fluoro, Ci2 alkoxy, 4-6 membered heterocyclyl and C3-6 cycloalkyl ; wherein 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); and where if 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted 127 with C1-3 alkyl; either Liiii-R3-ih is hydrogen; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. Also described herein is a compound represented by formula (V): n t cnon / zznz / q / υιλι or a pharmaceutically acceptable salt thereof, wherein: Xv is selected from the group consisting of -O- and N(Ra)-; Lves a linear or branched C1-8 alkylene or bond, wherein the C1-8 alkylene is optionally substituted with one or more hydroxyl or fluoro; R2~v is selected from the group consisting of hydrogen, halogen, cyano, -NRaRb, C1-2 alkoxy, C3-6 cycloalkyl-SO2-N (Ra) 128, C1-6 alkyl-SO2-N (Ra) -, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted on one or more available carbons with one, two or three substituents each independently selected from the group consists of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl or one, two or three halogens) and Ci-2 alkoxy (optionally substituted with one, two or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ray Rbse select each, independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl. In some embodiments, Xv of the compound or a pharmaceutically acceptable salt thereof is selected from the group n t cnon / zznz / q / υιλι 129 consisting of a link and -0-. In some embodiments, Lv of the compound or a pharmaceutically acceptable salt thereof is selected from the group n t cnon / zznz / q / υιλι represent the covalent attachment points to R2~v and Xv, respectively. In some embodiments, R2-v of the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of hydrogen, bromine, cyano, -OCH3, In some embodiments, R5, R6 and R7 of the compound or a pharmaceutically acceptable salt thereof are each hydrogen. Also described herein is a compound selected from the group consisting of: 5-{l-fluoro-3-hydroxy-7-[2-(morpholin-4yl)ethoxy]naphthalen-2-yl}-lÁ6, 2, 5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]-1-fluoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 130 5-[1-fluoro-3-hydroxy-7-(pyrrolidin-3-yl)naphthalen-2-yl ]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 8-fluoro-6-hydroxy-7(1,1,4-trioxo-lÁ6, 2,5-thiadiazolidin-2-yl)naphthalen-2-yl propan-2-ylcarbamate; 5-(9-fluoro-7-hydroxynaphtho[2,1-b]furan-8-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[2-(azetidin-l-yl)ethoxy]-lfluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3trione; 5-[1-finoro-3-hydroxy-7-methoxy (4-2H)naphthalen-2-yl] (4,42H2) — 1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[1-fluoro-3-hydroxy-7-(methylamino)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-finoro-3-hydroxy-7-[2-(piperidin-4yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-7-{[3-fluoro-l-(propan-2-yl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin1,1, 3-trione; 5-{1-fluoro-7-[(3-fluoropyrrolidin-3-yl)methoxy]-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}pentanenitrile; 5-{l-fluoro-3-hydroxy-7-[2-(piperidin-1yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-lH-pyrrole-3yl]-1-finoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidinn t cnon / zznz / q / υιλι 131 1,1,3-trione; 5-{1-finoro-3-hydroxy-7-[(piperidin-4yl)methoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{[8-finoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3,3dimethylpentanenitrile; 5-{7-[(3,3-dimethylbutyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(2H3)methyloxy]naphthalen-2-yl}1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2dimethylbutanenitrile; 5-{7-[2-(3-aminobicyclo[l,l,l]pentan-l-yl)ethoxy]-1fluoro-3-hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1 ,3triona; 5-(7-{[2-(dimethylamino)ethyl]amino}-l-fluoro-3hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4-2H2)1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-finoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1Á6, 2.5 n t cnon / zznz / q / υιλι 132 thiadiazolidin-1,1,3-trione; N- (2 — {[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5 thiadiazolidin-2-yl)naphthalen-2yl]amino}ethyl)cyclopropanesulfonamide; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]amino}naphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6,2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)cyclopropanesulfonamide; 5 - (l-fluoro-3-hydroxy-7{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)1λ6,2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile; [1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}methyl)cyclopropyl]acetonitrile; 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropylmethyl)-lH-pyrazol-4-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(lH-pyrazol-4yl)methoxy]naphthalen-2-yl}-lX6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methylpropoxy)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2n j cnon / zznz / q / υιλι 133 11]-ΙΑ6, 2,5-thiadiazolidin-l,1,3-trione; Ν-(cyclopropylmethyl)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo1λ6,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide; 5-[1-finoro-3-hydroxy-7-(2-{[ 2 (trifluororethoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-lA6,2,5thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl)amino]ethoxy}naphthalen-2-yl)-1AÉ, 2,5-thiadiazolidin1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[3-(methylamino)propyl]naphthalen2-yl}-lA6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(cyclopropylamino)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(methylamino)ethoxy]naphthalen-2yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(ethylamino)ethoxy]-1-finoro-3-hydroxynaphthalen-2yl}-1A6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2yl)amino]ethoxy}naphthalen-2-yl)-lA6,2,5-thiadiazolidin-l,1,3trione; n j cnon / zznz / q / υιλι 5-{7-[3-(diethylphosphoryl)propoxy]-1-fInoron-3 134 hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-finoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{1,4-difluoro-3-hydroxy-7-[(3methylbutyl)amino]naphthalen-2-yl}-1Λ6,2,5-thiadiazolidin-l,1,3trione; 5-{1-fInoro-3-hydroxy-7-[ (3R)-3-hydroxybutoxy]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4methylpentyl)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-{1-finoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2yl} -1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; N-[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2.5 n t cnon / zznz / q / υιλι thiadiazolidin-2-yl)naphthalen-2-yl]-3- methylbutanamide; 135 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 1- (2 — {[8-fluoro-6-hydroxy-7 - (1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropan-1carbonitrile; 5-(1-fluoro-3-hydroxy-7-{2-[1(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-(7-{[(cyclopropylmethyl)amino]methyl}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; —{7 —[ (2,2-difluoropropyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl} -1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(2-phenylethyl)amino]naphthalen-2yl} — 1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(4,4,4trifluorobutyl)amino]naphthalen-2-yl}-lÁ6, 2,5-tradiazolidin1,1,3-trione; 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1, 3 n t cnon / zznz / q / υιλι 136 friona; 5-{1-fluoro-3-hydroxy-7-[(3,3,3trifluoropropyl)amino]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3methylbutoxy)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-[7-(2-cyclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-({2-[(propan-2yl)oxy]ethyl}amino)naphthalen-2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]methoxy}naphthalen-2-yl)-lλ6, 2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino Jbutanenitrile; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(4-amino-3,3-dimethylbutoxy)-l-fluoro-3hydroxynaphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5— (7 — {[2-(azetidin-l-yl)ethyl]amino}-l-fluoro-3hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)azetidin-3-yl]oxy}-lfluoro-3-hydroxynaphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3 n t cnon / zznz / q / υιλι trione; 137 5-{l-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3,3,3trifluoropropoxy)naphthalen-2-i1]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 1-({[8-fluoro-6-hydrox1-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropan-1carbonitrile; 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-{1-fInoro-3-hydroxy-7-[3-(lH-pyrazol-1yl)propoxy]naphthalen-2-i1}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5- (7-{1- [ (4-aminophenyl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fInoro-3-hydroxynaphthalen-2-yl) -1Á6,2,5thiadiazolidin-1 ,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(hydroxymethyl)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)piperidin-3-yl]-1-fInoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropancarbonyl)pyrrolidin-2-yl]-1-fInoro3-hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(lH-pyrazol-1yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoron t cnon / zznz / q / υιλι 138 3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fInoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(piperidin-3-yl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-finoro-3-hydroxy-7-[2-(1methylcyclopropyl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1,1,3-trione; 5- (7-{1- [ (3-aminophenyl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fInoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5 thiadiazolidin- 1,1,3-trione; 5- (7-{1- [ (2-aminophenyl)methanesulfonyl]-2,5-dihydro-lHpyrrol-3-yl}-1-fInoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1 ,1,3-trione; 5-[7 -(2,2-difluoroethyl)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]1Λ6,2,5-thiadiazolidin-l,1,3-trione; 1—({[8-fluoro-6-hydrox1-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}methyl)cyclopropan-1 n t cnon / zznz / q / υιλι carbonitrile; 139 5-{l-fluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(2-methylpropyl)amino]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l, 1,3-trione; —{7 —[(cyclopropylmethyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; {[8-flucro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6, 2,5thiadiazolidin-2-i1)naphthalen-2-yl]oxy}acetonitrile; 5-[1-fluoro-3-hydroxy-7-(3-methylbutoxy)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fInoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropancarbonyl)azetidin-3-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lA6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile; 5-[7-(2-cyclopropylethyl)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(2,2-difluorocyclopropyl)methoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclopropylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(skylopropylmethoxy)ethoxy]-1-fInoro-3 n t cnon / zznz / q / υιλι 140 hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[2-(cyclobutyloxy)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2yl)oxy]ethoxy}naphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3trione; 5-[7-(3-ethoxypropoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[rae-(IR,2R)-2-ethylcyclopropyl]methoxy}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-l-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(l-chloro-3-hydroxypropan-2-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(cyclopropyloxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(2-cyclopropylethyl)amino]-1-fluoro-3 n t cnon / zznz / q / υιλι 141 hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methyl-lH-imidazol-2yl)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2yl]-IX6, 2,5-thiadiazolidin-l, 1,3-trione; [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile; 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-finoro-3-hydroxy-7-[(3-methyloxetan-3yl)methoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-lHpyrrol-3-yl]-1-fInoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5thiadiazolidin-1, 1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3trione; 5-{1-finoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen2-yl}-lÁ6,2,5-thiadiazolidin-l, 1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(8-chloro-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1Á6,2,5-thiadiazolidin-l,1,3-trione; n i cnon / zznz / q / υιλι 142 5-{7-[(3,3-difluorocyclobutyl)methοχi]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-cyclopropyl-l-fluoro-3-hydroxynaphthalen-2-yl)1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5—{7—[1—(cyclopropancarbonyl)-2,5-dihydro-lH-pyrrole-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3- trione; 5-(4-chloro-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(E)-2-cyclopropylethenyl]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[(1E)-4-methylpent-l-en-lyl]naphthalen-2-yl} -1Λ5, 2,5-thiadiazolidin-l,1,3-trione ; 5-{l-fluoro-3-hydroxy-7-[1(pentamethylphenyl)ethenyl]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1,1,3-trione; 5-{7 -[1-(cyclopropylmethyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1 ,3trione; 5-(4-bromo-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{7 -[1-(2-cyclopropylethyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl} -1Á6, 2,5-thiadiazolidin-l ,1,3trione; 5-{1-fInoro-3-hydroxy-7-[(1E)-3-methoxyprop-l-en-ln t cnon / zznz / q / υιλι 143 il]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-i1]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(1,l-dioxo-lÁ6-thian-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(cyclopropylmethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)-1Á6, 2, 5thiadiazolidin-1,1,3 -triona; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3 -triona; 5-(1-fluoro-3-hydroxy-7-{2-[methyl(2methylpropyl)amino]ethoxy}naphthalen-2-yl)-lÁ6,2,5-thiadiazolidin1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxolan-3-yl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7 -{[1-(cyclopropanesulfonyl)azetidin-3-yl]methyl}-1 n t cnon / zznz / q / υιλι 144 fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l, 1, 3trione; — (7 — {[l-(cyclopropanesulfonyl)pipenidin-4-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidin-l,1,3trione; - [l-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-[7-(difluoromethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[(pyrrolidin-3yl)methyl]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2,5-dihydrofuran-3-yl)-1-fluoro-3-hydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3,6-dihydro-2H-pyran-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2,5-dihydro-lH-pyrrol-3-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3-hydroxy-7-(pyridin-3-yl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; n t cnon / zznz / q / υιλι 145 5-{7-[(azetidin-3-yl)methyl]-1-fluoro-3-hydroxynaphthalen2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-lÁ6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]amino}acetamide; 4-{[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-N-metributanamide; N-ethyl-W-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo1λ6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl) urea; 5-{l-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(l-chloro-3-hydroxypropan-2-yl)oxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2yl} — 1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[(oxetan-3-yl)oxy]naphthalen-2yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[l-(2,2,2-trifluoroethyl)1,2,3, 6-tetrahydropyridin-4-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; 5-(l-fluoro-3,7-dihydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1Á6, 2, 5 n t cnon / zznz / q / υιλι 146 thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; {[8-Fluoro-6-hydroxy-7-(1,1,4-trioxo-ΐλβ,2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino¡acetic acid; N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-lÁ6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy}acetamide; N, JV-diethyl-2- {[ 8-f luoro-6-hydroxy-7- (1,1,4-trioxo1λ6, 2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy¡acetamide; 5-{l-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4yl]oxy}naphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁÉ,2,5-thiadiazolidin1 ,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin1,1 ,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropan-1sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6 ,2,5thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[l-(3,3,3-trifluoropropan-1sulfonyl)-2,5-dihydro-lH-pyrrole-3-yl]naphthalen-2-yl}-1λ6 , 2.5 n j cnon / zznz / q / υιλι 147 thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{1—[(oxan-2-yl)methanesulfonyl]2,5-dihydro-lH-pyrrol-3-yl}naphthalen-2-yl)-lÁ6,2 ,5thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutan-1sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6 ,2,5thiadiazolidin-1,1,3-trione; 5-{7 -[1-(butan-1-sulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl} -1Á6, 2,5-thiadiazolidin -l,1,3trione; 5— (7 — {1—[ (1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1Hpyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1Á6 , 2,5 thiadiazolidin-1,1,3-trione; 5-{3-[8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-lH- pyrrol-lsulfonyl}pentanenitrile; 5-{l-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁe,2,5-thiadiazolidin1 ,1,3-trione; 5—{7—[1—(ethanesulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1, 3triona; 5-{l-fluoro-3-hydroxy-7-[1-(propan-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁÉ,2,5-thiadiazolidin n t cnon / zznz / q / υιλι 1,1,3-trione; 148 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1,1,3- trione; N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3sulfonamide; 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(2-methylpropan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; 5-(7-ethoxy-l-fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-[7-(2,2-difluoroethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]—1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-lH-pyrazol-4-yl]-1-fluoro3-hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[(3R)-1(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ6,2,5thiadiazolidin-1,1,3- trione; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4yl]amino}naphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1, 3 n t cnon / zznz / q / υιλι trione; 149 5-(l-fluoro-7-{[3-fluoro-l - (methanesulfonyl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidin1,1,3-trione; 5-{1-finoro-3-hydroxy-7-[1-(propan-2sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-lÁ6,2,5thiadiazolidin-1,1,3-trione; 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(1,3-dimethyl-lH-pyrazol-4-sulfonyl)-2,5-dihydrolfl-pyrrol-3-yl]-1-fInoro-3-hydroxynaphthalen-2-yl}- 1λ6, 2,5thiadiazolidin-1,1,3-trione; N-(2-{[8-fInoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide; 5-{1-fluoro-7-[l-(furan-3-sulfon11)-2,5-dihydro-lHpyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin1, 1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(3-methylbutan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2, 5thiadiazolidin-1,1,3-trione; 5-{1-finoro-3-hydroxy-7-[1-(thiophene-3-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁg,2,5-thiadiazolidin1 ,1,3-trione; 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-1fInoro-3-hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-l,1, 3 n t cnon / zznz / q / υιλι trione; 150 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-lH-pyrrol-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin1,1,3- trione; methyl (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-ΐλ6, 2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy}butanoate; 5-{7-[(3,5-dimethyl-lH-pyrazol-4-yl)methoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione ; 5-[7-(3,5-dimethyl-lH-pyrazol-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclohexylethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]-lH-imidazole-4-carbonitrile; 5-{l-fluoro-3-hydroxy-7-[2-(2,2,4-trimethyl-l,3-dioxolan4-yl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidine- l,1,3trione; 5-[7-(3,4-dihydroxy-3-methylbutoxy)-l-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{7-[(4,4-difluorobutyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5- ( 7-{[rae-(2R,4R)-2,4-dihydroxypentyl]oxy}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-l,1,3-trione ; 5-{l-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-pyrazol-lyl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; n i cnon / zznz / q / υιλι 151 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl ]1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-3,6-dihydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-trione; 5-(6-amino-l-fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{6-[(4,4-difluorobutyl)amino]-1-fInoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{6-[(cyclopropylmethyl)amino]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-6-[(3-methylbutyl)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fluoro-3-hydroxy-6-[ (3-hydroxy-3methylbutyl)amino]naphthalen-2-yl]-1Λ6,2,5-thiadiazolidin-l,1,3trione; 5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 5-(1-finoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; tert-butyl (2-{[5-fluoro-7-hydroxy-6-(1,1,4-trioxo1Λ6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)carbamate; 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2n t cnon / zznz / q / υιλι 152 11]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-{7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3dimethylbutoxy)naphthalen-2-yl]-lÁ6,2,5-thiadiazolidin-l, 1,3trione; 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-l,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxy-2,2dimethylpropane-l-sulfonyl)-2,5-dihydro-lH-pyrrole-3yl]naphthalen-2-yl}-lÁ6 ,2,5-thiadiazolidin-l,1,3-trione; 5-{7-[1-(3-aminopropane-l-sulfonyl)-2,5-dihydro-lHpyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5 thiadiazolidin -1,1,3-trione; (3R)-5-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lA6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy- 3methylpentanenitrile; (3S)-5-{[8-fluoro-6-hydroxy-7- (1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-3-hydroxy- 3methylpentanenitrile; n j cnon / zznz / q / υιλι 5-{7-[(5-amino-3,3-dimethylpentyl)oxy]-1-fluoro-3 153 hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidine-l, 1,3-trione; 5-(1-fluoro-3-hydroxy-7-{3-[(propan-2yl)amino]propyl}naphthalen-2-yl)-1λ6,2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[2-(oxolan-3-yl)ethoxy]naphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(2-cyclobutylethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2(trifluorornetoxy)ethoxy]naphthalen-2-yl}-lÁe,2,5-thiadiazolidin1,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1Λ6, 2,5-thiadiazolidin-l,1,3trione; 5-[7-(2-cyclopropylethoxy)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(l-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl) 1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(7-ethyl-l-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidine-1,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-l-fluoro-3,6-dihydroxynaphthalenn t cnon / zznz / q / υιλι 154 2-11]-1λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3,6-dihydroxy-7-[2-(oxolan-2yl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2yl]-1Λ6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(2-cyclobutylethoxy)-l-fluoro-3,6-dihydroxynaphthalen2-yl]-lÁ6,2,5-thiadiazolidin-l,1,3-trione; 5-(7-butoxy-l-fluoro-3,6-dihydroxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-[7-(2-cyclopentylethoxy)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[7-(4,4-difluorobutoxy)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2dimethylbutanenitrile; 5-{l-fluoro-3,6-dihydroxy-7-[2-(oxolan-3yl)ethoxy]naphthalen-2-yl}-lÁ6, 2,5-thiadiazolidin-l,1,3-trione; 5-[l-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(3-hydroxypropane-lsulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2,5thiadiazolidine -1,1,3-trione; 5-(7-bromo-l-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidine-1,1,3-trione; n t cnon / zznz / q / υιλι 155 5-[l-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2yl]-1Á6, 2,5-thiadiazolidin-l, 1,3-trione; 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl ]-1Λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(oxetan-3-yl)ethoxyjnaphthalen2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[1(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[(4,4-difluoro-5-hydroxypentyl)oxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-(7 — {2 —[3-(aminomethyl)bicyclo[1,1,1]pentan-l-yl]ethoxy}1-fluoro-3-hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidin -l,1,3trione; 5-(1-fluoro-3-hydroxy-7-{[3- (2hydroxyethyl)bicyclo[1,1,1]pentan-l-yl]methoxy]naphthalen-2-yl)1Λ6, 2,5-thiadiazolidine- l,1,3-trione; 5—{7—[2—(bicyclo[l,1,l]pentan-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3 -triona; 5-(7 — {2 —[1-(aminomethyl)cyclobutyl]ethoxy}-l-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-lyl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidine-l,1,3- trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2S)-2(trifluoromethyl)pyrrolidin-l-yl]ethoxy}naphthalen-2-yl)-1Á6, 2.5 n t cnon / zznz / q / υιλι 156 thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl)(methyl)amino]ethoxy}naphthalen-2-yl)-lÁ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[2-(3,3-difluoropyrrolidin-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-1-fInoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-l,1,3 -triona; 5-{7-[2-(3,3-difluoroazetidin-l-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{l-fluoro-3,6-dihydroxy-7-[2-(1methylcyclopropyl)ethoxy]naphthalen-2-yl}-lÁg,2,5-thiadiazolidin1,1,3-trione; 5-{7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3,6dihydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-(7 — {2 —[ethyl(methyl)amino]ethoxy}-l-fluoro-3hydroxynaphthalen-2-yl)-1Λ6, 2,5-thiadiazolidine-l,1,3-trione; 3- [ (2-{[8-fluoro-6-hydroxy-7- (1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)(methyl)amino] propanenitrile; 5-(l-fluoro-3-hydroxy-7-{2-[(2,2,2trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; and a pharmaceutically acceptable salt thereof. n t cnon / zznz / q / υιλι In some embodiments, a compound described in the 157 herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is formulated as a pharmaceutically acceptable composition comprising a compound described and a pharmaceutically acceptable carrier. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is selected from a compound set out in Table 1. n j cnon / zznz / q / υιλι Table 1: Example compounds from the description. Compound number Structure Compound number Structure 100 o ή x o ó 101 0 0 F O=s-NH 0 XII 102 0 HN-—, F Oi'g-NH 1 Ύ T 103 O F 02g-NH \ . N. N T π ΤΎΎ OH 104 Cu o O Ζ~ω'° o 105 ^2. o M o o ζ-ώ'° 1 o 158 Compound number Structure Compound number Structure 106- 'o O—¿ O-TI / -A ° O Z-W'° IO__ / \ Z\ 2 o o 107 0 F OA'NH N Ñ A^0 TI T 108 T o M o o ζ-ώ'° 1 o 109 V o M o o ζ-ώ'° 1 Vi o 110 I y o M o o ζ-ω'° 1 V o 111 0 F O^s-NH n ^A° -QV 'Ά' ''· / 'qh 112 o o is Λα ° O Z-ó>'° 1 Vi o 113 O O'^z. o °^5 Ο=ω=θ Δ 114 o HN'^A F O'S-NH 115 z V O Z-¿L° 1 Vi o 116 0 F o^Vnh N N -^ / ^° A Ϊ J T 117 — A-\ o o ζ~ω-° 1 Vi o 118 0 F Ca's-'NH D \Z° νΛνΑχ / N Ό' T II T d A AA OH 119 o A . Or»?-2. O ° V5 or V 159 Compound number Structure Compound number Structure 120 o O o Ζ~ω'° 1 V o 121 o F O=g-NH N -Y^ O Λ7 Y 1 Y H2N '^^oh 122 / —z zz M ° o ζ-ω '° o 123 'b ° o ζ-ώ'° O Xl O 124 'o o ζ-ώ'° o 125 O 0 0 U F °'Y\H SL zNxz3·. JxznX0 Ί3Η 126 o Y z IZ 0 1 O / / X O 127 0 n O F Ols-NH jf o4 ° 0 129 o X o 133 Z I F o o z-¿^o 1 V o n t cnon / zznz / q / υιλι 160 Compound number Structure Compound number Structure 134 Λ z o'Tz, o ° ~νϊϊν o 1 135 0 OH F O'S'NH Jkñ0 XxX 136 ΞΖ^ \=o \í ) / —Ή )—< O o ζ-ω'° 1 or 137 .y or IZ or t; O Ζ-ά'-Ό 1 V 0 138 \ o iz o 8. o 1 M O 139 o y z P ° ^ZI 140 IZ o O ζ-σ>'° 1 V o 141 0 ° s onc OH 142 o z op?~ \ P o ZI <f 143 0 p Oig—NH / Ν^° h Ly / KJi 144 Λ z oT2; P o o ZI 145 O )2( o o ζ-ώ'° 1 o 146 o 0 F O'S-NH Ρ\Χ\ / Ο·χ / \Α / Ν i PxX OH 147 o ο^Ίζ-^ο 1 o 161 Compound number Structure Compound number Structure 148 1 zi ~~° o ζ-ω-° 1 V o 149 o F O'SNH γψ^γ Ñ oh UxX0H 150 o OH F O=s-NH A A / Ñ 0 OH 151 O· / I \ o o ζ-ω'° 1 o 152 O 0 F Oi's-NH ^^Xdh 153 o—< ΞΕ \ o O Z-w'° 1 o 154 T O / O Z-W'° 1 o 155 o A X op ?~\ P O VkX 0 l· 156 0 F O'S-NH \ / 0. Ñ ​​x^xxx OH 157 0 F O^NH TI XXX OH 158 0 F F O=s-NH Λ , n 159 O o O Z-W'° 1 M o 160 O X O'^~\ P O v^Zv o o / 161 T ¿^ ;X< o O z-co^O 1 o 162 Compound number Structure Compound number Structure 162 )2( o O ζ-ω-° o 163 o ~z ° o t C-J T 166 ZI O Z-W'° 1 o 167 0 F F O^g-NH Λ / ·νΛ>ν=° F oft 168 °-< z \C 7 / —Ή )—( O o z -ó>*° 1 M o 169 5 ZI Ο^Λ-^Ο 1 Vi o 170 \ o 5 o ° O ζ-ώ'° 1 V o 171 0 F O~SNH H 172 o F o=Vnh H II \ —- z-x ° ICZíCvlf 173 ο=ω=ο o 1=A~ o o ζ-ώ'° 1 V o 174 z ZI Λλ” o O Z-W'° 1 o 175 0 F O^s-NH Zh 163 Compound number Structure Compound number Structure 176 0 F O^s-NH .0. . Ñ ​​ΗΚ>τ^χχχ OH 177 0 F OX^NH OH 182 o cold o Z-C0'° 1 o 183 0 / ^N F O=VNH Ñ. .EITHER. . Ñ ​​0 XXX ^OH 184 h2n O)> ° \X( o / — F O'S-NH x- rNvAΛ.. ñ X 0 ξΧΧ 185 0 F O^s^NH ηοΊΑ OH 186 o 187 0 \\ 0 z-n / x7 f o^-nh νγγ^Ν^Λ0 188 O z O χχ” ° o z-JX° 1 o 189 0 / -X '0 F O-S-NH vyyLnJ=° 164 Compound number Structure Compound number Structure 190 0 r-Q F Oi's-NH iño 191 \ ZI *X< ° O Z-OT'° 1 o 192 Λ X ° vZS o 193 0 F Oi's-NH ^\z°ñ 194 Η2Ν·\ Ζν or λ--Ί| f o=s-nh ° ιΟο OH 195 / (Y>— nh2 o \U2< O / — F O=s-NH ° IvZMIzL 196 O F O'S^NH vogc 197 Λ X p O VvZv o 4 LL LL 198 O F Osg-NH .X. Ñ F ΊϋΟ OH 199 o o^z-^o 1 M o 200 O F O='^NH N 'Y^'V^'V Ñ 'y^=O 201 0 I u F O^NH N Ñ ^=0 XXX ^OH 202 O X O^'zx / ° O 203 O X p ° o .? 165 Compound number Structure Compound number Structure 204 o Λ z °P?~PP o 205 0 F F OVg-NH ogo Oh 206 X z O. / z V'° 207 <^=0 z \( ) / —Ή )--( O O Z-OT'° 1 Vi o 208 0 F o=Vnh Νχ I । V=n O / N Z^° OH 209 o z-«Vo 1 Vi o 210 0 F Oóg-NH n X=° F Xoov. 211 1 o ° O ζ-ω'° 1 Vi o 212 V o o o o z-^° 1 Vi o 213 o F O=?s-NH ñ '^t=° 214 o ;VV o o ζ-ώ'° 1 Vi o 215 O - ° O z-có'° 1 Vi o 216 o íV z o'-p-p P o o o ) 217 ​​o o O ζ-ω-° 1 Vi o 166 Compound number Structure Compound number Structure 218 Λ z o \ 219 o fS z o^. ° ° ~vzS 220 \ / 0 f O-'s-NH H 221 O^. T \__ / \ — γγ - o o z-co-° o 222 O Z-CO'° 1 M o 223 0 F Ο^ΝΗ Ό. Jk , Ñ -V^0 ζ-ω^° 1 o 228 O 10 z O^~zx o O v-Zv ^z 229 o z o^-\ p °_νϊϊν a 230 o F O^s-NH 231A 0 0 / — F O=s-NH NI ^ >=00 XTi Br n t cnon / zznz / q / υιλι 167 Compound number Structure Compound number Structure 231B 0 or / =¾. F O=s-NH ° kXx v γ OH Br 232 0 ΗΝ-η F O^NH ©O ^^OH 233 0 HN^. F O^SNH iño OH 234 0 Cl F Oi©NH ΛΧ / L .Ñ^ / ^0 ©O OH 235 o z Oú?-Z. P °kk o β LL 236 o O ζ-ω-° o 237 o z Oú?'z o °kí 238 © ——\CxZ— )--( O o ζ-ώ'° o 239 o F O=S'NH ^ ^^XDH 240 \C 7 / —H )—( O O ζ-ω'° 1 o 241 \C ) / —H / --( ° O ζ-ω'° 1 o 242 / 1 0 A Λ1 F O=VNH Vn^y-©y^©° 168 Compound number Structure Compound number Structure 243 'o o o 244 ? z o o ζ-ώ'Ο 1 o 245 c / \C 7 / —Ή )—( O O Z-OT-° 1 o 246 Λ X °PP\ p o o o 247 o F O=S'NH N ^=° 248 Λ x oppp p o Ζ^λ LL—(( OH o 249 z°\ F OPg-NH 250 o 251 o O Z-tflíO 1 M o 252 o ñ X o'P-p p ° '—z 253 o ñ X P ° vZS o z— V 254 P o Ο^Ίζ-^Ο 1 o 255 0 0^ F Oc?s-NH iQgC 256 o F O=s-NH TO1O1 V ° 169 Compound number Structure Compound number Structure 257 o F Olg-NH .^x / x^ / ^Jx^^ Ñ 258 0 / NH F O'S'NH \A^^A,ñ^z=° iQo 259 0 Λ zo F OA -NH ^sz, Λ / ΝχΛ0 ° / z trxxx 260 0 F Osg-NH R .0. Jk / Ñ \ / ^° TXxX OH 261 o Ñ ​​lüo 264 0 F Oi's-NH 265 / x Z Cj O O ζ-ω'° 1 o 266 \C^z o O Z-W'° 1 o 267 o O^~\ ° °jd> ^z I 268 o Λ O u F O='ANH z\ 11 Η 1 1 \: ΓΊ N i / víTvi H L¿a-¿L!sa>L 269 0 O F O=s-NH \Ñ H W XOH 270 o o F oA'NH H H αΑΑΙ ^' ^'Όη 170 Compound number Structure Compound number Structure 271 P o ° o z-¿P° 1 o 275 Ι—Έ. B° O 1 V o 276 T o \( 7 / —T1 )--( O o ζ-ω'° o 277 I o o cCzYPo o 278 p O ζ-ώΡ° 1 M o 279 o oTz. o ° - o p- 280 0 O u F O=VNH 11 H II \ / -η HO κΒρΒΓ 281 Λ x ο'Ύ ° o o4 ZI i 282 O X ° vzS o oP o 283 o íP X OÓ?'2X o ° _ / PP\ o P. O \ 171 Compound number Structure Compound number Structure 285 Ο=ω=Ο z o o ζ-«'° 1 Vi o 286 o Y—' o / —Ί F Os'c-NH ^KVvV>» ° iVo r / W ''OH 287 F ° \ O ,—, F O-O-NH 288 0 __0 / — F Oég-NH ^ΙτΛζχΑζν2ο ° iño ΌΗ 289 o \__ / O F Ol's-NH ° kXX V / ''OH 290 ° Xo o=s F\ ^N —' f 4 θ. ,Ν^χΟ-0 fX— 291 O \__ O / -- F O-'s-NH ° kXX 292 θ \__ / O F O=s-NH ^XNvA^ / xΛχ / ^00 LÓO — OH 293 Xo o= s Ύ* F\__IxA o 0-~<W0^OH tA '6 294 0 V-x o x fo=Vnh Η^ίτΛ v / v / 'OH 295 O o / — F O~s-NH ΜάΑ / χΑλΑ0 ° iüo OH 296 0 x o r~~, F oXnh Λ° i OH 297 △'-P 0 AnA F O~SNH 298 0 °\3< p F °=rNL 172 Compound number Structure Compound number Structure 299 0 HN^X F Os's-NH U\AUA ° 300 __l O ,—, F Oéc-NH rHAxAzA00 KXX OH 304 o . F O=q-NH F Oag-NH As' M 'vA / o A / N A á « An V-V Compound number Structure 313 o \__ O , p O'VWH Α^'Ν Jxxl Ñ A° ° ΚΣΑΑ1 314 O 0 F Os's-NH ga OH 315 1 Ο=ω=Ο z M o O z-cn'° 1 M o 316 0 0 ¡-- F oO-NH ArNvtx / AAA° ° TOTOX xAAoh 317 0 0 F O^-NH x. / AYA0 YA W 318 I Ox yj / o M ° O Z-Ó>í° 1 o 319 0 n-A f o=Anh HN' A / x 1 N >0 AM OH 320 o F O=s-NH / χ / χΑ / ^χ A / N A^0 CAYo 'x / ' W QH 321 0 / ΓΝΗ F O=S-NH νξ^\,Α / x AnY° n i; 322 ζΟψ Ϊ o ° O Z-W''° 1 o 323 0 F O=s-NH / Χχ / X .0. / X. A-NxA° H0Y^XXX OH 324 A x oOY o °A IZ J u_ 325 0 OH OH F O~s-NH AAx / °xXyA / N A^ Ά\Αοη 326 o F O=s-NH cN^°yÁ,1 'x=o hnAo ΑΑΑΑοη 327 h o o z-A° 1 o 328 ΞΕ O \( ) / —T1 )--( O o z-A° 1 A o 174 Compound number Structure Compound number Structure 329 o F Osg—NH Γ 1 T h2n 330 Ί IZ 1 o 331 0 F O^s-NH γγγίγγΝ-γ^0 V H 332 0 F O^s-NH H 333 O F O=s-NH Á° h°j jA¿kaL N ίχΧχΑο H H 334 O F O~s-NH ,γγΑΑΑ^30 h°j KZyKZzL yYyYq^yy'yy'Yo h 335 0 F O^s-NH jQo 0 OH 336 o F O=s-NH yyyA- ñ H ί Η T Υ^ΟγΝ^θΑΛΑοΗ ' o 337 0 F O=s-NH yÁ / NA0 h,n^.0XXA0H 338 o Ο''Γ\ P ° —oh o 1 339 0 F O^s-NH yJAy^ ° I Γ 1 Y 340 0 F O=s-NH ,^χΑγΆ0 y^XXX \γ YY YY YY Yh F 341 0 F O=s-NH γγ.,Αγχ χγ, N -A=° HÓ ' L A 1 yy Yy ' oh 342 I o o )=\ ° o ζ-ώ'° 1 M o 175 Compound number Structure Compound number Structure 343 0 F Olg-NH ΓΊ U j-, T-^ γ iT ho '' L .k JL OH 344 O O=CZ)=O y I 345 r? o / °Y o Z-C / )~n 1 M O 346 o F ,c—N H 1 0 ' An Y«Y-N -7° t\A Γ'ΟΗ T jf T 347 z Y ΞΕ \ oA O M o O z-¿ 'í° 1 o 348 O F Oz-g-NH H2N N ^k=O a TXT 349 V IZ o (X )= / o O Ζ-(Λ'° 1 o 350 2 O )= / o O Z-M '° 1 V o 351 0 F oY-NH 1, Ñ \J L XI K'A\A\qH 352 1 o 1 o 353 0 F O=s-NH Ñ Ά0 U T T I 354 o T o o 355 O F O~s-NH ΧζΧγΟγ^Τχ / Ñ ..T' ° HOk 111 356 .1 o o / =\ ° O Z-OT^° 1 o 357 ΞΓ \ O O / =\~ ° o ζ-ώ-° o 358 ΞΕ \ ° 2 A=( o o ζ-ώ-° o 176 Compound number Structure Compound number Structure 359 .1 o o / =\ ° o 1 V o 360 o F O=s-NH N -Y^0 <¿j III HCr^'^-'XDH 361 .1 o o o O Z-«¡ iO 1 o 362 o Y z / ° o / =\ o o V 363 o Y z oTz. ,° ° YY o o I 364 o F O~S'NH Ñ X=° <H III 365 0 F F Oig—NH N XoF XXI 366 0 p O=q-NH 367 O Y z Op?~\ z° ° YY 368 0 F O~s-NH Ñ Χ=Ο XXI HO'xX / X^'OH 369 I O o / -- Ο-ω— z o 1 o 370 O F O~s--NH Br\xxXv^ ú X^0 III ΗοΧΧΧόπ 371 I \ o / X O Z-OT'° 1 V o 372 r o M o O Z-c / >'° 1 V o 177 Compound number Structure Compound number Structure 373 1 o ° cTVe^o 1 V o 374 o OH F OBs-NH JT^° ñ u 1T T 375 o F F F O'S'NH Ll / I '-' '-' ΌΗ 376 O p OTg -NH H2N^ / 8¿Z 8 377 O ​​F O=s-NH ITT 378 / \ ii r> O z-w''J o 379 o NH2 F OBs-NH u IIT 380 o I z o T o 381 0 F O'S' NH z 3 z J ,'ÍZ:- C ITT O F F F 382 I z o''?-z o T o z— o \ 383 Π -Π Ó o M o O Z-¿GO 11 o 384 o I z oBTz o T o z —. 10 385 o T z op?-p P ° ti o 1 386 0 F O-s-NH < ITT 387 0 F Osg-NH rlU X Ti ^·Τ B OH 1 Λ. J. HO OH 388 ) —z o M o Óz-JjBo 11 o 178 Compound number Structure Compound number Structure 389 z c i ÓZ-^O 1 o 390 y IZ o M ° O Z-CO'° o n j cnon / zznz / q / υιλι Preparation Methods of Example Compounds The compounds of the present disclosure can be better understood in connection with the following synthesis reaction schemes and methods that illustrate a means by which the compounds can be prepared. The compounds of this invention can be prepared by a variety of synthetic procedures. Representative synthesis procedures are shown, but not limited to, in Reaction Schemes 1-13. The variables R1, R2, R3, R4, R5, R6 and R7 are defined as detailed in this document, that is, in the synthesis. Reaction Scheme 1: Representative reaction scheme for the synthesis of example compounds of the description. R1II r' ii Br o R ​​1 1 CO.H '.'^rCH.Br ;j, .co,HDPPAf-BuOI I j T T - I 11 R' y y· OH rio-iisís R' · -··' OCH.Ar Δ R R R- R·’ (1-1) (1-2) A'= 3'ilc ccdc',3lrne',te SubStituidc 179 br or K·. H .1. N. Ή Rr or Bí n t cnon / zznz / q / υιλι kj OCH-.Ar R' Br or R. R' <. .CO; TO N. h OCHy.Ar fi. R' (1-6i R7 R1 BrQ R2 OCH2Ar (1-8) KSO2NH2 R3 R4R5 Br o R1 RR O R. .N . Τ'H OCH.Ar R 1j NCOSO. CI. f-BuOH 2) go CO2- (C1-C4 alkyl) alkoxide base Br Or or R5(1-9) R2 R3 Or lack of protection R4R5(1-10) H2O cross-coupling reaction R1 H.O. >Ar R3 R4R5(1-11) or FO=s-NH Ό R1 R2 R3 R4(1-12) OFO=s-NH rA7OH R5 As shown in the compounds of formula (1-9) (1-11) and formula (1-12) Reaction formula scheme 1, the (1-10), the formula can be prepared from the compounds of the formula (1-1) (1-1) can be alkylated optionally substituted (for Compounds of the formula with a benzyl bromide, for example benzyl bromide, 4-methoxybenzyl bromide or 3,4-dimethoxybenzyl) 180 in the presence of a base such as cesium carbonate in a solvent such as N, N-dimethylformamide. The carboxylic acid group also reacts under these conditions producing a benzyl ester. The benzyl ester can be hydrolyzed with a base such as lithium hydroxide or sodium hydroxide in methanol or a methane mixture! and water to give the compounds of formula (1-2). The compounds of the formula (1-2) can be reacted under Curtius reaction conditions (diphenyl phosphorazidate, tert-butanol, triethylamine in hot toluene) to give the compounds of the formula (1-3). The tert-butoxycarbonyl moiety can be removed from the compounds of formula (1-3) by treatment with hot diethylenetriamine to give the compounds of formula (1-4). Compounds of formula (1-4) can be reacted with 2-bromoacetates of formula (1-5) in the presence of a base such as potassium carbonate in hot solvent such as but not limited to a mixture of N,Ndimethylformamide and water to give the compounds of formula (1-6). The compounds of the formula (1-6) can then be fluorinated with a reagent such as N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran or Selectfluor® in optionally hot N,N-dimethylformamide to give the compounds of the formula (1-6) 1-7). Compounds of formula (1-7) can be reacted with chlorosulfonyl isocyanate and tert-butanol in the presence of an amine base n j cnon / zznz / q / υιλι 181 tertiary such as triethylamine in a solvent such as cold dichloromethane. Subsequent treatment under acidic conditions such as trifluoroacetic acid in dichloromethane to remove the tert-butoxycarbonyl group provides compounds of formula (1-8). Compounds of formula (1-8) can be reacted with an alkoxide base, for example, sodium methoxide in optionally hot methanol or a mixture of methanol and water or potassium tert-butoxide in tetrahydrofuran and then neutralized with an acid such as 1 M hydrochloric acid to give the compounds of formula (1-9) or formula (1-10). Compounds of formula (1-9) can be converted to compounds of formula (1-11) with water under cross-coupling reaction conditions such as water in the presence of a precatalyst, RockPhos Pd G3, a base, carbonate cesium and a hot solvent, N,Ndimethylformamide. The optionally substituted benzyl ether of compounds of formula (1-10) can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at -60 to -80 °C to give the compounds of the formula (1-12 ). Compounds of formula (1-12) are representative of compounds of formula (I). n j cnon / zznz / q / υιλι Reaction scheme 2: Representative reaction scheme 182 for the synthesis of example compounds of the description. n j cnon / zznz / q / υιλι Or r| F O'.'g-NH Br· · N ' ]| .1 .1 r'-R· R'OCHAr R-R': EITHER R I O-S-NH '.TO. Yo. iNb--o J...J.R'R R'। 'f OH R';RR·'1,N. r- - H1' (2-3 > ’ R □crdicicreá of 'eacdon of cross-plating N· 2· oeáCOteodó'1.o. R-' H1> (2-5) * RO R' R' I Olg-NH Ñ. ' .1. < , .J ...... RCR R' and । OH R R (2-1 i EITHER R1F O--'s-NNo... * ñ(5j .. ... ...... R'RR । ' -f OH R R (2-6) EITHER Ri f O-'s-nh. .. .. 1. L._ Ñ O .J .. ... .. ... RRr । γΌΗr· r7(2-a í As shown in the compounds of formula (2-2) (2-6) and formula (2-8) Reaction scheme 2, formula (2-4), formula can be prepared from compounds of formula (1-9). The compounds of the formula 183 (1-9) can be reacted under C cross-coupling reaction conditions. For example, Suzuki reaction conditions can be used to couple compounds of formula (1-9) with compounds of formula (2-1 ), where A represents an alkene, cyclopropyl or aromatic or partially unsaturated ring residue. Reaction conditions for coupling compounds of formula (1-9) with compounds of formula (2-1) may include a catalyst, (tetrakis(triphenylphosphine)palladium (0), 1,1-bis( diphenylphosphino)ferrocene-palladium (II)-dichloromethane or [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II)) dichloride) and a base (sodium carbonate, potassium carbonate or cesium carbonate) in hot dioxane, a mixture of dioxane and water or a mixture of tetrahydrofuran and water. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5pentamethylbenzene in dichloromethane at -60 to -80 °C to give the compounds of formula (2-2). Additionally, an unsubstituted benzyl ether can be removed by treatment with hydrogen and a palladium catalyst in a solvent such as dioxane or tetrahydrofuran. Compounds of formula (2-2) or the protected precursor can also be modified as known n i cnon / zznz / q / υιλι 184 one skilled in the art and as illustrated in the Examples. Compounds of formula (1-9) can be reacted under N cross-coupling reaction conditions. For example, Buchwald-Hartwig reaction conditions can be used to couple compounds of formula (1-9) with compounds of the formula (2-3). For example, compounds of formula (1-9) and compounds of formula (2-3) can be coupled in the presence of a precatalyst (BrettPhos Pd G3 or RuPhos Pd G3) or catalyst (palladium (II) acetate), a ligand (BrettPhos, RuPhos or Xantphos) and a base (sodium tert-butoxide or cesium carbonate), in a hot solvent such as dioxane, N, N-dimethylacetamide or tert-amyl alcohol. Subsequently, the optionally substituted benzyl ether protecting group can be removed as previously described to give the compounds of formula (2-4), wherein NR2-1R2“2 represents a cyclic or acyclic moiety of R2. The compounds of formula (2-4) or the protected precursor can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of the formula (1-9) can be reacted under O cross-coupling reaction conditions. For example, cross-coupling reaction conditions can be used to couple compounds of the formula (1-9) with compounds of the formula (2-5) . For example, compounds of the formula (1-9) and compounds of the formula (2 n t cnon / zznz / q / υιλι 185 5) can be coupled in the presence of a precatalyst, RockPhos Pd G3 and a base, cesium carbonate, in a hot solvent such as N,N-dimethylformamide. Subsequently, the optionally substituted benzyl ether protecting group can be removed as previously described to give the compounds of formula (2-6), wherein OR2-3 represents an ether moiety of R2. The compounds of formula (2-6) or the protected precursor can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of the formula (1-9) can be reacted under C cross-coupling reaction conditions. For example, compounds of the formula (1-9) can be coupled with allyl compounds of the formula (2-7). , where R2-4represents the R2 residue beyond the allyl residue. Reaction conditions for coupling compounds of formula (1-9) with compounds of formula (2-7) may include a catalyst, such as palladium (II) acetate, a phosphine ligand, such as 2-(di -tert-butylphosphino)biphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl or 4,5bis (diphenylphosphino)-9,9-dimethylxanthene and a base, such as a tertiary amine base, for example, triethylamine or cesium carbonate, in a hot solvent, such as N,Ndimethylformamide or dioxane. Subsequently, the optionally substituted benzyl ether protecting group can be removed as previously described to give the n t cnon / zznz / q / υιλι compounds. 186 formula to give the compounds of formula (2-8). The n j cnon / zznz / q / υιλι compounds of formula (2-8) or the protected precursor can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (2-2), formula (2-4), formula (2-6) or formula (2-8) are representative of compounds of formula (I) or are precursors of the compounds of formula (I). Reaction scheme 3: Representative reaction scheme for the synthesis of example compounds of the description. 0 0 1 O-’S-MI 1 1 1 d R' 1 ’° 1; R< '-LO1. base ¿ R1 .1. 1 O.-’s-NH '^0 J ..-1 Rh R' - ΪΙ R' I Γ OCH Ai 2 ' i : ’γ ’γ Rh R' OH R R? 1 R R- (1-11 ) L R- r'1 1.3- 1) O R' F O.--S - NH ccndiac-ies de -eacciin M its11 Γ'θΙ)1 J q 1 1 * | .... ...... H R ¿o □esc'dtsdcjc'' ^2 T Κ- ι 3 Ύ R -Ti OH 0 r' ·' R1 i O.-g-NH VR'-'-NCO DMAP 0. 1 Y r' '-'O ► H ¥ 2j desc'ctsccicn 0 i R . R R q- OI 1 R“ R i.· 1-2 i As shown in Reaction Scheme 3, compounds of formula (3-1) and formula (3-2) can be prepare from compounds of the formula (1-11). The 187 compounds of the formula (1-11) can be alkylated with compounds of the formula R3-1-LG1, where LG1 is a leaving group such as chloro, bromo, iodo or sulfonate and R3-1 is an optionally substituted alkyl, optionally heterocyclyl substituted or optionally substituted cycloalkyl. Alkylation conditions may include treatment with a base, such as but not limited to cesium carbonate or sodium hydride, in an optionally hot solvent, such as N,N-dimethylformamide. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at -60 to -80 °C to give the compounds of the formula (3-1 ). An unsubstituted benzyl ether can also be removed by reduction with hydrogen in the presence of a palladium on carbon catalyst in a solvent such as tetrahydrofuran at or near room temperature. The compounds of formula (3-1) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. The OR3-1 group represents an n t cnon / zznz / q / υιλι ether residue of R2. 188 An alternative preparation of compounds of the formula (3-1) involves the reaction of compounds of the formula (1-11) with compounds of the formula R3-1-OH, where R3-1 is an optionally substituted alkyl or optionally substituted cycloalkyl. , under Mitsunobu reaction conditions. Accordingly, compounds of formula (1-11) and compounds of formula R3-1-OH can be treated with (E) diazen-1,2-diylbis(piperidin-l-ylmethanone) and tri-nbutylphosphine in a solvent such as hot tetrahydrofuran. Subsequent removal of the benzyl protecting group as described above gives compounds of the formula (3-1). The compounds of formula (3-1) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of the formula (1-11) can also be transformed into compounds of the formula (3-2). Compounds of the formula (1-11) can be reacted with compounds of the formula R3-2-NCO, where R3-2 is an optionally substituted Ci-6 alkyl, in the presence of 4-dimethylaminopyridine in a solvent such as N, Ndimethylformamide to give the corresponding carbamate. Subsequent removal of the benzyl protecting group as described above gives compounds of the formula (3-2). The OC(O)NHR3~2 group represents a carbamate residue of R2. The n t cnon / zznz / q / υιλι compounds of the formula (3-2) or the corresponding 189 protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (3-1) and formula (3-2) are representative of compounds of formula (I) or are precursors of compounds of formula (I). Reaction Scheme 4: Representative reaction scheme for the synthesis of example compounds of the description. , 2. .ltJrfo orro P R-B ORrR' i Oás-NHBr-.. ,1;., ,A, ,N ' R^o 0Rrdti 1 .i N 2^0 'l , / ,,. (4-1Ί RBO' γ, , -1 R R I ... ... R.ÍR' R [ j OCII.Ar r- -,-.-· -γ- ocH.Ar R“ Rk'Π'9' (4-2iR.1-i g’ I >4-3) de accclamie^td zr^zasz C T o r'fO-'-s-NH Rl'1- ί-, .-4-.. .. N -.., I. R': RR । । Oh R R (4-4 i As shown in Reaction Scheme 4, compounds of formula (4-4) can be prepared from compounds of formula (1-9). Compounds of formula (1-9) can be reacted under cross-coupling reaction conditions with a boron reagent of formula (41), such as bis(pinacolato)diboron, where one RB connects to another RB, to give the compounds of formula (4-2). The reaction conditions for coupling compounds of the formula n j cnon / zznz / q / υιλι (1-9) with compounds of the formula (4-1) may include a 190 catalyst ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II), complex with dichloromethane) and base (potassium acetate or potassium carbonate) in hot dioxane. Compounds of formula (4-2) can be further coupled with compounds of formula (4-3), where R2c represents an aromatic or partially unsaturated ring, an alkyl group or an alkylene group and LG2 is a leaving group such as iodine. , bromine or chlorine. Reaction conditions for coupling compounds of formula (4-2) with compounds of formula (4-3) may include a catalyst (tetrakis(triphenylphosphine)palladium(0), XPhos Pd G2 or meCgPPh Pd G3) and a base (sodium carbonate, potassium phosphate or potassium carbonate) in a hot mixture of toluene and ethanol or dioxane and water or N-methyl-2-pyrrolidinone. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at -60 to -80 °C to give the compounds of the formula (4-4 ). The compounds of formula (4-4) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (4-4) are representative of n t cnon / zznz / q / υιλι 191 compounds of formula (I) or are precursors of compounds of formula (I). Reaction scheme 5: Representative reaction scheme n j cnon / zznz / q / υιλι for the synthesis of exemplary compounds of the description R1 i 0 H· - 0 .-'S-NH ' B \_rpr -N--, Ü ' 1 R R' j... F 0 O.-.'s -NH N. _I 0 11 ...1 ...1 R · · R4 R' (1-9: R1, R 1 - OCH¿Ar ocndicicres of 'eaco R1 i 1 'and R·'· T' Rr ' (5-31 1 R - R' ΌΗ 1 2.· 2esc'2iecoc° A Or pg: R1(O--g-N ' b \_r~'R •i· . · N' J ,1 ,1 k'- k _____XV_______________________ R· γ oR’R PG?ccrsix-esde-e^ (5-2; f=t2édzx 2) desc'ctecdcr As shown in Reaction Scheme 5, compounds of formula (5-3) can be prepared from compounds of formula (1-9). Compounds of formula (1-9) can be coupled with compounds of formula (5-1), where RPR is a potassium trifluoroborate or carboxylic acid moiety and where B represents an optionally substituted heterocyclyl or optionally substituted alkyl. under photoredox conditions. The conditions for coupling compounds of formula (1-9) and compounds of formula (5-1) are treatment with N1CI2 dimethoxyethane adducts, a ligand (4,4'-di-tert-buty1-2,2'- dipyridyl), a base 192 (cesium carbonate) and bis[3,5-difluoro-2-[5(trifluoromethi1)-2-pyridyl]phenyl]iridium(1 +) ; 2- (2pyridyl)pyridine; hexafluorophosphate in solvents such as dioxane with optional N,N-dimethylacetamide in a 450 nm LED photoreactor. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by hydrogenation in the presence of palladium on carbon catalyst in tetrahydrofuran to give the compounds of formula (5-3). Alternatively, the reaction conditions described above also couple compounds of formula (51) with compounds of formula (5-2), where PG3 is (2methoxyethoxy)methyl. Deprotection of one or more protecting groups can be achieved by treatment with hydrochloric acid in dioxane to give the compounds of formula (5-3). The compounds of formula (5-3) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (5-3) are representative of compounds of formula (I) are precursors of the n j cnon / zznz / q / υιλι 193 compounds of formula (I). Reaction Scheme 6: Representative reaction scheme for the synthesis of example compounds of the description. O Ho pg1 R’FO--S-N, οΛ-ΝΗ v.R-z1i . 1 Z >O X. X ¿R7 i:6'2i- T I X Z * R Y Y or OPG' <:r OH . ·· either O Q-· ocroiacnes de'eacicn,। of accplamiertcK K|G-Ú(6-3! 2; aesc-ctecdc cpoc-a n j cnon / zznz / q / υιλι As shown in Reaction Scheme 6, compounds of formula (6-3) can be prepared from compounds of formula (6-1). Compounds of the formula (6-1), wherein PG1 is a protecting group such as (2methoxyethoxy)methyl and PG2 is an optionally substituted benzyl group or (2-methoxyethoxy)methyl can be coupled with compounds of the formula (6-2) , where R6-1 is an optionally substituted alkyl group, optionally substituted cycloalkyl group or optionally substituted heterocyclyl group. The conditions for coupling compounds of formula (6-1) with compounds of formula (6-2) are treatment with a catalyst (Pd SPhos G4) in hot N,N-dimethylacetamide. When present, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, a benzyl ether does not Substituted 194 (PG2) can be removed by hydrogenation in the presence of a palladium catalyst on carbon or after treatment with trichloroborane in dichloromethane to give the compounds of formula (6-3). When PG1 or PG2 is a (2-methoxyethoxy)methyl group, one or both can be removed by treatment with an acid such as hydrochloric acid in dioxane to give the compounds of formula (6-3). The compounds of formula (6-3) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (6-3) are representative of n t cnon / zznz / n / υιλι compounds of formula (I) or are precursors of compounds of formula (I). Reaction Scheme 7: Representative reaction scheme for the synthesis of example compounds of the description. o p, o R-FO-.-g-NH Η1I O--S--NH ,rβΓJ... J. fsj 2:-desc'dtecoe'’ Br... ..--0-,. .- TO:--. .- N -,fθ C' \ J ... J R2R;* 0, R' p O-SNH Xv-. --L A.. , ñ ... J.-X. R'R' R y' OH R:Rr’ (2-2) As shown in Reaction Scheme 7, compounds of formula (2-2) can be prepared from compounds 195 of formula (1-9) in a reverse synthetic sequence of that described in Reaction Scheme 2. In the first step, the optionally substituted benzyl moiety can be removed using conditions known to one skilled in the art and depending on the ether particular benzylic. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at -60 to -80 °C to give the compounds of the formula (7-1 ). Compounds of formula (7-1) can be reacted under C cross-coupling reaction conditions. For example, Suzuki reaction conditions can be used to couple compounds of formula (7-1) with compounds of formula (2-1), where A represents an alkene moiety, a cyclopropyl ring or an aromatic ring or a partially unsaturated ring. The corresponding boronic acids of compounds of formula (2-1) are also suitable for the coupling reaction. Reaction conditions for coupling compounds of formula (7-1) with compounds of formula (2-1) may include a catalyst (1, 1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride) and a base (sodium carbonate or potassium carbonate) in hot dioxane or a mixture of dioxane and water. The compounds of formula (2-2) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. 196 Compounds of formula (2-2) are representative of n j cnon / zznz / q / υιλι compounds of formula (I) or are precursors of compounds of formula (I). Reaction Scheme 8: Representative reaction scheme for the synthesis of example compounds of the description. h2o cross-coupling reactionRiF RsyC02-(crC4 alkyl)hd I ' d l| I I alkoxide base --------------* (8 6) R4R5 oRiFoíXnu (8-8) As shown in Reaction Scheme 8, compounds of formula (8-7) and formula (8-8) can be prepared from compounds of formula (8-1). Compounds of formula (8-1) can be brominated with bromine in chloroform at room temperature to give compounds of 197 formula (8-2). Compounds of formula (8-2) can be selectively debrominated with tin in the presence of an acid such as concentrated hydrochloric acid in heated ethanol to provide compounds of formula (8-3). Compounds of formula (8-3) can be fluorinated by treatment with Nfluoro-N-(phenylsulfonyl)benzenesulfonamide in tetrahydrofuran, treatment with N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran or Selectfluor® in N, V-dimethylf ormamide optionally heated to give compounds of formula (8-4). Compounds of formula (84) can be reacted with 2-bromoacetates of formula (1-5) in the presence of a base such as N,Ndiisopropylethylamine or potassium carbonate in hot solvent such as but not limited to a mixture of N ,Ndimethylformamide and water to give the compounds of formula (8-5). Compounds of formula (8-5) can be reacted with sulfurisocyanatid chloride and tert-butanol in the presence of a tertiary amine base such as triethylamine in a solvent such as cold dichloromethane. Subsequent treatment under acidic conditions such as trifluoroacetic acid in dichloromethane to remove the tert-butoxycarbonyl group provides compounds of formula (8-6). Compounds of formula (8-6) can be reacted with an alkoxide base, for example, sodium methoxide in optionally hot methanol or a mixture of methanol and water n j cnon / zznz / q / υιλι 198 or potassium tert-butoxide in tetrahydrofuran and then neutralized with an acid such as 1 M hydrochloric acid to give the compounds of formula (8-7). Compounds of formula (8-7) can be converted to compounds of formula n j cnon / zznz / q / υιλι (8-8) with water under cross-coupling reaction conditions such as water in the presence of a precatalyst, ( RockPhos Pd G3), a ligand (RockPhos), a base (cesium carbonate) and a hot solvent, N,N-dimethylacetamide. Reaction Scheme 9: Representative reaction scheme for the synthesis of example compounds of the description. oR r> p 0~¿-NH,N. ->11 'A R9 RAAyAA^A0 1»(9-1) r6 R / -----------* Br ~Τ OCH2Ar reaction conditions R4Rcross coupling N (8-7) 2) checkout .0. r9-3 (9-3) O cross-coupling reaction conditions EITHER (9 2) EITHER 2) checkout As shown in Reaction Scheme 9, compounds of formula (8-7) can be reacted under N cross-coupling reaction conditions. For example, Buchwald-Hartwig reaction conditions can be used to couple compounds of formula (8-7) with compounds of the 199 formula (9-1). For example, compounds of formula (8-7) and compounds of formula (9-1) can be coupled in the presence of a precatalyst (BrettPhos Pd G3 or RuPhos Pd G3) or catalyst (palladium (II) acetate), a ligand (BrettPhos, RuPhos or Xantphos) and a base (sodium tert-butoxide or cesium carbonate), in a hot solvent such as dioxane, tert-amyl alcohol or N,N-dimethylformamide. Subsequently, the optionally substituted benzyl ether protecting group can be removed as previously described to give the compounds of formula (9-2), wherein NR9-1R9“2 represents a cyclic or acyclic moiety of R3. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, an unsubstituted benzyl ether can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane at -60 to -80 °C followed by heating to 0 °C to give the compounds of the formula (9-2). An unsubstituted benzyl ether can also be removed by reduction with hydrogen in the presence of a palladium on carbon catalyst in a solvent such as tetrahydrofuran at or near room temperature. Another alternative involves the removal of an unsubstituted benzyl ether by transfer hydrogenation using a n t cnon / zznz / q / υιλι catalyst. 200 palladium on carbon in the presence of ammonium formate in optionally heated ethanol. The compounds of formula (9-2) or the protected precursor can also be modified as is known to one skilled in the art and as illustrated in the Examples. Compounds of formula (9-2) are representative of compounds of formula (I) or are precursors of compounds of formula (I). Compounds of formula (8-7) can be reacted under O cross-coupling reaction conditions. For example, cross-coupling reaction conditions can be used to couple compounds of formula (87) with compounds of formula ( 9-3). For example, compounds of formula (8-7) and compounds of formula (9-3) can be coupled in the presence of a precatalyst (RockPhos Pd G3) or a catalyst (tris(dibenzylideneacetone)dipalladium(0)), a catalyst optional (di-tere-butyl(2',4',6'-triisopropyl-3,6-dimethoxy[ 1,1'-biphenyl]-2-yl)phosphine) and a base (cesium carbonate), in a heated solvent such as N,N-dimethylformamide or N,Ndimethylacetamide. Subsequently, the optionally substituted benzyl ether protecting group can be removed as previously described to give the compounds of formula (9-4), wherein OR9-3 represents an ether moiety of R3. Compounds of formula (9-4) or the protected precursor can also be modified as known to one skilled in the art and as n t cnon / zznz / q / υιλι 201 is illustrated in the Examples. Compounds of formula (9-4) are representative of compounds of formula (I) or are precursors of compounds of formula (I). Reaction Scheme 10: Representative reaction scheme for the synthesis of example compounds of the description. oRiF0®s-NH o r21 1 ¿I >o R' f Ods-NH ji γ η 'i - D R10’-LG'. base r- 1 i n Λ1 1 r6|< _______. Τύύ ho y y οαΐΛ rio-i II .1 .1 r6R'(^5 2) deprotection (8-8)R4 RJ(10 1) As shown in Reaction Scheme 10, compounds of formula (10-1) can be prepared from compounds of formula (8-8). Compounds of formula (8-8) can be alkylated with compounds of formula R10-:-LG1, where LG1 is a leaving group such as chloro, bromo, iodine or sulfonate and R10-1 is an optionally substituted alkyl. The alkylation conditions may include treatment with a base, such as, but not limited to, cesium carbonate, potassium phosphate or sodium hydride, optionally in the presence of tetrabutylammonium bromide in an optionally heated solvent, such as N,N- dimethylformamide or N, N-dimethylacetamide. Subsequently, the optionally substituted benzyl ether protecting group can be removed using conditions known to one skilled in the art and depending on the particular benzyl ether. For example, a benzyl ether does not Substituted 202 can be removed by treatment with trichloroborane in the presence of 1,2,3,4,5-pentamethylbenzene in dichloromethane or by catalytic hydrogenation or transfer hydrogenation as described in Reaction Scheme 9 to provide compounds of formula (10- 1). The compounds of formula (10-1) or the corresponding protected precursors can also be modified as is known to one skilled in the art and as illustrated in the Examples. The OR10-1 group represents an ether moiety of R3. Compounds of formula (10-1) are representative of compounds of formula (I) or are precursors of compounds of formula (I) Reaction Scheme 11: Representative reaction scheme for the synthesis of example compounds of the description. n j cnon / zznz / q / υιλι BrN'SO2NHf ρόγ(:°2 CO2-(CrC4 alkyl) r1f Reycor(c,-C4 alkyl) JLAY(w;(31) NaOCH3 AtCH-0 'yY'OCHW ¿4 p5 2) OCNSO,CI. f-BuOH (11 3)K K R1 ArCH,0 R4 OCH:Ar R5 1)H* dalkoxide base (11 4) (11 I>) O R reaction F o1s„nh •η couplingRcross μ jT / -'D, _______ 1 A A r- R hoYy^oh 2) lack of protection ', 1., (11-6) 203 As shown in Reaction Scheme 11, compounds of formula (11-6) can be prepared from compounds of formula (11-1). Compounds of formula (11-1) can be fluorinated by treatment with N-fluoro-N(phenylsulfonyl)benzenesulfonamide in tetrahydrofuran, treatment with N-fluorobenzenesulfonimide (NFSI) in a solvent such as tetrahydrofuran, or treatment with Selectfluor® in N, ΛΖ -dimethylformamide optionally heated to give compounds of formula (11-2). Compounds of formula (11-2) can be reacted with trifluoroacetic anhydride in a solvent such as acetonitrile. Subsequent reaction with 2-bromoacetates of formula (1-5) in the presence of a base such as N,7V-diisopropylethylamine or potassium carbonate in heated solvent such as, but not limited to, N,N-dimethylformamide or a mixture of N,Ndimethylformamide and water provides compounds of formula (113). Compounds of formula (11-3) can be converted to compounds of formula (11-4) in a two-step process. Compounds of formula (11-3) can be reacted with sodium methoxide in optionally heated methanol to remove the trifluoroacetyl group. Then, reaction with chlorosulfonyl isocyanate and tert-butanol in the presence of a tertiary amine base such as triethylamine in a solvent such as cooled dichloromethane provides compounds of formula (11-4). Another two-stage sequence transforms n j cnon / zznz / q / υιλι 204 compounds of formula (11-4) in compounds of formula (11-5). Treatment under acidic conditions such as trifluoroacetic acid in dichloromethane removes the tert-butoxycarbonyl group. Then, reaction with an alkoxide base, ex vivo, sodium methoxide in optionally heated methanol or a mixture of methanol and water or potassium tert-butoxide in tetrahydrofuran followed by inactivation with an acid such as 1 M hydrochloric acid provides compounds of formula (115) . Compounds of the formula (11-5) can be converted to compounds of the formula (11-6). Compounds of formula (11-5) can be cross-coupled under the cross-coupling reaction conditions described in Reaction Scheme 1, Reaction Scheme 2, Reaction Scheme 4, Reaction Scheme 5, Reaction Scheme 6 o Reaction scheme 7 to introduce the representative residues of R2. Removal of the two phenol protecting groups under conditions for one skilled in the art provides compounds of formula (11-6). Compounds of formula (116) are representative of compounds of formula (I). n j cnon / zznz / q / υιλι 205 Reaction Scheme 12: Representative reaction scheme n j cnon / zznz / q / υιλι for the synthesis of example compounds of the description. As shown in Reaction Scheme 12, compounds of formula (12-3) can be prepared from compounds of formula (11-5). Compounds of formula (11-5) can be cross-coupled with water to provide compounds of formula (12-1). Compounds of formula (12-1) can be alkylated with R12-2-LG1, where LG1 is a leaving group such as chloro, bromo, iodine or sulfonate and R12-2 is an optionally substituted alkyl, -Ci-6 alkylene-C3 cycloalkyl -6 optionally substituted, -optionally substituted heterocyclyl, -optionally substituted 5-6-membered alkylene Ci-g-heteroaryl, -optionally substituted 4-6-membered alkylene Ci-6-heterocyclyl or optionally substituted cycloalkyl. Alkylation conditions may include treatment with a base, such as but not limited to 206 cesium carbonate or sodium hydride, in an optionally hot solvent, such as N,N-dimethylformamide. Compounds of formula (12-2) can also be modified as is known to one skilled in the art and as illustrated in the Examples. Removal of the two phenol protecting groups under conditions for one skilled in the art provides compounds of formula (12-3). Compounds of formula (123) are representative of compounds of formula (I). Reaction Scheme 13: Representative reaction scheme for the synthesis of example compounds of the description. n j cnon / zznz / q / υιλι As shown in Reaction Scheme 13, compounds of formula (13-4) can be prepared from compounds of formula (1-11). Compounds of formula (1-11) can be alkylated with 2-bromo-l,1-dimethoxyethane and then further hydrolyzed under acidic conditions to give compounds of formula (13-1). Compounds of the formula (13-1) can be reductively alkylated with compounds of the formula 207 (13-2); wherein R13-2 is independently in each occurrence hydrogen, optionally substituted Ci-& alkyl or optionally substituted C3-6 cycloalkyl or the compounds of formula (13-2) are an optionally substituted 4-6 membered heterocyclyl; to give the compounds of formula (13-3). Compounds of formula (13-3) can also be modified as is known to one skilled in the art and as illustrated in the Examples. Removal of the phenol protecting groups under conditions for one skilled in the art provides compounds of formula (13-4). Compounds of the formula (13-4) are representative of compounds of the formula (I). Pharmaceutical compositions The present description provides pharmaceutical compositions comprising a compound described herein, ex vivo, a compound of formula (I), formula (Ha), formula (Ilb), formula (III), formula (IV) or formula (V ). In some embodiments, the pharmaceutical composition also comprises a pharmaceutically acceptable excipient. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) is provided in an effective amount in the pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective quantity is a quantity n j cnon / zznz / q / υιλι 208 prophylactically effective. The pharmaceutical compositions described herein can be prepared by any method known in the pharmacological art. In general, such preparatory methods include the steps of bringing the described compound (the active ingredient) into association with a carrier and / or one or more other accessory ingredients, and then, if necessary and / or desirable, forming and / or package the product in a desired single or multiple dose unit. The pharmaceutical compositions may be prepared, packaged and / or sold in bulk, in the form of a single unit dose, and / or in the form of a plurality of single unit doses. As used herein, a unit dose is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject and / or a convenient fraction of such a dosage such as, for example, one-half or one-third of the dosage. The relative amounts of a compound described herein, for example, a compound of formula (I), formula (Ha), formula (Ilb), formula (III), formula (IV) or formula (V), of the pharmaceutically acceptable excipient, and / or of any additional ingredient in a n t cnon / zznz / q / υιλι 209 pharmaceutical composition of the description will vary, depending on the identity, size and / or condition of the treated subject and also depending on the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w / w) of a compound described herein. The term pharmaceutically acceptable excipient refers to a non-toxic carrier, adjuvant, diluent or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the description are any of those that are well known in the art of pharmaceutical formulations and include inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrants, binding agents, preservatives, buffering agents, lubricating agents and / or oils. Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the disclosure include without limitation, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes, such as n t cnon / zznz / q / υιλι 210 such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, copolymers of polyethylene-polyoxypropylene block, polyethylene glycol and lanolin. The compositions of the present disclosure may be administered orally, parenterally (including subcutaneous, intramuscular, intravenous and intradermal administration), by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. . In some embodiments, the compounds or compositions provided may be administered intravenously and / or orally. The term parenteral, as used herein, includes subcutaneous, intravenous, intramuscular, infraocular, intravitreal, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intraperitoneal, intralesional, and intracranial injection or infusion techniques. It is preferred that the compositions be administered orally, subcutaneously, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this disclosure may be aqueous or oleaginous suspensions. These suspensions can be formulated according to n t cnon / zznz / q / υιλι techniques 211 known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally acceptable non-toxic diluent or solvent, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. The pharmaceutically acceptable compositions of this disclosure may be administered orally in any orally acceptable dosage form including, without limitation, capsules, tablets, suspensions or aqueous solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn cotton. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents can also be added. In some embodiments, an oral formulation is formulated for immediate release or n t cnon / zznz / q / υιλι release. 212 sustained / delayed. In some embodiments, the composition is suitable for buccal or sublingual administration, including tablets, lozenges and lozenges. A compound described herein may also be in microencapsulated form. The compositions of the present disclosure can be administered transdermally, topically, formulated as application sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders and aerosols. Oral preparations include tablets, lozenges, powder, dragees, capsules, liquids, lozenges, tablets, gels, syrups, suspensions, etc., suitable for ingestion by the patient. Preparations in solid form include powders, tablets, pills, capsules, capsules, suppositories and dispersible granules. Liquid form preparations include solutions, suspensions and emulsions, for example, water or water / propylene glycol solutions. The compositions of the present disclosure may additionally include components to provide sustained release and / or comfort. Such components include high molecular weight anionic mucomimetic polymers, gelling polysaccharides and finely divided drug carrier substrates. These components are discussed in greater detail in US Patent Nos. 4,911,920; 5,403,841; 5,212,162 and 4,861,760. The totality n t cnon / zznz / q / υιλι 213 of the content of these patents is incorporated herein by reference for all purposes. The compositions of the present disclosure may also be supplied as microspheres for slow release into the body. For example, microspheres can be administered by intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7: 623-645, 1995), as biodegradable gel formulations. and injectables (see, for example, Gao Pharm. Res.12: 857-863, 1995), or, as microspheres for oral administration (see, for example, Eyles, J. Pharm. Pharmacol. 49:669-674, 1997 ). In another embodiment, the formulations of the compositions of the present description can be administered through the use of liposomes that fuse with the cell membrane or are endocytosed, that is, using receptor ligands attached to the liposome, which bind to protein receptors. surface membrane of the cells, resulting in endocytosis. Through the use of liposomes, particularly when the surface of the liposome carries receptor ligands specific for the target cells, or when preferentially directed to a specific organ, the release of the compositions of the present disclosure in the cells can be focused. in vivo target. (See, ex vivo, Al-Muhammed, J. Microencapsul. 13:293306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; n j cnon / zznz / q / υιλι 214 Ostro, J. Hosp. Pharm. 46: 1576-1587, 1989). The compositions of the present invention can also be administered in the form of nanoparticles. Alternatively, the pharmaceutically acceptable compositions of this disclosure may be administered in the form of suppositories for rectal administration. The pharmaceutically acceptable compositions of this disclosure may also be administered topically, especially when the target of treatment includes areas or organs easily accessible by topical application, including diseases of the eye, skin or lower intestinal tract. Suitable topical formulations are easily prepared for each of these areas or organs. In some embodiments, in order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug by subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with poor solubility in water. The rate of drug absorption then depends on its rate of dissolution, which, in turn, may depend on the size of its crystals and its crystalline form. Alternatively, delayed absorption of a parenterally administered form of drug is carried out by dissolving or suspending the drug in an oleaginous vehicle. n j cnon / zznz / q / υιλι 215 Although the descriptions of pharmaceutical compositions provided herein are primarily oriented toward pharmaceutical compositions that are suitable for administration to humans, the skilled person will understand that such compositions are generally suitable for administration to animals of all types. The modification of pharmaceutical compositions suitable for administration to humans in order to make the compositions suitable for administration to various animals is well understood, and the veterinary pharmacologist of ordinary skill can design and / or modify with experimentation. ordinary. The compounds provided herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) are typically formulated in unit form dosage, ex vivo, single unit dosage form, for ease of administration and dosage uniformity. It will be understood, however, that the total daily use of the compositions of the present description will be decided by the attending physician within the scope of sound medical judgment. The therapeutically effective dose level for any particular subject or organism will depend on a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient used; the n j cnon / zznz / q / υιλι 216 specific composition used; the subject's age, body weight, general health, sex, and diet; the time of administration, the route of administration and the rate of excretion of the specific active ingredient used; the duration of treatment; drugs used in combination or coincidentally with the specific active ingredient used; and similar factors well known in medicine. The exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending on, for example, the species, age and general condition of a subject, severity of side effects or disorder, identity of the compound(s). particular compounds, mode of administration, and the like. The desired dose may be administered three times a day, twice a day, once a day, once every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be administered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or more administrations). It will be understood that the dosage ranges described herein provide guidance for administration of the provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or adolescent, can be determined by n t cnon / zznz / q / υιλι 217 a doctor or expert, and may be less than or equal to that administered to an adult. It will also be understood that a compound or composition described herein may be administered in combination with one or more additional pharmaceutical agents. The compounds or compositions may be administered in combination with additional pharmaceutical agents that improve their bioavailability, reduce and / or modify their metabolism, inhibit their excretion and / or modify their distribution within the body. It will also be understood that the therapy employed may achieve a desired effect for the same disorder, and / or may achieve different effects. The compound or composition may be administered simultaneously with, before or after, one or more additional pharmaceutical agents, which may be useful as, for example, combination therapies. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Each additional pharmaceutical agent may be administered at a dose and / or according to a time schedule determined for the pharmaceutical agent. The additional pharmaceutical agents may also be administered together with each other and / or together with the compound or composition described herein in a single dose or may be administered separately in different doses. The combination n t cnon / zznz / q / υιλι 218 particular to be used in a regimen will take into account the compatibility of the compound of the invention with the additional pharmaceutical agents and / or with the therapeutic and / or desired effect to be obtained. In general, it is expected that additional pharmaceutical agents used in combination will be used at levels that do not exceed the levels at which they are used individually. In some embodiments, the levels used in combination will be lower than those used individually. Examples of additional pharmaceutical agents include, without limitation, antiproliferative agents, anticancer agents, antidiabetes agents, anti-inflammatory agents, immunosuppressive agents, and pain relieving agents. Pharmaceutical agents include small organic molecules such as drug compounds (for example, compounds approved by the United States Food and Drug Administration under the Code of Federal Regulations (CFR)), peptides , proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small protein-bound molecules, glycoproteins, spheroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins and cells. n t cnon / zznz / q / υιλι 219 The pharmaceutical compositions provided by the present invention include compositions wherein the active ingredient (e.g., the compounds described herein, including embodiments and examples) is contained in a therapeutically effective amount, that is, in an amount effective to achieve the intended purpose. The total effective amount effective for a particular application will depend, among other things, on the condition being treated. When administered in methods of treating a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, for example, inhibition of the activity of a target molecule (for example, PTPN2 and / or PTPN1), and / or or reduction, elimination or slowing of the progression of disease symptoms. Determination of a therapeutically effective amount of a compound described herein is well within the capabilities of those skilled in the art, especially in light of the detailed description herein. The dose and frequency (single or multiple doses) administered to a mammal can vary depending on a variety of factors, for example, whether the mammal suffers from another disease, and the route of administration; size, age, sex, health, body weight, body mass index and diet of the recipient; the nature and extent of symptoms of n t cnon / zznz / q / υιλι 220 disease being treated, type of concurrent treatment, complications caused by the disease being treated, or other health-related problems. Other therapeutic regimens or agents may be used in conjunction with the methods, compounds and compositions described herein. Adjustment and manipulation of established doses (e.g., frequency and duration) are well within the ability of those skilled in the art. For any compound described herein, the therapeutically effective amount can initially be determined from cell culture assays. The target concentrations will be those concentrations of the active compound(s) that are capable of obtaining the results described herein, measured using the methods described herein or known in the art. As is well known in the art, therapeutically effective amounts for use in humans can also be determined from animal models. For example, a human dose may be formulated to achieve a concentration that has been found to be effective in animals. Dosage in humans can be adjusted by monitoring the effectiveness of the compounds and adjusting the dose up or down, as described above. Adjusting the dose to achieve maximum effectiveness in non-t cnon / zznz / q / υιλι beings 221 humans based on the methods described above and other methods is well within the capabilities of the person skilled in the art. Doses can be varied depending on the patient's requirements and the compound used. The dose administered to a patient, in the context of the present disclosure, should be sufficient to effect a beneficial therapeutic response in the patient over time. The magnitude of the dose will also be determined by the existence, nature and extent of any adverse side effects. Determining the appropriate dosage for a particular situation is within the physician's ability. Generally speaking, treatment is started with smaller dosages that are less than the optimal dose of the compound. Subsequently, the dosage is increased in small increments until the optimal effect under the circumstances of the case is achieved. Dosage amounts and intervals can be individually adjusted so as to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that will be commensurate with the severity of the individual's disease state. Using the teachings provided herein, a treatment regimen can be planned n t cnon / zznz / q / υιλι 222 effective prophylactic or therapeutic that does not cause substantial toxicity and is nevertheless effective in treating the clinical symptoms demonstrated by the individual patient. This planning should include careful choice of the active compound considering factors such as the potency of the compound, its relative bioavailability, the patient's body weight, the presence and severity of adverse side effects, the preferred mode of administration, and the toxicity profile of the drug. selected agent. Also included herein are kits (e.g. pharmaceutical containers). The kits provided herein may be useful for preventing and / or treating a disease (e.g., cancer, type 2 diabetes, obesity, a metabolic disease, or other disease or condition described herein). The kits provided may comprise a pharmaceutical composition or compound of the invention and a container (for example, a vial, an ampoule, a bottle, a syringe and / or dispensing container or other suitable container). In some embodiments, the kits provided may optionally further include a second container comprising a pharmaceutical excipient for the dilution or suspension of a pharmaceutical composition or compound of the invention. In some embodiments, the pharmaceutical composition or compound of the invention provided in the container and the second n t cnon / zznz / q / υιλι 223 container are combined to form a unit dosage form. Thus, in one aspect, kits are provided that include a first container comprising a compound described herein. In certain embodiments, the kits are useful in the prevention and / or treatment of a proliferative disorder in a subject. In certain embodiments, the kits also include instructions for administering a compound described herein to a subject to prevent and / or treat a disease described herein. Treatment methods The present description presents compounds, compositions and methods comprising a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V). In some embodiments, the compounds, compositions and methods described herein are used in the prevention or treatment of a disease, disorder or condition. The diseases, disorders or conditions described include, but are not limited to, cancer, type 2 diabetes, metabolic syndrome, obesity or a metabolic disease. Cancer In some embodiments, a compound described herein is used, ex vivo, a compound of formula (I), n j cnon / zznz / q / υιλι 224 formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) to treat cancer. As used herein, the term cancer refers to human cancers and carcinomas, sarcomas, adenocarcinomas (e.g., papillary adenocarcinomas), lymphomas, leukemias, melanomas, etc., including solid and lymphoid cancers, kidney cancer, breast, lung, bladder, colon, ovary, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, liver cancer, including hepatocellular carcinoma, lymphoma, including B acute lymphoblastic lymphoma, lymphomas non-Hodgkin lymphomas (for example, Burkitt, small cell, and large cell lymphomas), Hodgkin lymphoma, leukemia (including AML, ALL, and CML), and / or multiple myeloma. In some other cases, the term cancer refers to lung cancer, breast cancer, ovarian cancer, epithelial ovarian cancer, leukemia, lymphoma, melanoma, pancreatic cancer, sarcoma, bladder cancer, bone cancer, bile ducts, cancer of the adrenal gland, cancer of the salivary glands, bronchial cancer, mouth cancer, cancer of the mouth or pharynx, cancer of the larynx, kidney cancer, gynecological cancers, brain cancer, cancer of the central nervous system, cancer of the peripheral nervous system, hematological cancer, cancer of the small intestine or appendix, cervical cancer, colon cancer, esophageal cancer, gastric cancer, liver cancer, head and neck cancer, cancer n t cnon / zznz / q / υιλι 225 kidney, myeloma, thyroid cancer, prostate cancer, metastatic cancer or carcinoma. As used herein, the term cancer refers to all types of cancer, neoplasia or malignant tumors found in mammals, including leukemia, lymphoma, carcinomas and sarcomas. Examples of cancers that can be treated with a compound, pharmaceutical composition or method provided herein include lymphoma, B cell lymphoma, heavy chain disease, alpha heavy chain disease, gamma heavy chain disease, heavy chain disease mu, Waldenstrom macroglobulinemia, monoclonal gammopathy of undetermined significance, sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer , myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma , lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, n t cnon / zznz / q / υιλι 226 small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, acoustic neuroma, retinoblastoma, astrocytoma, craniopharyngioma, hemangioblastoma, pinealoma, ependymoma, oligodendroglioma, meningioma, glioma or melanoma. Additional examples include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head and neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, or medulloblastoma. , Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, immunocytic amyloidosis, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulinoma, malignant carcinoid, bladder cancer urinary tract, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, cancer of the genitourinary tract, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary carcinoma of thyroid, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's disease of the nipple, Phyllodes tumors, lobular carcinoma, ductal carcinoma, pancreatic stellate cell cancer, hepatic stellate cell cancer, or prostate cancer. n t cnon / zznz / q / υιλι 227 The term leukemia refers broadly to progressive, malignant diseases of the blood-forming organs and is usually characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally classified clinically on the basis of (1) the duration and character of the disease: acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenic), or monocytic; and (3) increase or no increase in the number of abnormal cells in the blood - leukemic or aleukemic (subleukemic). Examples of leukemias that can be treated with a compound, pharmaceutical composition or method provided herein include, for example, chronic leukemia, acute non-lymphocytic leukemia, acute lymphocytic leukemia, B-cell acute lymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, leukocytemic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, acute myelogenous leukemia, chronic myelocytic leukemia, cutaneous leukemia, embryonal leukemia, leukemia eosinophilic, erythroleukemia, Gross leukemia, hairy cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, monocytic leukemia n t cnon / zznz / q / υιλι 228 acute, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphocytic leukemia, lymphoid leukemia, lymphosarcoma leukemia, mast cell leukemia, megakaryocyte leukemia, micromyelobular leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, granulocytic myeloid leukemia ethics, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, polycythemia vera, promyelocytic leukemia, Rieder cell leukemia, Schilling leukemia, stem cell leukemia, subleukemic leukemia or undifferentiated cellular leukemia. The term sarcoma refers broadly to a tumor that is made up of a substance similar to embryonic connective tissue and is generally composed of tightly packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that can be treated with a compound, a pharmaceutical composition or a method provided in the present invention include a chondrosarcoma, fibrosarcoma, liomyosarcoma, lymphosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy sarcoma, adipose sarcoma, liposarcoma, sarcoma alveolar soft tissue, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, n t tumor sarcoma cnon / zznz / q / υιλι 229 Wilms, endometrial sarcoma, endotheliosarcoma, stromal sarcoma, Ewing sarcoma, Ewing sarcoma, sarcoma sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma B cell, lymphoma, T cell immunoblastic sarcoma, Jensen sarcoma, Kaposi sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, osteogenic sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, Serocystic sarcoma , synovial sarcoma or telangiectal sarcoma. The term melanoma refers to a tumor that arises from the melanocytic system of the skin and other organs. Melanomas that can be treated with a compound, pharmaceutical composition or method provided herein include, for example, acrallentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman melanoma, S91 melanoma, Harding-Passey melanoma, melanoma juvenile, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma. The term carcinoma refers to a new malignant growth formed by epithelial cells that tend to infiltrate surrounding tissues and give rise to metastasis. Exemplary carcinomas that can be treated with n t cnon / zznz / q / υιλι 230 a compound, pharmaceutical composition or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinous carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, adenomatous carcinoma, adrenal cortex carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basal cell carcinoma, bile duct carcinoma, bladder carcinoma, breast carcinoma, Brenner tumor, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cervical carcinoma, carcinoma cholangiocellular, chordoma, chorionic carcinoma, clear cell carcinoma, colloid carcinoma, colon carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, shell carcinoma, cutaneous carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, cystadenocarcinoma, duct carcinoma , ductal carcinoma, durum carcinoma, embryonal carcinoma, encephaloid carcinoma, endometrioid carcinoma, squamous cell carcinoma, epithelial carcinoma, adenoid epithelial carcinoma, exophytic carcinoma, ex-ulcerative carcinoma, fibrous carcinoma, gelatiniform carcinoma, gelatinous carcinoma, giant cell carcinoma, gigantocellular carcinoma, glandular carcinoma, granulosa cell carcinoma, hair matrix carcinoma, hematoid carcinoma, hepatocarcinoma, carcinoma n t cnon / zznz / q / υιλι 231 hepatocellular, Hurthle carcinoma, hyaline carcinoma, hypernephroid carcinoma, childhood embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher carcinoma, Kulchitzky cell carcinoma, large cell carcinoma, lenticular carcinoma, lenticular carcinoma, carcinoma lipomatous, lobular carcinoma, lung carcinoma, lymphoepithelial carcinoma, medullary carcinoma, medullary carcinoma, melanotic carcinoma, mucosal carcinoma, mucinous carcinoma, carcinoma muciparum, mucocellular carcinoma, mucoepidermoid carcinoma, mucosal carcinoma, mucosal carcinoma, myoma carcinoma, nasopharyngeal carcinoma, carcinoma of non-papillary renal cell, oat cell carcinoma, ossificans carcinoma, osteoid carcinoma, ovarian carcinoma, pancreatic ductal carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pulpaceous carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatodes carcinoma, Schneiderian carcinoma, scirrhous carcinoma, scroti carcinoma, sebaceous gland carcinoma, seminoma, serous carcinoma, signet ring cell carcinoma, simplex carcinoma, small cell carcinoma, solanoid carcinoma, spherical cell, spindle cell carcinoma, carcinoma spongiosum, squamoid carcinoma, squamous cell carcinoma string carcinoma gland carcinoma n t cnon / zznz / q / υιλι 232 sudoriparas, carcinoma telangiectaticum, transitional cell carcinoma, tuberosum carcinoma, tubular carcinoma, tuberous carcinoma, undifferentiated carcinoma, verrucous carcinoma or carcinoma villosum. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (Ha), formula (Ilb), formula (III), formula (IV) or formula (V) is used to treat pancreatic cancer, breast cancer, multiple myeloma, secretory cell cancer. For example, certain methods herein treat cancer by slowing or reducing or preventing the occurrence, growth, metastasis or progression of cancer. In some embodiments, the methods described herein can be used to treat cancer by decreasing or eliminating a symptom of cancer. In some embodiments, a compound described herein, for example, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V), they can be used as a single agent in a composition or in combination with another agent in a composition to treat a cancer described herein (for example, pancreatic cancer, breast cancer, multiple myeloma, cell cancer secretory). In some embodiments, the compounds (compounds described herein, ex vivo, a compound of n j cnon / zznz / q / υιλι 233 Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V)) and compositions (ex vivo, compositions comprising a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V)) are used with a cancer immunotherapy (ex vivo, a blocking antibody checkpoints) to treat a subject (ex vivo, a human subject), ex vivo, suffering from a disease or disorder described herein (ex vivo, abnormal cell growth, ex vivo, cancer (ex vivo, a cancer described in the present document)). The methods described herein comprise administering a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula ( V) and an immunotherapy to a subject who has abnormal cell growth such as cancer. Exemplary immunotherapies include, but are not limited to, the following. In some embodiments, the immunotherapeutic agent is a compound (e.g., a ligand, an antibody) that inhibits the immune checkpoint blockade pathway. In some embodiments, the immunotherapeutic agent is a compound that inhibits the indoleamine 2,3-dioxygenase (IDO) pathway. In some embodiments, the immunotherapeutic agent is a compound that agonizes the STING pathway. Immunotherapy of n j cnon / zznz / q / υιλι 234 cancer refers to the use of the immune system to treat cancer. Three groups of immunotherapy used to treat cancer include cell-based, antibody-based, and cytokine-based therapies. All groups show cancer cells displaying subtly different structures (e.g., molecular structure; antigens, proteins, molecules, carbohydrates) on their surface that can be detected by the immune system. Cancer immunotherapy (e.g., antitumor immunotherapy or antitumor immunotherapeutics) includes, but is not limited to, immune checkpoint antibodies (e.g., PD-1 antibodies, PD-L1 antibodies, PD-L2 antibodies, CTLA-4 antibodies, TIM3 antibodies, LAG3 antibodies, TIGIT antibodies); and cancer vaccines (for example, antitumor vaccines or neoantigen-based vaccines such as a peptide or RNA vaccine). Cell-based therapies (for example, cancer vaccines) usually involve the removal of immune cells from a subject suffering from cancer, whether from the blood or a tumor. Tumor-specific immune cells will activate, grow and return to a subject suffering from cancer where the immune cells provide an immune response against the cancer. Cell types that can be used in this pathway are, for example, natural killer cells, lymphokine-activated killer nt cnon / zznz / q / υιλι cells, cytotoxic T cells, 235 dendritic cells, CAR-T therapies (for example, chimeric antigen receptor T cells that are T cells manipulated by specific target antigens), TIL therapy (for example, administration of tumor-infiltrating lymphocytes), TCR gene therapy, protein vaccines and nucleic acid vaccines. A cell-based therapy is Provengo. In some embodiments, the cell-based therapy is a CAR-T therapy. Interleukin-2 and interferon-alpha are examples of cytokines, proteins that regulate and coordinate the behavior of the immune system. Cancer vaccines with neoantigens Neoantigens are antigens encoded by tumor-specific mutated genes. Technological innovations have made it possible to analyze the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that the recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy. Many novel therapeutic approaches have been developed that selectively enhance T cell reactivity against this class of antigens. One approach to targeting neoantigens is through cancer vaccination. These vaccines can be developed using n t cnon / zznz / q / υιλι peptides 236 or RNA, for example, synthetic peptides or synthetic RNA. Antibody therapies are antibody proteins produced by the immune system that bind to a target antigen on the surface of a cell. Antibodies are typically encoded by an immunoglobulin gene or genes or their fragments. In normal physiology antibodies are used by the immune system to combat pathogens. Each antibody is specific for one or a few proteins and those that bind to cancer antigens are used, for example, for cancer treatment. Antibodies are capable of binding specifically with an antigen or epitope. (Fundamental Immunology, 3rd Edition, W.E., Paul, ed., Raven Press, N.Y. (1993). Specific binding occurs with the corresponding antigen or epitope even in the presence of a heterogeneous population of proteins and other biological agents. Specific binding of an antibody indicates that it binds to its target antigen or epitope with an affinity that is substantially greater than binding to irrelevant antigens. The relative difference in affinity is often at least 25% greater, more often at least one. 50% higher, with maximum frequency, at least 100% higher The relative difference can be at least 2 times, at least 5 times, at least 10 times, at least 25 times, at least 50 times, at least 100 times. or at least 1000 times, for example. Example antibody types include sin n t cnon / zznz / q / υιλι 237 limitation human, humanized, chimeric, monoclonal, polyclonal, single-stranded, antigen-binding fragments and diabodies. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, prevent a receptor from interacting with its ligand, or deliver a chemotherapy or radiation load, all of which can lead to cell death. Exemplary antibodies for the treatment of cancer include, but are not limited to, Alemtuzumab, Bevacizumab, Bretuximab vedotin, Cetuximab, Gemtuzumab ozogamicin, Ibritumomab tiuxetane, Ipilimumab, Ofatumumab, Panitumumab, Rituximab, Tositumomab, Trastuzumab, Nivolumab, Pembrolizumab, Avelumab, durvalumab and pidilizumab. Checkpoint blocking antibodies The methods described herein comprise, in some embodiments, the treatment of a human subject suffering from a disease or disorder described herein, comprising the administration of a composition comprising a cancer immunotherapy (e.g., a immunotherapeutic agent). In some embodiments, the immunotherapeutic agent is a compound (e.g., an inhibitor or antibody) that inhibits the immune checkpoint blockade pathway. Immune checkpoint proteins, under normal physiological conditions, maintain self-tolerance n t cnon / zznz / q / υιλι 238 (for example, they prevent autoimmunity) and protect tissues from damage when the immune system responds to, for example, a pathogenic infection. Immune checkpoint proteins can be deregulated by tumors as an important immune resistance mechanism (Pardoll, Nature Rev. Cancer, 2012, 12, 252-264). Agonists of costimulatory receptors, or antagonists of inhibitory signals (e.g., immune checkpoint proteins), provide amplification of antigen-specific T cell responses. Antibodies that block immune checkpoints do not target tumor cells directly, but generally target lymphocyte receptors or their ligands to enhance endogenous antitumor activity. Exemplary checkpoint blocking antibodies include, but are not limited to, anti-CTLA-4, anti-PD-1, antiLAG3 (e.g., lymphocyte activation gene 3 antibodies), and anti-TIM3 (e.g. , antibodies against T cell membrane protein 3). Exemplary anti-CTLA-4 antibodies include, but are not limited to, ipilimumab and tremelimumab. Exemplary anti-PD-1 ligands include, but are not limited to, PD-L1 (e.g., B7-H1 and CD274) and PD-L2 (e.g., B7-DC and CD273). Exemplary anti-PD-1 antibodies include, but are not limited to, nivolumab (i.e., MDX-1106, BMS-936558, or ONO-4538), CT-011, AMP-224, pembrolizumab (brand name n j cnon / zznz / q / υιλι 239 registered Keitruda) and MK-3475. Exemplary PD-L1 specific antibodies include, but are not limited to, BMS936559 (e.g., MDX-1105), MEDI4736, and MPDL-3280A. Exemplary checkpoint blocking antibodies also include, but are not limited to, IMP321 and MGA271. Regulatory T cells (e.g., CD4+, CD25f, or Treg) are also involved in policing the distinction between self and non-self antigens (e.g., foreign) and may represent an important mechanism in suppressing the immune response in many cancers. T-reg cells can emerge from the thymus (e.g., natural T-reg) or can differentiate from mature T cells under circumstances of peripheral tolerance induction (e.g., induced T-reg). Therefore, strategies that minimize the action of T-reg cells are expected to facilitate the immune response to tumors. IDO pathway inhibitors The IDO pathway regulates the immune response by expressing T cell function and allowing immune escape from the local tumor. Expression of IDO by antigen-presenting cells (APCs) can lead to tryptophan depletion and result in antigen-specific T cell energetics and regulatory T cell recruitment. Some tumors even express IDO to protect themselves from the immune system. A compound that inhibits IDO or the IDO pathway activates the n t cnon / zznz / n / υιλι 240 immune system to attack cancer (for example, tumor in a subject). Exemplary IDO pathway inhibitors include indoximod, epacadostat, and EOS200271. STING pathway agonists Stimulator of interferon genes (STING) is an adapter protein that plays an important role in the activation of type I interferons in response to cytosolic nucleic acid ligands. Evidence indicates the involvement of the STING pathway in the induction of the antitumor immune response. For example, activation of the STING-dependent pathway in cancer cells can result in tumor infiltration with immune cells and modulation of the anti-cancer immune response. STING agonists have been developed as a class of anticancer therapeutic agents. Exemplary STING agonists include MK-1454 and ADU-S100. Costimulatory antibodies The methods described herein comprise, in some embodiments, the treatment of a human subject suffering from a disease or disorder described herein, comprising the administration of a composition comprising a cancer immunotherapy (e.g., a immunotherapeutic agent). In some embodiments, the immunotherapeutic agent is a costimulatory inhibitor or antibody. In some embodiments, the methods described herein n t cnon / zznz / q / υιλι 241 document comprise depleting or activating anti-4-lBB, anti-OX40, anti-GITR, anti-CD27 and anti-CD40 and their variants. The methods of the present disclosure contemplate single and multiple administrations of a therapeutically effective amount of a compound as described herein. The compounds, for example, a compound as described herein, may be administered at regular intervals, depending on the nature, severity and extent of the subject's condition. In some embodiments, a compound described herein is administered in a single dose. In some embodiments, a compound described herein is administered in multiple doses. Metabolic diseases In some embodiments, a compound described herein is used, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) to treat a metabolic disease. As used herein, the term metabolic disease refers to a disease or condition that affects a metabolic process in a subject. Exemplary metabolic diseases that can be treated with a compound described herein, for example, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) include non-alcoholic steatohepatitis (NASH), n t cnon / zznz / q / υιλι disease 242 nonalcoholic fatty liver disease (NAFLD), fibrous liver disease, obesity, heart disease, atherosclerosis, arthritis, cystinosis, diabetes (e.g., type I diabetes, type II diabetes, or gestational diabetes), metabolic syndrome, phenylketonuria, proliferative retinopathy, or disease by Kearns-Sayre. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is used to treating a metabolic disease (ex vivo, a metabolic disease described herein) by decreasing or eliminating a symptom of the disease. In some embodiments, the treatment method comprises decreasing or eliminating a symptom comprising elevated blood pressure, elevated blood sugar, weight gain, fatigue, blurred vision, abdominal pain, flatulence, constipation, diarrhea, jaundice and the like. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) can be used as a single agent in a composition or in combination with another agent in a composition to treat a metabolic disease. Infectious diseases In some embodiments, a compound described in the n j cnon / zznz / q / υιλι 243 herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) is used to treat an infectious disease. Examples of infectious diseases that can be treated with a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) include bacterial infections, viral infections (ex vivo, herpes, shingles, influenza, common cold, encephalitis), and parasitic infections. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is used to treating an infectious disease (ex vivo, an infectious disease described herein) by decreasing or eliminating a symptom of the disease. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) can be used as a single agent in a composition or in combination with another agent in a composition to treat an infectious disease. Parasitosis In some embodiments, a compound described herein is used, ex vivo, a compound of formula (I), n j cnon / zznz / q / υιλι 244 formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) to treat a parasitic infection. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is used to treat a parasitic infection by reducing or eliminating a symptom of the disease. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) can be used as a single agent in a composition or in combination with another agent in a composition to treat a parasitic infection. Immunodeficiency diseases In some embodiments, a compound described herein is used, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) to treat an immunosuppressive disease. In some embodiments, a compound described herein, ex vivo, a compound of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is used to treat an immunosuppressive disease by decreasing or eliminating a symptom of the disease. In some embodiments, a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula n j cnon / zznz / q / υιλι 245 (Ilb), formula (III), formula (IV) or formula (V) can be used as a single agent in a composition or in combination with another agent in a composition to treat an immunosuppressive disease. In some embodiments, the compounds described herein are provided as pharmaceutical compositions that include a described compound, ex vivo, of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula (V) and a pharmaceutically acceptable excipient. In embodiments of the method, a compound described, ex vivo, of Formula (I), Formula (lia), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is co-administered with a second agent (ex live, therapeutic agent). In other embodiments of the method, a described compound, ex vivo, of Formula (I), Formula (lees), Formula (Ilb), Formula (III), Formula (IV) or Formula (V) is co-administered with a second agent ( ex vivo, therapeutic agent), which is administered in a therapeutically effective amount. Combined therapy The present description provides a pharmaceutical composition comprising a compound described herein, ex vivo, a compound of formula (I), formula (lia), formula (Ilb), formula (III), formula (IV) or formula ( V), as well as a second agent (ex vivo, a second therapeutic agent). In some embodiments the composition n j cnon / zznz / q / υιλι 246 pharmaceutical includes a second agent (for example, a second therapeutic agent) in a therapeutically effective amount. In some embodiments, the second agent is an agent for treating cancer, a metabolic disease (e.g., type 2 diabetes or obesity), or a disease or disorder that responds favorably to PTPN2 or PTP1B inhibitor treatment. The compounds described herein can be used in combination with each other, with other active agents that are known to be useful for treating cancer, a metabolic disease (for example, type 2 diabetes or obesity) or a disease or disorder that respond favorably to PTPN2 inhibitor or PTP1B treatment, or with adjuvant agents that may not be effective alone but may contribute to the effectiveness of the active agent. In some embodiments, coadministration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Coadministration includes administering two active agents simultaneously, approximately simultaneously (e.g., within approximately 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, concomitant administration may be accomplished by co-formulation, i.e., preparation of a single pharmaceutical composition that includes both n t cnon / zznz / q / υιλι agents. 247 active. In other embodiments, the active agents may be formulated separately. In another embodiment, the active agents and / or adjuvants may be linked or conjugated to each other. In some embodiments, the compounds described herein may be combined with treatments for a cancer, a metabolic disease (e.g., type 2 diabetes or obesity), or a disease or disorder that responds favorably to PTPN2 or PTP1B inhibitor treatment. In embodiments, the second agent is an anti-cancer agent. In embodiments, the second agent is a chemotherapeutic. In embodiments, the second agent is an agent for treating a metabolic disease. In embodiments, the second agent is an antidiabetic agent. In some embodiments, the second agent is an anti-obesity agent. Anticancer agents Anticancer agent is used according to its full common meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) that has antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anticancer agent is a chemotherapeutic agent. In some embodiments, an anticancer agent is an agent identified herein as having utility in cancer treatment methods. In some embodiments, an anticancer agent is an approved agent n j cnon / zznz / q / υιλι 248 by the FDA or similar regulatory agency of a country other than the United States, for the treatment of cancer. Examples of anticancer agents include, but are not limited to, MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib / AZD6244, GSK1120212 / trametinib, GDC -0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethyleneimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin), triazenes (decarbazine), antimetabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analogue (e.g., methotrexate), or pyrimidine analogues (e.g. fluorouracil, floxouridine, cytarabine), purine analogues (e.g. mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g. vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc. ), topoisomerase inhibitors (e.g., irinotecan, topotecan, n t cnon / zznz / q / υιλι 249 amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g. doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), based compounds platinum (e.g., cisplatin, oxaloplatin, carboplatin), anthracendione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methylhydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide) , epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g., U0126, PD98059 , PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gosifol, genasense, polyphenol E, chlorofusin, acid all-trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all-trans-retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib ( Gleevec.RTM.), geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 1 1-7082, PKC412, PD184352, 20-epi-l, 25 dihydroxyvitamin D3; n t cnon / zznz / q / υιλι 250 5-ethynyluracil; abiraterone; aclarubicin; acylphen; adecipenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; dorsalizing morphogenetic antiprotein- 1; antiandrogen, prosthetic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; regulators of apoptosis; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinstatin 1; axinstatin 2; axinstatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonists; benzochlorines; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafida; bistratene A; bizelesin; breflato; bropyramine; budotitan; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage-derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorines; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; n t cnon / zznz / q / υιλι 251 cladribine; clomiphene analogues; clotrimazole; colismycin A; colismycin B; combretastatin A4; combretastatin analogue; conagenin; Crambescidin 816; crisnatol; crypto office 8; cryptocurrency A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocphosphate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodemnin B; dyslorelin; dexamethasone; dexyphosphamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; spiromustine diphenyl; docosanol; dolasetron; doxyfluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitfur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; gallocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; hereguline; hexamethylene bisacetamide; hypericin; Ibandronic acid; idarubicin; idoxifene; idramanthone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulating peptides; n-like growth factor receptor inhibitor t cnon / zznz / q / υιλι 252 insulin-1; interferon agonists; interferons; interleukins; iobenguane; iodoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazol; isohomohalichondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentine sulphate; leptolstatin; letrozole; leukemia inhibitory factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear analogue of polyamine; lipophilic disaccharide peptide lipophilic platinum compounds; lysoclinamide 7; lobaplatin; worm; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysophilin; Utic peptides; maytansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarona; meterelina; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double-stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafida; fibroblast growth factor-saporin mitotoxin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotropin; monophosphoryl lipid A+mycobacterial cell wall; mopidamol; multidrug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; micaperoxide B; cell wall extract of n t cnon / zznz / q / υιλι 253 mycobacteria; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavine; nafterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrulline; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; oracina; oral cytokine inducer; ormaplatinum; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxitriol; panomifene; parabactin; pazelliptin; pegaspargase; peldesin; sodium pentosan polysulfate; pentostatin; pentrozole; perflubron; perfosfamide; peryl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pyrarubicin; pyritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; glitters; pyrazoloacridine; pyridoxylated polyoxyethylated hemoglobin conjugate; raf antagonists; raltitrexed; ramosetron; n t cnon / zznz / q / υιλι inhibitors 254 ras farnesyl protein transferase; ras inhibitors; ras-GAP inhibitor; demethylated reteliptin; rhenium Re 186 etidronate; riizoxin; ribozymes; retinamide RII; rogletimide; rohitukin; romurtida; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopina; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence-derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparphosic acid; spicamycin D; spiromustine; splenopentine; spongistatin 1; squalamine; stem cell inhibitor; stem cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradist; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methodide; tauromustine; Tazarotene; tecogalan sodium; tegafur; tellurapirillium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; taliblastin; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; timotrinan; thyroid stimulating hormone; tin etioglitter; tirapazamine; n t cnon / zznz / q / υιλι 255 titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; triphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramin; verdines; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatinum; zilascorb; zinostatin stimalamer, adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronin; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; woodruff; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; sodium breguinar; bropyramine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatinum; dezaguanine; dezaguanine mesylate; n t cnon / zznz / q / υιλι 256 diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatinum; enpromato; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine sodium phosphate; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; interleukin II (including recombinant interleukin II, or rlL. sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; alpha-n3 interferon; interferon beta-la; interferon gamma-lb; Latin iprop; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; methoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mythosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisure; pegaspargase; peliomycin; pentamustine; n t cnon / zznz / q / υιλι 257 peplomycin sulfate; perfosfamide; pipobromán; piposulfan; pyroxantrone hydrochloride; plicamycin; plumber; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; Puromycin; Puromycin hydrochloride; pyrazofurin; riboprin; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sodium sparfosate; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatinum; streptonigrin; streptozocin; sulofenur; thalisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; thiazofurin; toremifene citrate; trestolone acetate; tricyribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglicinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatinum; zinostatin; zorubicin hydrochloride, agents that arrest cells in G2-M phases and / or modulate microtubule formation or stability, (e.g., Taxol, i.e. paclitaxel), Taxotere, compounds comprising the taxane backbone, Erbulozole (i.e. R-55104), Dolastatin 10 (i.e. DLS10 and NSC-376128), Mivobulin isethionate (i.e. as CIn t cnon / zznz / n / υιλι 258 980), Vincristine, NSC-639829, Discodermolide (i.e. as NVPXX-A-296), ABT-751 (Abbott, i.e. E-7010), Altorhyrtins (e.g., Altorhyrtin A and Altorhyrtin C), spongistatins (e.g., spongistatin 1 , spongistatin 2, spongistatin 3, spongistatin 4, spongistatin 5, spongistatin 6, spongistatin 7, spongistatin 8 and spongistatin 9), cemadotin hydrochloride (e.g. LU-103793 and SC-D669356), epothilones (e.g. epothilone A , epothilone B, epothilone C (i.e. deoxypothilone A or dEpoA), epothilone D (i.e. KOS-862, dEpoB and desoxypothilone B), epothilone E, epothilone F, epothilone N-oxide, epothilone N-oxide A, 16-azaepothilone B, 21-aminoepothilone B (i.e., BMS-310705), e. e. NSC-654663), Soblidotin (i.e. TZT-1027), LS-4559-P (Pharmacia, i.e. LS-4577), LS-4578 (Pharmacia, i.e. LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-1 12378 (Aventis), Vincristine Sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i. and. WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e. ILX-651 and LU-223651), SAH-49960 (Lilly / Novartis), SDZ-268970 (Lilly / Novartis), AM-97 (Armad / Kyowa Hakko), AM- 132 (Armad), AM- 138 (Armad / Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 ( i.e. LY-355703), AC-7739 (Ajinomoto, i.e. AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, i.e. AVE-8062, AVE-8062A, n t cnon / zznz / q / υιλι 259 CS-39-L-Ser.HC1, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e. NSC-106969), T-138067 (Tularik, i.e. T-67, TL-138067 and TI - 138067), COBRA-1 (Parker Hughes Institute, i.e. DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A 1 (i.e. BTO-956 and WHI-261). and. BTO-956 and DIME), DDE- 313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e. SPIKET-P), 3-IAABU (Cytoskeleton / Mt. Sinai School of Medicine, i.e. MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton / Mt. Sinai School of Medicine, i.e. MF-191), TMPN (Arizona State University), Vanadocene Acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocin (i.e. NSC698666), 3-IAABE (Cytoskeleton / Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tularik, i.e. T-900607), RPR115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleutherobin, Isoeleutherobin A and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, Ά-293620 (Abbott), NPI- 2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-) Phenillahistine (i.e. NSCL-96F037), D-688 (Asta Medica), D-68836 (Asta Medica), Myoseverin, D-434 (Zentaris, i.e. n j cnon / zznz / q / υιλι 260 D-862), A-2899 (Abott), Abbott-3318 (Hit!), SPA- (Hiti), (i.e. Trifluoropherol), Sodium Resorate (NCI), Zyl21823 (ZY), Restaferol), Phosphate sodium (NCI) National Institutes of Health Research), and SSR-25041 1 (Sanofi), spheroids (ex vivo, dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone (GnRH) agonists such as goserelin or leuprolide, adrenocorticosteroids (ex vivo, prednisone), progestins (ex vivo, hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (ex vivo, diethylstilbestrol, ethinyl estradiol), antiestrogen (ex vivo, tamoxifen), androgens (ex vivo , testosterone propionate, fluoxymetherone), antiandrogen (ex vivo, flutamide), immunostimulants (ex vivo, Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-inferone, etc.), monoclonal antibodies (ex vivo, antibodies anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR and anti-VEGF monoclonals), immunotoxins (for example, anti-CD33 monoclonal antibody conjugated with calicheamicin, anti-CD22 monoclonal antibody conjugated with pseudomonas exotoxin, etc. .), radioimmunotherapy (for example, anti-CD20 monoclonal antibody conjugated with ulIn,90Y, o131I, etc. ), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topot...

Claims

1. A compound represented by the formula (I): O p Osg—NH R2. I J. r6 R3 OH R4 R5(I); or a pharmaceutically acceptable salt thereof, characterized in that: R1 is selected from the group consisting of hydrogen, halogen, Ci-6 alkyl, C3-6 cycloalkyl, Ci-e -O-alkyl, Ci-g N (Ra)-alkyl, and Ci-g 5-6-membered -alkylene heterocyclyl; wherein Ci-g alkyl, C3-6 cycloalkyl, C1-6 -O-alkyl, Ci-g -N (Ra)-alkyl, and Ci-g 5-6-membered -alkylene heterocyclyl may be optionally substituted at one or more available carbons with one, two, three, or more substituents, each independently selected from R'f; and wherein if the 5-6-membered Ci-6-heterocyclyl alkylene contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh;R2 is selected from the group consisting of hydrogen, halogen, hydroxyl, -CHF2, -CH2OH, -CH2CN, -ClR-O-C1-6 alkyl, -CH2-N(Ra)-C1-6 alkyl, C2-6 alkyl, C2-6 alkenyl, -O-C1-6 alkyl, -N(Ra)-C1-6 alkyl, -S(O)-C1-6 alkyl, -C(O)-N(Re)-C1-6 alkyl, -N(Ra)-C1-6 alkyl, -OC(O)-N(Ra)-C1-6 alkyl, -N(Ra)-C1-6 alkyl, -C3-6 cycloalkyl, -C3-6 cycloalkyl, -C3-6 alkylene, -C3-6 cycloalkyl, -C3-6 cycloalkyl, -C3-6 alkylene, -C3-6 cycloalkyl, -C3-6 alkylene, -C3-6 cycloalkyl Ci-g-cycloalkyl C3-6, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, O-alkylene Oí-g-5-6 membered heteroaryl, -O-4-6 membered heterocyclyl, -N(Ra) -4-6 membered heterocyclyl, alkylene Ci-g-4-6 membered heterocyclyl and -O-alkylene Cig-4-6 membered heterocyclyl;where -CH2-0-C1-6 alkyl, -CH2-N(Ra)-C1-e alkyl, C2-6 alkyl, C2-6 alkenyl, -O-C1-6 alkyl, -N(Ra)-C1-6 alkyl, -S(O)-C1-6 alkyl, -C(O)-N(Ra)-C1-6 alkyl, -N(Ra)-C(O)-C1-6 alkyl, -O-O(O)-N(Ra)-C1-s alkyl, -N(Ra)-C(O)-O-C1-g alkyl, -C3-6 cycloalkyl, -O-C3-6 cycloalkyl, -C3-e cycloalkyl, -C3-6 alkylene, -C3-6 cycloalkyl, -C3-6 alkenylene, -C3-6 cycloalkyl, -C3-6 alkylene, -C3-6 cycloalkyl, -C3-6 alkylene, -C3-6 5-6 membered heteroaryl, -C3-e membered heteroaryl 5-6 members, 4-6 member heterocyclyl, -O-4-6 member heterocyclyl, -N(Ra)4-6 member heterocyclyl, -alkylene Ci-e-4-6 member heterocyclyl and -O-alkylene Ci-6-4-6 member heterocyclyl may be optionally substituted at one or more available carbons with one, two, three or more substituents each nt cnon / zznz / q / υιλι 858 selected independently from Rt;and wherein if the 5-6 membered heteroaryl, 4-6 membered heterocyclyl, N(Ra)-4-6 membered heterocyclyl, -alkylene Ci-4-6 membered heterocyclyl or -O-alkylene Ci-e-4-6 membered heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; or R1 and R2, taken together with the atoms to which they are attached, form a 5-6 membered aryl or heteroaryl; wherein the aryl or heteroaryl may be optionally substituted with one or more substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, Ci-s alkyl and Ci-g alkoxy; wherein Ci-6 alkyl and Ci-6 alkoxy may be optionally substituted with one, two, three or more substituents each independently selected from Rp;R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, -NH2, -C1-6 alkyl, -O-C1-6 alkyl, -O-C3-6 cycloalkylene, -O-C1-6 alkylene-N(Ra)-C(O)-C3-6 alkyl, -N(Ra)-C1-6 alkyl, -N(Ra)-C3-6 cycloalkylene, -S(O)-C3-e alkyl, -C(O)-N(Ra)-C1-6 alkyl, -N(Ra)-C(O)-C1-6 alkyl and -C3-g 4-6-membered heterocyclyl alkylene; wherein -C1-6 alkyl, -O-C1-6 alkyl, -O-C3-6 cycloalkyl alkylene, -O-C1-6 alkylene-N(Ra)-O(O)-O-C1-6 alkyl, -N(Ra)-C3-6 cycloalkyl alkylene, -N(Ra)-C1-6 alkyl, -N(Ra)-C3-6 cycloalkyl alkylene, S(O)w-C1-6 alkyl, -C(O)-N(Ra)-C1-6 alkyl, -N(Ra)-C(O)-C1-6 alkyl and -C>-g-heterocyclyl 4-6 membered alkylene may be optionally substituted at one or more available carbons by one, two, three or more substituents each independently selected from Rg;and wherein if the 4-6-membered C1-6 alkylene heterocycle contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; R4 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, and the 4-6-membered C1-6 alkylene heterocycle; wherein the C1-6 alkyl, C3-6 cycloalkyl, and the 4-6-membered Ci-e alkylene heterocycle may be optionally substituted at one or more available carbons with one, two, three, or more substituents, each independently selected from Rg; and wherein if the 4-6-membered Ci-g alkylene heterocycle contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; wherein at least one of R1, R2, R3, and R4 is not hydrogen; R5 is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl and 4-6 membered Ci-eheterocyclyl -alkylene;wherein C1-6 alkyl, C3-6 cycloalkyl and Ci-6-4-6-membered alkylene heterocyclyl may be optionally substituted at one or more available carbons with one, two, three or more substituents each independently selected from Rg; and wherein if Ci-g-4-6-membered alkylene heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with Rh; R6 is hydrogen; R7 is hydrogen;Rg is selected independently for each occurrence of the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, oxo, -C(O)OH, RaRbN-, RdRbN-C(O)-, RaRbN-SO«-, RaRbN-C (O)-N (Ra)-, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, C1-6 alkylene, C3-6 cycloalkyl, -O-alkylene, Ci-6-cycloalkyl, -(CO) (NRa)-alkylene, Ci-6-cycloalkyl, C1-6 alkoxy, C3-6 alkenyl-oxy, C3-6 alkynyl-oxy, C3-6 cycloalkoxy, Ci-gC(O)- alkyl, C1-6-OC(O)- alkyl, C1-6-C alkyl (O)-O-, alkyl Ci-6-S(O)w-, alkyl Ci-gN (Ra)-, alkyl Ci-gN (Ra)-C (O)-, alkyl Ci-gC (O)N(Ra), alkyl Ci-6-N (Ra)-C (O)-N (Ra) -, alkyl Ci-6-N (Ra)-SOW-, cycloalkyl C3-6-N (Ra)-SO«-, alkyl Ci-6-SOw-N (Ra) -, cycloalkyl C3-6-SOw-N (Ra)-, 4-6 membered heterocyclyl-SOwN(Ra)-, alkoxy C1-6-C (O)-N (Ra)-, alkyl Ci-gC (O) -N (Ra) -alkyl Ci-6-, alkyl Ci-gN (Ra)-C (O)-alkyl Ci-g-, -P (O) (alkyl C1-3) 2 and alkoxy Ci-g-alkyl C1-6-;where C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-e cycloalkyl, phenyl, C1-6 alkylene, C3-6 cycloalkyl, -O-alkylene, C3-6 cycloalkyl, -(CO) nt cnon / zznz / q / υιλι 861 (NRa) -alkylene, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 alkenyl, C3-6 cycloalkoxy, C3-6 alkyl, C6-C(O)- alkyl, C6-gC(O)- alkyl, C1-6-C(O)-O- alkyl, C6-S(O)w- alkyl, C6-gN(Ra)-C(O)- alkyl, C6-gC (O)N(Ra), Ci-6-N (Ra)-C (O)-N (Ra) - alkyl, Ci-6-N (Ra)-SOW- alkyl, C3-6-N (Ra)-SO«- cycloalkyl, Ci-6-SOw-N (Ra) - alkyl, C3-6-SOw-N (Ra) cycloalkyl 4-6 membered heterocyclyl-SOwN(Ra)-, Ci-gC (O)-N (Ra)-alkoxy C1-6-C (O) -N (Ra) -C1-6-alkyl, Ci-sN (Ra)-C (O)-alkyl Ci-e-, -P (O) (C1-3)2 alkyl and Ci-g-C1-6-alkoxy may be optionally substituted with one, two, three or more substituents each independently selected from Rp;or 2 R9 on adjacent atoms, together with the atoms to which they are attached, form a 5-6 membered aryl or heteroaryl; Rh is selected independently for each occurrence of the group consisting of Ci-e alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, Ci-e-cycloalkyl-C3-6 alkyl, Ci-6-S(O)2- alkyl, 3-6-8(O)2- cycloalkyl, 4-6-membered heterocyclyl-S(O)2-, 4-6-membered heterocyclyl-Ci-6-S(O)2- alkyl, 5-6-membered heteroaryl-S(O)2-, phenyl-S(O)2-, Ci-6-S(O)2- phenylalkyl, C1-6-C(O)- alkyl, 1-5C(O)- cycloalkyl, Ci-6-C(O)- alkoxy, RaRbN-C(O)-, RaRbN-SO2- and -P(O) (rent €1-3)2;where Ci-e alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, Ci-6-alkyl, C3-6-cycloalkyl, C1-6 alkyl, S(O)2-, cycloalkyl, 4-6-membered heterocyclyl, S(O)2-, 4-6-membered heterocyclyl, C1-&-S(O)2-, 5-6-membered heteroaryl, S(O)2-, phenyl, Ci-gS(O)2-, Ci-gC(O)-, cycloalkyl, Ci-eC(O)-, alkoxy, RaRbN-C(O)-, RaRbN-SO2- and -P(O) (alkyl 1-3)2 may be optionally substituted with one, two, three or more substituents each independently selected from Rp; RP is independently selected for each occurrence from the group consisting of halogen, hydroxyl, cyano, Ci-e alkyl, C1-6 alkoxy, C3-6 cycloalkyl, 46-membered heterocyclyl, RaRbN-, RaRbN-carbonyl-, RaRbN-SO2- and RaRbN-carbonylN(Ra)-; Ra and Rb are independently selected for each occurrence from the group consisting of hydrogen, Ci-e alkyl and C3-6 cycloalkyl;wherein the C1-6 alkyl may be optionally substituted with one or more substituents, each independently selected from the group consisting of halogen, cyano, oxo, hydroxyl, and C1-6 alkoxy (optionally substituted with one, two, or three fluorine atoms); or Ra and Rb together with the nitrogen to which they are attached form a 4-6 membered heterocycle, wherein the heterocycle may be optionally substituted with one or more substituents, each independently selected from the group consisting of halogen, cyano, oxo, and hydroxyl; yn 1 cnon / zznz / q / υιλι 863 w es 0, 1, or 2.; 2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that one, two, three or more hydrogen atoms of the compound may optionally be deuterium atoms; and wherein all other atoms of the compound are present in their natural isotopic abundance.

3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, characterized in that one, two, three or more hydrogen atoms may optionally be deuterium atoms to one, two, three or more groups each independently selected from R1, R2, R4, R5, R6, R7 and Rg.

4. The compound according to any of claims 1-3 or a pharmaceutically acceptable salt thereof, characterized in that R1 is selected from the group consisting of hydrogen, deuterium, chlorine and fluorine.

5. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered heterocyclyl; wherein R2 may be optionally substituted at one or more available carbons with one, two or three substituents each independently selected from Rg, wherein if the 4-6 membered heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from Rh.

6. The compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered heterocyclyl; wherein R2 may be optionally substituted at one or more available carbons with one, two or three substituents each independently selected from the group consisting of hydrogen and Ci-s alkyl;and wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of hydrogen, Ci-6 alkyl (optionally substituted with one, two, or three fluorine atoms), Ci-6-alkyl-C3-6 cycloalkyl, Ci-gC(O)- cycloalkyl, Ci-gS(O)2- alkyl (optionally substituted with cyano, methoxy, hydroxyl, -NRaRb, or one, two, or three fluorine atoms), C3-6-S(O)2- cycloalkyl, 4-6-membered S(O)2- heterocyclyl, 4-6-membered Ci-6-S(O)2- alkyl heterocyclyl, 5-6-membered S(O)2- heteroaryl, phenyl S(O)2-, C1-6-S(O)2- phenylalkyl (optionally replaced with RaRbN-) and -P(O) (C1-3 alkyl)2 ·; 7. The compound according to any of claims 1-6 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: 865 nt cnon / zznz / q / υιλι 866 8. The compound according to any one of claims 1-4 or one of these, characterized in that the pharmaceutically acceptable salt of R2 is a 5-6 membered heteroaryl; wherein R2 may be optionally substituted at one or more available carbons with one, two or three substituents each independently selected from Rg and wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from R'n.

9. The compound according to claim 8 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 5-6 membered heteroaryl; wherein R2 may be optionally substituted at one or more available carbons with one, two, or three substituents each independently selected from the group consisting of hydrogen, cyano, Ci-6 alkyl, Ci-6 alkoxy, and -P(O) (Ci3)2 alkyl; and wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of hydrogen, -Ci-6 alkyl, -C3-6 cycloalkyl, and -O3-6-8(O)2-cycloalkyl.

10. The compound according to claim 8 or 9 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: nt cnon / zznz / q / uili 868 11. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered -O-alkylene Ci-g-heterocyclyl, wherein R2 may be optionally substituted at one or more available carbons with one, two or three substituents each selected independently of R^ (optionally 2 P¿'! on adjacent atoms, together with the atoms to which they are attached, form a 5-6 membered aryl or heteroaryl), and wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from Rh.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered -O-alkylene Ci-e-heterocycle, wherein R2 may be optionally substituted at one or more available carbons with one, two, or three substituents each independently selected from the group consisting of hydrogen, halogen, hydroxyl, and Ci-e alkyl (optionally substituted with one, two, or three fluorine atoms), optionally wherein the heterocycle of R2 may be substituted at two adjacent atoms, and the two substituents, together with the atoms to which they are attached, form a fused phenyl, and wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of hydrogen, Ci-g alkyl, and Ci-6-S alkyl (O) 2- .

13. The compound according to claim 11 or 12 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of:

14. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 5-6-membered -O-alkylene Ci-6~ heteroaryl.

15. The compound according to claim 14 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: nt cnon / zznz / q / υιλι 16. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of C2-6 alkyl, C2-6 alkenyl and C3-6 cycloalkyl; wherein R2 may be optionally substituted with one, two, three or more substituents each independently selected from R^.

17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of C2-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, Ci-6-C3-6 alkylene and Ci-e-C3-6 cycloalkyl alkenylene; wherein R2 may be optionally substituted with one, two, three or more substituents each independently selected from the group consisting of cyano, chlorine, fluorine, hydroxyl, C1-6 alkoxy, phenyl and RaRbN-.

18. The compound according to claim 16, 871 or 17 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: nt cnon / zznz / q / uili 19. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is -O-alkyl Ci-e; wherein R2 may be optionally substituted with one, two, three or more substituents each selected independently of R9.

20. The compound according to claim 19 or a pharmaceutically acceptable salt thereof, characterized in that R2 is -O-alkyl Ci-g; where R2 can be optionally substituted by one, two, three or more substituents, each of which may be independently selected from the group consisting of cyano, deuterium, chlorine, fluorine, hydroxyl, oxo, alkoxy, C3-6 cycloalkyl (optionally substituted by one, two or three fluorine atoms), C3-6 cycloalkyl, -O-alkyl, C3-6 cycloalkyl, -(CO)-(NRa)-alkyl, C3-6 cycloalkyl, C3-gOC(O)-alkyl, RaRbN- (where Rb is optionally substituted by -OCH3 or -OCF3), C3-gN(Ra)-alkyl (where C3-e-alkyl is optionally substituted by fluoro, cyano or -OCH3), RaRbN-C(O)-, -P(O)(alkyl O1-3)2, alkyl C1-6N(Ra)-C(O)-, Ci-6-N alkyl (Ra)-C (O)-N (Ra)-, Ci-6-SO2N(Ra)-alkyl, C3-6-SO2-N(Ra)-cycloalkyl- and 4-6-membered heterocyclyl-SOp-N(Ra)-. nt cnon / zznz / q / υιλι 21. The compound according to claim 19 or 20 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: 873 nt cnon / zznz / q / υιλι 874 nt cnon / zznz / q / υιλι 22. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a C3-6 -O-cycloalkyl or a 4-6 membered -O-heterocyclyl; wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from Rh.

23. The compound according to claim 22 or a pharmaceutically acceptable salt thereof, characterized in that R2 is C3-6 -O-cycloalkyl or 4-6 membered -O-heterocyclyl; wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of C1-6-SO2-N (Ra)- alkyl and C3-6-SO2-N (Ra)- cycloalkyl.

24. The compound according to claim 22 or 23 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of:

25. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is -N(Ra)-Ci-6 alkyl, wherein R2 may be optionally substituted with one, two or three substituents each selected independently of R9.

26. The compound according to claim 25 or a pharmaceutically acceptable salt thereof, characterized in that R2 is -N(Ra)-C3-6 alkyl, wherein R2 may be optionally substituted with one, two or three substituents each independently selected from the group consisting of fluoro, -C(O)OH, cyano, oxo, RaRbN-, C3-6 alkoxy, phenyl, C3-6 cycloalkyl, C3-6 cycloalkyl-SO2-N(Ra)- and -(CO)-(NRa)C3-g-cycloalkyl alkylene.

27. The compound according to claim 25 or 26 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: nt cnon / zznz / q / υιλι 876 nt cnon / zznz / q / υιλι 28. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is C3-6 Ci-e-cycloalkyl -O-alkylene, wherein R2 may be optionally substituted with one, two or three substituents each selected independently of Rg.

29. The compound according to claim 28 or a pharmaceutically acceptable salt thereof, characterized in that R2 is C3-6 Ci-g-cycloalkyl - O-alkylene, wherein R2 may be optionally substituted with one, two, or three substituents each independently selected from the group consisting of fluoro, hydroxyl, RaRbN-, cyano, and C1-3 alkyl; wherein the C1-3 alkyl may be optionally substituted with a substituent selected from the group consisting of hydroxyl, RaRbN, cyano, and C1-3 alkoxy.

30. The compound according to claim 28 or 29 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: 877 OH nj cnon / zznz / q / υιλι of the 31. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is -OC(O)-N(Ra)-Ci-6 alkyl.

32. The compound according to claim 31 or a pharmaceutically acceptable salt thereof, characterized in that R2 is represented by H 33. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered -N(Ra) “heterocyclyl, wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from Rh.

34. The compound according to claim 33878 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered -N(Ra)-heterocyclyl, wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of C1-6-SO2-N(Ra)- alkyl and C3-6-SO2-N(Ra)- cycloalkyl.

35. The compound according to claim 33 or 34 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: nt cnon / zznz / q / uili 36. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered Ci-6-alkylene heterocyclyl, wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by a substituent selected from Rh.

37. The compound according to claim 36 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a 4-6 membered Ci-g-alkylene heterocyclyl, wherein if R2 contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a substituent selected from the group consisting of Ci-6 alkyl, C1-6-SO2-N (Ra) alkyl and C3-6-SO2-N (Ra) cycloalkyl, wherein the C1-6 alkyl may be optionally substituted with one, two or three fluorine atoms.

38. The compound according to claim 36 or 37 or a pharmaceutically acceptable salt thereof, 39. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is selected from the group consisting of: -CHF2, -CH2OH, -CH2OCH3, -CH2CN, -OH, 40. The compound according to any of claims 1-4 or a pharmaceutically acceptable salt thereof, characterized in that R2 is a halogen, wherein R2 is optionally selected from the group consisting of fluorine, chlorine and bromine, wherein R2 is further bromine.

41. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that R1 and R2 taken together with the atoms to which they are attached form a 5-membered heteroaryl.

42. The compound according to claim 41 or a pharmaceutically acceptable salt thereof, characterized in that R1 and R2 taken together with the atoms to which they are attached form furanyl.

43. The compound according to claim 41 or 42 or a pharmaceutically acceptable salt thereof, characterized in that it is represented by: nt cnon / zznz / q / υιλι 44. The compound according to any of claims 1-43 or a pharmaceutically acceptable salt thereof, characterized in that R3 is hydrogen.

45. The compound according to any of claims 1-43 or a pharmaceutically acceptable salt thereof, characterized in that R3 is OH or -NH2.

46. ​​The compound according to any of claims 1-43 or a pharmaceutically acceptable salt thereof, characterized in that R3 is -N(Ra)-alkyl Ci-6, wherein -N(Ra)-alkyl Ci-6 may be optionally substituted with one, two or three substituents each independently selected from the group consisting of fluoro and hydroxyl.

47. The compound according to claim 46 or a pharmaceutically acceptable salt thereof, characterized in that R3 is selected from the group consisting of:

48. The compound according to any of claims 1-43, or a pharmaceutically acceptable salt thereof, characterized in that R3 is -N(Ra)-C3-6-cycloalkyl alkylene, wherein -N(Ra)-C3-6-cycloalkyl alkylene may be optionally substituted by one, two, or three substituents, each independently selected from the group consisting of fluoro and hydroxyl.

49. The compound according to claim 48 or a pharmaceutically acceptable salt thereof, characterized in that R3 is represented by:

50. The compound according to any of claims 1-43 or a pharmaceutically acceptable salt thereof, characterized in that R3 is -O-C1-6 alkyl; wherein the -O-C1-6 alkyl may be optionally substituted with one, two, three or more substituents each independently selected from the group consisting of fluorine, hydroxyl and RaRbN-.

51. The compound according to claim 50 or a pharmaceutically acceptable salt thereof, characterized in that R3 is selected from the group consisting of: nt cnon / zznz / q / υιλι 52. The compound according to any of claims 1-43, or a pharmaceutically acceptable salt thereof, characterized in that R3 is C3-6-cycloalkyl -O-alkylene, wherein C3-6-cycloalkyl -O-alkylene may be optionally substituted with one, two, or three substituents each independently selected from the group consisting of fluoro and hydroxyl.

53. The compound according to claim 52 or a pharmaceutically acceptable salt thereof, characterized in that R3 is represented by:

54. The compound according to any of claims 1-43 or a pharmaceutically acceptable salt thereof, characterized in that R3 is C1-6-N (Ra)-O (O)- O-alkyl Ci-g. 883 55. The compound according to claim 54 or a pharmaceutically acceptable salt thereof, characterized in that R3 is represented by: nt cnon / zznz / q / υιλι 56. The compound according to any of claims 1-55 or a pharmaceutically acceptable salt thereof, characterized in that R4 is hydrogen.

57. The compound according to any of claims 1-56 or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from the group consisting of hydrogen, deuterium, bromine, chlorine and fluorine.

58. The compound according to any of claims 1-57 or a pharmaceutically acceptable salt thereof, characterized in that R6 is selected from the group consisting of hydrogen and deuterium.

59. The compound according to any of claims 1-58 or a pharmaceutically acceptable salt thereof, characterized in that R7 is selected from the group consisting of hydrogen and deuterium.

60. The compound according to any of claims 1-59 or a pharmaceutically acceptable salt thereof, characterized in that all atoms of the compound are present in their naturally occurring isotopic abundance. 884 61. A compound represented by the formula (lia): O ^-NH i NF OH R5 (lia) or a pharmaceutically acceptable salt thereof, characterized in that: X is selected from the group consisting of -O- and -N(Ra)-; L is a linear or branched Ci-s alkylene, wherein the Ci-s alkylene is optionally substituted with one or more hydroxyl or one or more fluoro groups; R2-iia is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N (Ra)- cycloalkyl, C1-6-SO2-N (Ra)- alkyl, phenyl, 5-6-membered heteroaryl, 4-6-membered heterocyclyl, and C3-6 cycloalkyl;wherein C1-2 alkoxy, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, and C3-6 cycloalkyl may be optionally substituted at one or more available carbons with one, two, or three substituents each independently selected from the group consisting of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl, or one, two, or three halogens), and C1-2 alkoxy (optionally substituted with one, two, or three halogens); and wherein if 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium, and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium;and Ra and Rb are each independently selected for each occurrence of the group consisting of hydrogen and C1-3 alkyl (optionally substituted with one or more halogens, cyano or C1-2 alkoxy); 62. The compound according to claim 61 or a pharmaceutically acceptable salt thereof, characterized in that X is selected from the group consisting of -O-, -N(H)- and N(CH3)-.

63. The compound according to claim 61 or 62 or a pharmaceutically acceptable salt thereof, characterized in that L is selected from the group consisting of nj cnon / zznz / q / υιλι 886 nt cnon / zznz / q / υιλι where * and # represent the covalent attachment points to R2-11 and X, respectively.

64. The compound according to any one of claims 61-63, or a pharmaceutically acceptable salt thereof, characterized in that R2-11 is selected from the group consisting of hydrogen, cyano, -NH2, -N(CH3)2, -N(H)CH2CF3, N(CH3)(CH2CH3), -N(CH3)(CH2CH2OCH3), -N(CH3)(CH2CH2CN), -OCH3, 65. The compound according to any of claims 61-64 or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from the group consisting of hydrogen, deuterium, chlorine and fluorine.

66. A compound represented by the formula (Ilb): 887 OF Obrg — NH R2< VXNL TXX r* r7 Y^ OH R5 (Ilb) or a pharmaceutically acceptable salt thereof, characterized in that: X is selected from the group consisting of -O- and -N(Ra)-; L is a linear or branched C1-6 alkylene; R2-Iib is selected from the group consisting of hydrogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N (Ra)- cycloalkyl, C1-6-SO2-N (Ra)- alkyl, phenyl, 5-6-membered heteroaryl, 4-6-membered heterocyclyl, and C3-g cycloalkyl; wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted at one or more available carbons with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens);and wherein if a 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a C1-3 alkyl; R5 is selected from the group consisting of hydrogen, deuterium, and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ra and Rb are each independently selected, for each occurrence, from the group consisting of hydrogen and a C1-3 alkyl.

67. The compound according to claim 66 or a pharmaceutically acceptable salt thereof, characterized in that X is selected from the group consisting of -O-, -N(H)- and N(CH3)-.

68. The compound according to claim 66 or 67 or a pharmaceutically acceptable salt thereof, characterized in that L is selected from the group consisting of nt cnon / zznz / q / υιλι covalent bonding sites to R2-11 and X, respectively.

69. The compound according to any one of claims 66-68 or a pharmaceutically acceptable salt thereof, characterized in that R2-11 is selected from the group consisting of hydrogen, cyano, -NH2, -N(CH3)2, -OCH3, , 889 FFH N. .O os nh2 NH NH 70. The compound according to any one of claims 66-69 and a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from the group consisting of hydrogen, deuterium, chlorine, and fluorine.

71. A compound represented by formula (III): € > Π N c KN c σ cu > co and a pharmaceutically acceptable salt thereof, characterized in that: X111 is selected from the group consisting of a linkage, -CH2-, -NRa-, -O-, -O-CH2-, and -OCH2-CH2nesl, 2, or 3; R1111 is selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, -NRaRb, Ci-2 alkyl (optionally substituted with one, two, or three halogens), and Ci-2 alkoxy (optionally substituted with one, two, or three halogens); 890 R2-111 is selected from the group consisting of hydrogen, C1-4 alkyl, -C(O)-C1-4 alkyl, -C(O)-O-C1-4 alkyl, -C(O)N(Ra)-C1-4 alkyl, -S(O)2-C1-4 alkyl and -S(O)2-C3e cycloalkyl;wherein C1-4 alkyl, -C(O)-C1-4 alkyl, -C(O)-O-C1-4 alkyl, -C(O)-N(Ra)-C1-4 alkyl, -S(O)2-C1-4 alkyl and -S(O)2-C3-6 cycloalkyl may be optionally substituted with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, cyano, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens); R5 is selected from the group consisting of hydrogen, deuterium and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ra and Rb are each selected independently, for each occurrence, from the group consisting of hydrogen and Ci-3 alkyl.; 72. The compound according to claim 71 or a pharmaceutically acceptable salt thereof, characterized in that X111 is selected from the group consisting of a CH2-, -O-, -NH- and -O-CH2- linkage.

73. The compound according to claim 71 or 72 or a pharmaceutically acceptable salt thereof, characterized in that R2-111 is selected from the group consisting of hydrogen, isopropyl, -CH2CF3, -S(O)2-CH3 and -S(O)2cyclopropyl.

74. The compound according to any of claims 71-73 or a pharmaceutically acceptable salt thereof, characterized in that R5 is selected from the group consisting of hydrogen, deuterium, chlorine and fluorine.

75. A compound represented by formula (IV): OF Oírcj —NH l1 í r6 r7r3-iíT R5 (iv) or a pharmaceutically acceptable salt thereof, characterized in that: X111 is selected from the group consisting of -O- and N(Ra); L111 is a linear or branched Ci-g alkylene, wherein the C1-6 alkylene is optionally substituted with hydroxyl or fluoro; R3-111 is selected from the group consisting of hydrogen, -NRaRb, -N (Ra) —C (O) -O-C1-e alkyl, hydroxyl, fluoro, Ci2 alkoxy, 4-6 membered heterocyclyl, and C3-6 cycloalkyl; wherein 4-6 membered heterocyclyl and C3-6 cycloalkyl may be optionally substituted at one or more available carbons 892 with one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, -NRaRb, C1-2 alkyl (optionally substituted with one, two or three halogens) and C1-2 alkoxy (optionally substituted with one, two or three halogens);and where if the 4-6 membered heterocycle contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with C1-3 alkyl; or Liii-r3-iii is hydrogen; R5 is selected from the group consisting of hydrogen, deuterium, and halogen; R6 is selected from the group consisting of hydrogen and deuterium; R7 is selected from the group consisting of hydrogen and deuterium; and Ra and Rb are each independently selected, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl.

76. A compound represented by the formula (V): nt cnon / zznz / q / υιλι or a pharmaceutically acceptable salt thereof, characterized in that: 893 Xv is selected from the group consisting of -O- and N(Ra) Lv is a linear or branched Ci-8 linkage or alkylene, wherein the Ci-s alkylene is optionally substituted with one or more hydroxyl or fluoro groups; R2-v is selected from the group consisting of hydrogen, halogen, cyano, -NRaRb, C1-2 alkoxy, C3-6-SO2-N (Ra) cycloalkyl, C1-6-SO2-N (Ra) alkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, and C3-6 cycloalkyl;wherein phenyl, 5-6 membered heteroaryl, 4-6 membered heterocyclyl, and C3-6 cycloalkyl may be optionally substituted at one or more available carbons with one, two, or three substituents each independently selected from the group consisting of halogen, hydroxyl, NRaRb, C1-2 alkyl (optionally substituted with -NRaRb, hydroxyl, or one, two, or three halogens), and C1-2 alkoxy (optionally substituted with one, two, or three halogens); and wherein if the 5-6 membered heteroaryl or 4-6 membered heterocyclyl contains a replaceable ring nitrogen atom, that ring nitrogen atom may be optionally substituted with a C3-alkyl; R5 is selected from the group consisting of hydrogen, deuterium, and halogen; R6 is selected from the group consisting of hydrogen and deuterium; 894 R7 is selected from the group consisting of hydrogen and deuterium;and Ra and Rb are each selected independently, for each occurrence, from the group consisting of hydrogen and C1-3 alkyl.; 77. The compound according to claim 76 or a pharmaceutically acceptable salt thereof, characterized in that Xv is a u-O- linkage.

78. The compound according to claim 76 or 77 or a pharmaceutically acceptable salt thereof, characterized in that Lv is selected from the group consisting of nt cnon / zznz / q / υιλι where * and # represent the covalent attachment points to R2-v and Xv, respectively.

79. The compound according to any of claims 76-78 or a pharmaceutically acceptable salt thereof, characterized in that R2-v is selected from the group consisting of hydrogen, bromine, cyano, -OCH3, 895 80. The compound according to any of claims 76-79 or a pharmaceutically acceptable salt thereof, characterized in that R5, R6 and R7 are each hydrogen.

81. Un compuesto caracterizado porque es seleccionado del grupo que consta de: 5-{l-fluoro-3-hidroxi-7-[2-(morfolin-4il)etoxi]naftalen-2-il}-1λ6, 2,5-thiadiazolidin-l,1,3-triona; 5-{7-[1-(cyclopropanesulfonyl)pirrolidin-3-il]-1-fluoro3-hidroxinaftalen-2-il}-1λ6, 2,5-thiadiazolidin-l,1,3-triona; 5-[1-fluoro-3-hidroxi-7-(pirrolidin-3-il)naftalen-2-il]1λ6, 2,5-thiadiazolidin-l,1,3-triona; 8-fluoro-6-hidroxi-7(1,1,4 - trioxo- 1λ6, 2,5-thiadiazolidin-2-yl)naphthalene-2-yl propan-2-ylcarbamate; 5-(9-fluoro-7-hidroxinaphtho[2,1-b]furan-8-yl)-1λ6, 2,5thiadiazolidin-1,1,3-triona; 5—{7—[2—(azetidin-1-yl)ethoxy]-1-fluoro-3hidroxinaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-[1-fluoro-3-hidroxy-7-methoxy (4-2H) naphthalene-2-yl] (4,42H2) -1Λ6, 2,5-thiadiazolidin-l, 1,3-triona; 5-[1-fluoro-3-hidroxi-7-(methylamino)naphthalene-2-11]1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-{1-fluoro-3-hidroxi-7[2-(piperidin-4-yl)ethoxi]naphthalene-2-yl}-16, 2,5thiadiazolidin-1,1,3-triona;5-(1-fluoro-7-{ [3-fluoro-1-(propan-2-yl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidin t cnon / zznz / q / uili 896 1,1,3-trione; 5-{1-fluoro-7-[ (3-fluoropyrrolidin-3-yl)methoxy]-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-{ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxi{pentanonitrile; 5-{1-fluoro-3-hydroxy-7-[2-(piperidin-1yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1H-pyrrol-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(piperidin-4yl)methoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidine-2-yl)naphthalen-2-yl]oxy}-3,3dimethylpentanenitrile; 5-{7-[(3,3-dimethylbutyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6,2,5-thiadiazolidine-1,1,3-trione; 5-(1,4-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidine-1,1,3-trione;5-{1-fluoro-3-hydroxy-7-[(2H3)methyloxy]naphthalen-2-yl}1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-methoxyethoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-1,1,3-trione; 4-{ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2 nt cnon / zznz / q / uili 897 dimethylbutaneonitrile; 5-{7-[2-(3-aminobicyclo[1,1,1]pentan-1-yl)ethoxy]-lfluoro-3-hydroxynaphthalen-2-yl}-1Á6,2,5-thiadiazolidin-1,1,3trione; 5-(7-{[2-(dimethylamino)ethyl]amino}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)(4,4-2H2)1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-(1-fInoro-3-hydroxy-7-methoxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1X6,2,5thiadiazolidin-2-yl)naphthalen-2yl]amino}ethyl)cyclopropanesulfonamide; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]amino}naphthalen-2-yl)-1λ6,2,5-thiadiazolidin-1,1,3-trione;N- (2 - { [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)cyclopropanesulfonamide; 5 - (1-fluoro-3-hydroxy-7{[1-(methanesulfonyl)azetidin-3-yl]amino}naphthalen-2-yl)1Á6,2,5-thiadiazolidin-1,1,3-trione; 4-{ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}butanenitrile; [1-({ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}methyl)cyclopropyl]acetonitrile; nt cnon / zznz / q / uili 898 5-{7-[2-(dimethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen2-yl} -1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(ciclopropilmetil)-1H-pyrazol-4-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(1H-pyrazol-4yl)methoxy]naphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7- (2-methylpropoxi)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxypropoxy)naphthalen-2yl]-1Λ6,2,5-thiadiazolidine-1,1,3-trione;N-(ciclopropylmetil)-8-fluoro-6-hydroxy-7-(1,1,4-trioxo1Á6,2,5-thiadiazolidin-2-yl)naphthalene-2-carboxamide; 5-[1-fluoro-3-hydroxy-7-(2-{[ 2 (trifluoronetoxy)ethyl]amino}ethoxy)naphthalen-2-yl]-1A6,2,5thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl)amino]ethoxy]naphthalen-2-yl)-1H6,2,5-thiadiazolidine 1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[3-(metilamino)propyl]naphthalen2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[3-(ethylamino)propyl]-1-fluoro-3-hydroxynaphthalen-2yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[5-(dimethylphosphoryl)thiophen-2-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(ciclopropylamino)ethoxy]-1-fluoro-3 nt cnon / zznz / q / yl 899 hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(metilamino)ethoxy]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(ethylamino)ethoxy]-1-fluoro-3-hydroxynaphthalen-2yl}-1Λ6,2,5-thiadiazolidine-1,1,3-trione;5-(1-Fluoro-3-hydroxy-7-{2-[(propan-2yl)amino]ethoxy}naphthalen-2-yl)-1α6,2,5-thiadiazolidine-1,1,3trione; 5-{7-[3-(Diethylphosphoryl)propoxy]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-Fluoro-3-hydroxy-7-[(3S)-3-hydroxybutoxy]naphthalen-2-yl}-1α6,2,5-thiadiazolidine-1,1,3-trione; 5-{1,4-difluoro-3-hydroxy-7-[(3-methylbutyl)amino]naphthalen-2-yl}-1Λ6,2,5-thiadiazolidine-1,1,3trione; 5-{1-Fluoro-3-hydroxy-7-[(3R)-3-hydroxybutoxy¡naphthalen-2-yl}-1X6,2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-cyclopropyl-2-hydroxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1α6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-Fluoro-3-hydroxy-7-[(4R)-4-hydroxypentyl]naphthalen-2-yl}-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(4S)-4-hydroxypentyl]naphthalen-2-yl}-1,6,2,5-thiadiazolidine-1,1,3-trione;nt cnon / zznz / q / vili 900 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-4met Upen til) naphthalen-2-yl]-1Á6, 2,5-thiadiazolidin-1 ,1,3triona; 5-{1-fluoro-3-hydroxy-7-[(3-oxopentyl)oxy]naphthalen-2yl}-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-hydroxybutoxy)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-1,1,3-trione; N-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]-3-methylbutanamide; 5-[1-fluoro-3-hydroxy-7-(4,4,4-trifluorobutoxy)naphthalen2-yl]-1λ6,2,5-thiadiazolidin-1,1,3-trione; 1-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1λ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)cyclopropane-1carbonitrile; 5-(1-fluoro-3-hydroxy-7-{2-[1(methoxymethyl)cyclopropyl]ethoxy}naphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-(7-{[(cyclopropylmethyl)amino]methyl]-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; 5-{7-[ (2,2-difluoropropyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione;5-{7-[3,3-dimethyl-4-(methylamino)butoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(2-feniletil)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; nt cnon / zznz / q / yili 901 5-[7-(3-amino-3-methylbutoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-1Á6, 2,5-thiadiazolidin-1,1,3-triona; 5-{l-fluoro-3-hydroxy-7-[(4,4,4trifluorobutyl)amino]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidine1,1,3-trione; 5-[7-(difluoromethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{7-[1-(dimethylphosphoryl)-2,5-dihydro-1H-pyrrol-3-yl]-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[ (3,3,3trifluoropropyl)amino]naphthalen-2-yl]-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxy-3methylbutoxy)naphthalen-2-yl]-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-ciclopropylpropoxy)-1-fluoro-3-hydroxynaphthalen2-yl]-1Á6,2,5-thiadiazolidin-1,1,3-trione;5-[l-fluoro-3-hydroxy-7-({2-[ (propan-2-yl)oxy]ethyl}amino)naphthalen-2-yl]-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-(l-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)pyrrolidin-3yl]methoxy}naphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 4-{ [8-fluoro-6-hydroxy-7-(l,l,4-trioxo-lÁ6, 2,5thiadiazolidine-2-yl)naphthalen-2-yl]amino}butanenitrile; nt cnon / zznz / q / uili 902 5-[1-fluoro-3-hydroxy-7-(2-hydroxyethyl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-[7-(4-amino-3,3-dimethylbutoxy)-1-fluoro-3hydroxynaphthalen-2-yl]-1Λ6, 2,5-thiadiazolidine-1,1,3-trione; 5— (7 — { [2-(azetidin-1-yl)ethyl]amino}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5- ( 7-{ [1- (cyclopropanesulfonyl)azetidin-3-yl]oxy}-1fluoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(2-methoxyethyl)amino]naphthalen-2yl} -1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3,3,3trifluoropropoxy)naphthalen-2-yl]-1Λ6,2,5-thiadiazolidine-1,1,3trione;1-({ [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1Á6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino}methyl)cyclopropane-1carbonitrile; 5-[1-fluoro-3-hydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-1,1,3trione; 5-{1-fluoro-3-hydroxy-7-[3-(1H-pyrazol-1yl)propoxy]naphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-(7-{1-[ (4-aminofenil)methanesulfonyl]-2,5-dihydro-1Hpyrrol-3-yl}-1-fluoro-3-hidroxinaphthalen-2-yl)-1Á6,2,5thiadiazolidin-1,1,3-triona; nt cnon / zznz / q / yili 903 5-[1-fluoro-3-hydroxy-7-(hydroxymetil)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-{7-[1-(cyclopropansulfonyl)piperidin-3-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(cyclopropanecarbonyl)pyrrolidin-2-yl]-1-fluoro3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(1H-pyrazol-1yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione;5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro3-hidroxinaftalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-triona; 5-{7-[1-(cyclopropanesulfonyl)pyrrolidin-2-yl]-1-fluoro3-hidroxinaftalen-2-yl}-1λ6, 2,5-thiadiazolidin-l,1,3-triona; 5-[1-fluoro-3-hidroxy-7-(piperidin-3-yl)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-l,1,3-triona; 5-{7-[2-(2,2-difluorocyclopropyl)ethoxy]-l-fluoro-3hidroxinaphthalene-2-yl} -1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-{l-fluoro-3-hidroxi-7-[2 - (1methylcyclopropyl)ethoxy]naphthalene-2-yl}-lÁe,2,5-thiadiazolidin1,1,3-triona; 5- ( 7-{1- [ (3-aminophenyl)methanesulfonyl]-2,5-dihidro-lHpirrol-3-yl}-1-fluoro-3-hidroxinaphthalene-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-triona; 5- (7-{1- [ (2-aminophenyl)methanesulfonyl]-2,5-dihidro-lHpirrol-3-yl}-1-fluoro-3-hidroxinaphthalene-2-yl)-1Á6, 2,5thiadiazolidin-1,1,3-triona; nt cnon / zznz / q / υιλι 904 5-[7-(2,2-difluoroethyl)-1-fluoro-3-hidroxinaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-1,1,3-triona;5-[1-fluoro-3-hydroxy-7-(2,2,2-trifluoroethoxy)naphthalen-2-yl]-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-7-(2-fluoroethoxy)-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-1,1,3-trione; 1-({[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxi}metil)ciclopropan-1carbonitrilo; 5-{1-fluoro-3-hydroxy-7-[(3-metilbutil)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(2-metilpropyl)amino]naphthalen2-yl]-1Á6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(ciclopropylmetil)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; { [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-yl6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetonitrillo; 5-[1-fluoro-3-hydroxy-7-(3-metilbutoxy)naphthalen-2-yl]1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-(1,8-difluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)azetidin-3-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione;5-{7-[1-(cyclopropancarbonyl)azetidin-3-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1-6, 2,5-thiadiazolidin-1,1,3-trione; nt cnon / zznz / q / uili 905 (2E)-3-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1-6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]prop-2-enenitrile; 5-[7-(2-cyclopropylethyl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1-6, 2,5-thiadiazolidin-1,1,3-trione; 5—{7 —[(2,2-difluorociclopropil)methoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1-6, 2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2-ciclopropyletoxi)-1-fluoro-3-hydroxynaphthalen-2yl]-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(ciclopropylmethoxy)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2-(oxolan-2-yl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(ciclobutiloxi)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(propan-2-yl)oxy]ethoxy]naphthalen-2-yl)-1λ6,2,5-thiadiazolidine-1,1,3trione;5-[7-(3-ethoxypropoxi)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-tert-butoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5- (7-{ [rao-(IR,2R)-2-ethylcyclopropil]methoxy}-1-fluoro-3hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-methylpentyl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidine-1,1,3-trione; nt cnon / zznz / q / yli 906 5-{7-[3-(2,2-dimethylpropyl)pyrrolidin-1-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidin-1,1,3-triona; 5-[7-(1-chloro-3-hydroxypropan-2-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[1-(ciclopropylmetil)pyrrolidin-3-yl]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(ciclopropyloxi)-1-fluoro-3-hydroxynaphthalen-2-yl]1Á6,2,5-thiadiazolidin-1,1,3-trione; 5-{7-[(2-ciclopropyletil)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione;5-[1-fluoro-3-hydroxy-7-(4-methyl-1H-imidazol-2yl)naphthalen-2-yl]-16,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(azetidin-3-yl)-1-fluoro-3-hydroxynaphthalen-2-yl]16,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(5-methoxythiophen-2-yl)naphthalen-2yl]—16,2,5-thiadiazolidin-1,1,3-trione; [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1X6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]acetonitrile; 5-[1-fluoro-3-hydroxy-7-(methoxymethyl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(3-methyloxetan-3yl)methoxy]naphthalen-2-yl}-1X6, 2,5-thiadiazolidine-1,1,3-trione; 5-{4-bromo-7-[1-(cyclopropanesulfonyl)-2,5-dihydro-1Hpyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5thiadiazolidine-1,1,3-trione; nj cnon / zznz / q / yli 907 5-{4-bromo-7-[1-(cyclopropansulfonyl)-1H-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-1Á6,2,5-thiadiazolidin-1,1,3trione; 5-{1-fInoro-3-hydroxy-7-[(3S)-pyrrolidin-3-yl]naphthalen2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione;5-{l-fluoro-3-hydroxy-7-[(3R)-pyrrolidin-3-yl]naphthalen2-yl}-lÁ6,2,5-thiadiazolidine-l,1,3-trione; 5-(8-chloro-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6,2,5-thiadiazolidine-l,1,3-trione; 5-{7-[(3,3-difluorocyclobutyl)methoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidine-l,1,3-trione; 5-(7-ciclopropil-l-fluoro-3-hydroxynaphthalen-2-yl)1Á6,2,5-thiadiazolidine-l,1,3-trione; 5-{7-[1-(cyclopropanecarbonyl)-2,5-dihydro-1H-pyrrol-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine1,1,3-trione; 5-(4-chloro-1-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[(E)-2-cyclopropylethenyl]-1-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(1E)-4-methylpent-1-en-yl]naphthalen-2-yl}-1λ5, 2,5-thiadiazolidine-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1(pentametilfenil)ethenyl]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidine1,1,3-trione;nt cnon / zznz / q / uili 908 5-{7-[1-(ciclopropilmetil)-2,5-dihydro-lH-pyrrol-3-yl ]1-fluoro-3-hydroxynaphthalen-2-yl} -1A6, 2,5-thiadiazolidin-l,1,3trione; 5-(4-bromo-l-fluoro-3-hydroxy-7-methoxynaphthalen-2-yl)1A6, 2,5-thiadiazolidin-l,1,3trione; 5—{7—[1—(2-ciclopropiletil)-2,5-dihydro-lH-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl} -1A6, 2,5-thiadiazolidin-l,1,3trione; 5-{l-fluoro-3-hydroxy-7-[(1E)-3-methoxyprop-l-en-yl]naphthalen-2-yl}-lA6,2,5-thiadiazolidine-l,1,3-trione; 5-[7-(2-ethoxyethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1A6,2,5-thiadiazolidine-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(3-methoxypropoxy)naphthalen-2-yl]1A6,2,5-thiadiazolidine-l,1,3-trione; 5-[7-(1,1-dioxo-lA6-thian-4-yl)-l-fluoro-3hydroxynaphthalen-2-yl]-1A6,2,5-thiadiazolidine-l,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(oxan-3-yl)naphthalen-2-yl]1A6,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(ciclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1A6, 2,5-thiadiazolidin-1,1,3-trione;5-(l-fluoro-3-hydroxy-7-{ [1-(2,2,2trifluoroethyl)pyrrolidin-3-yl]methyl}naphthalen-2-yl)- 1A6 , 2,5thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(2,2,2trifluoroethyl)piperidin-4-yl]methyl}naphthalen-2-yl)-1A6,2,5 nt cnon / zznz / q / myl 909 thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[metil(2metilpropil)amino]ethoxi}naphthalen-2-yl)-lÁ6,2,5-thiadiazolidine1,1,3-triona; 5-{l-fluoro-3-hydroxy-7-[(oxolan-2-yl)methoxy]naphthalen-2yl} -1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7- (oxolan-3-yl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5- (7 — { [1-(cyclopropanesulfonyl)azetidin-3-yl]methyl} -1fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-1,1,3trione; 5- ( 7-{ [1-(cyclopropanesulfonyl)piperidin-4-yl]methyl}-1fluoro-3-hydroxynaphthalen-2-yl)-1Á6,2,5-thiadiazolidine-1,1,3trione; 5-[l-fluoro-3-hydroxy-7-(pyrrolidin-2-yl)naphthalen-2-yl]1Á6, 2,5-thiadiazolidin-1,1,3-trione;5- ( 7-{ [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl}-1fluoro-3-hidroxinaftalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3triona; 5-[7-(difluoromethoxy)-1-fluoro-3-hidroxinaftalen-2-yl]1λ6, 2,5-thiadiazolidin-l,1,3-triona; 5- ( 7-{ [1-(cyclopropanesulfonyl)pirrolidin-3-yl]methyl}-1fluoro-3-hidroxinaftalen-2-yl)-1λ6, 2,5-thiadiazolidin-l,1,3triona; 5-{1-fluoro-3-hidroxi-7-[(pyrrolidin-3n t cnon / zznz / n / υιλι 910 11)methyl]naphthalene-2-yl}-16,2,5-thiadiazolidin-1,1,3-triona; 5-[7-(2,5-dihidrofuran-3-yl)-1-fluoro-3-hidroxinaphthalene2-yl]-16,2,5-thiadiazolidin-1,1,3-triona; 5-[7-(3,6-dihidro-2H-pyran-4-yl)-l-fluoro-3hidroxinaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-[7-(2,5-dihydro-1H-pyrrol-3-yl)-1-fluoro-3hidroxinaftalen-2-yl]-1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5-[1-fluoro-3-hidroxy-7-(pyridin-3-yl)naphthalen-2-yl]1λ6, 2,5-thiadiazolidin-1,1,3-triona; 5 —{7 —[ (azetidin-3-yl)methyl]-1-fluoro-3-hidroxinaftalen2-yl} -1λ6, 2,5-thiadiazolidin-1,1,3-triona;N- (2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]amino}acetamide; 4-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1,6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy]-N-methylbutanamide; N-ethyl-N'-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo1,6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)urea; 5-{1-fluoro-3-hydroxy-7-[(oxan-3-yl)methoxy]naphthalen-2-yl}-1,6,2,5-thiadiazolidin-1,1,3-trione; 5-{7 - [ (1-chloro-3-hydroxypropan-2-yl)oxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(oxan-4-yl)methoxy]naphthalen-2yl} -1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[ (oxetan-3-yl)oxy]naphthalen-2 nt cnon / zznz / q / uili 911 il} -1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(2,2,2-trifluoroethyl) 1,2,3,6-tetrahydropyridin-4-yl]naphthalen-2-yl}-1Á6,2,5thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3,7-dihydroxynaphthalen-2-yl)-1X6,2,5thiadiazolidin-1,1,3-trione;5-[1-fluoro-3-hydroxy-7-(2-hydroxyethoxy)naphthalen-2-yl]1α6,2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-propoxynaphthalen-2-yl)-1λ6,2,5thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[(propan-2-yl)oxy]naphthalen-2yl}-1α6,2,5-thiadiazolidine-1,1,3-trione; {[8-Fluoro-6-hydroxy-7-(1,1,4-trioxo-ΐλ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]amino¡acido acetic; N-(2-cyclopropylethyl)-2-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-ΐλ6,2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy}acetamide; N, N -diethyl-2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo1λ6,2,5-thiadiazolidin-2-yl)naphthalen-2-yl]oxy}acetamide; 5-{1-fluoro-3-hydroxy-7-[2-oxo-2-(pyrrolidin-1-yl)ethoxy]naphthalen-2-yl}-1α6,2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4yl]oxy}naphthalen-2-yl)-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{l-Fluoro-3-hydroxy-7-[1-(oxolane-3-sulfonyl)-2,5dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-lAe, 2,5-thiadiazolidine j cnon / zznz / q / υили 912 1,1,3-trione;5-{1-fluoro-3-hydroxy-7-[1-(2-methoxyethanesulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1,6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3,3,3-trifluoropropane-1sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1,6,2,5thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7 - [1-(3,3,3-trifluoropropane-1sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1,6,2,5thiadiazolidine-1,1,3-trione; 5-(1-Fluoro-3-hydroxy-7-{1-[(oxan-2-yl)methanesulfonyl]2,5-dihydro-1H-pyrrol-3-yl}naphthalen-2-yl)-1λ6,2,5thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(4,4,4-trifluorobutane-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1α6,2,5-thiadiazolidine-1,1,3-trione; 5-{7-[1-(buphan-1-sulfonyl)-2,5-dihydro-1H-pyrrol-3-yl]1-fluoro-3-hydroxynaphthalen-2-yl}-1Λ6,2,5-thiadiazolidine-1,1,3trione; 5-(7-{1-(1,4-dioxan-2-yl)methanesulfonyl]-2,5-dihydro-1Hpyrrol-3-yl}-1-fluoro-3-hydroxynaphthalen-2-yl)-1α6,2,5-thiadiazolidin-1,1,3-trione;5-{3-[8-fluoro-6-hydrox1-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]-2,5-dihydro-lH-pyrrol-l nt cnon / zznz / q / υιλι sulfonyl}pentanonitrile; 913 5-{l-fluoro-3-hydroxy-7-[1-(pentane-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁÉ, 2,5-thiadiazolidine1,1,3-trione; 5-{7-[1-(ethanesulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-lfluoro-3-hydroxynaphthalen-2-yl}-lÁ6,2,5-thiadiazolidine-l,1,3trione; 5-{1-fInoro-3-hydroxy-7-[1-(propan-2-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁg, 2,5-thiadiazolidine1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-1,2,3,6-tetrahydropyridin4-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine1,1,3-trione; N-(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)oxetane-3sulfonamide; 5-[1-fluoro-3-hydroxy-7-(piperidin-4-yl)naphthalen-2-yl]1Λ6,2,5-thiadiazolidin-l,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[1-(2-methylpropan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁ6,2,5thiadiazolidine-1,1,3-trione;5-(7-ethoxy-l-fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidine-1,1,3-trione; 5-[7-(2,2-difluoroethoxy)-l-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[1-(cyclopropanesulfonyl)-1H-pyrazol-4-yl]-1-fluoron t cnon / zznz / q / uili 914 3-hydroxynaphthalen-2-11}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[(3R)-1(methanesulfonyl)pyrrolidin-3-yl]amino}naphthalen-2-yl)-1λ6,2,5thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{[1-(methanesulfonyl)piperidin-4-yl]amino}naphthalen-2-yl)-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-(7-{[1-(cyclopropanesulfonyl)pyrrolidin-3-yl]amino}-1fluoro-3-hydroxynaphthalen-2-yl)-1Á6,2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-7-{[3-fluoro-1-(methanesulfonyl)pyrrolidin-3yl]methoxy}-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(propane-2sulfonyl)pyrrolidin-3-yl]naphthalen-2-yl}-1Á6,2,5thiadiazolidine-1,1,3-trione; 5-[7-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1Λ6, 2,5-thiadiazolidine-1,1,3-trione;5-{7-[1-(1,3-dimethyl-lH-pyrazol-4-sulfonyl)-2,5-dihydrolH-pyrrol-3-yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5thiadiazolidine-1,1,3-trione; N- (2 — { [8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl)ethanesulfonamide; 5-{1-fluoro-7-[l-(furan-3-sulfon11)-2,5-dihydro-lHpyrrol-3-yl]-3-hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin nt cnon / zznz / q / υιλι 1,1,3-trione; 915 5-{l-fluoro-3-hydroxy-7-[1-(3-methylbutan-l-sulfonyl)2,5-dihydro-lH-pyrrol-3-yl]naphthalen-2-11}-1λ6, 2,5thiadiazolidine-1,1,3-trione; 5-{1-fInoro-3-hydroxy-7-[1-(thiophen-3-sulfonyl)-2,5dihydro-lH-pyrrol-3-yl]naphthalen-2-yl}-lÁe,2,5-thiadiazolidine1,1,3-trione; 5-{7-[1-(benzenesulfonyl)-2,5-dihydro-lH-pyrrol-3-yl]-1fluoro-3-hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-l,1,3trione; 5-{7-[1-(cyclobutanesulfonyl)-2,5-dihydro-lH-pyrrol-3yl]-1-fluoro-3-hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine1,1,3-trione;methyl (2S)-2-amino-4-{[8-fluoro-6-hydroxy-7-(1,1,4trioxo-yl, 2,5-thiadiazolidin-2-yl)naphthalen-2yl]oxy}butanoate; 5-{7-[(3,5-dimethyl-1H-pyrazol-4-yl)methoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-[7-(3,5-dimethyl-1H-pyrazol-4-yl)-1-fluoro-3hydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-[7-(2-cyclohexylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 2-[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-1X6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]-1H-imidazol-4-carbonitrile; 5-{1-fluoro-3-hydroxy-7-[2-(2,2,4-trimetil-1,3-dioxolan4-yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolida-1,1,3n t cnon / zznz / q / vili 916 friona; 5-[7-(3,4-dihydroxy-3-metilbutoxy)-1-fluoro-3hydroxynaphthalen-2-yl]-1λ6,2,5-thiadiazolidine-1,1,3-trione; 5-{7- [ (4,4-difluorobutyl)amino]-1-fluoro-3hidroxinaphthalen-2-yl}-1λ6,2,5-thiadiazolidine-1,1,3-trione;5- (7-{ [rae-(2R, 4R)-2,4-dihydroxypentyl]oxy}-1-fluoro-3hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(2-oxoimidazolidin-yl)ethoxy]naphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(2-hydroxybutoxy)naphthalen-2-yl]1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1Á6, 2,5thiadiazolidine-1,1,3-trione; 5-(6-amino-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ6,2,5thiadiazolidine-1,1,3-trione; 5-{6-[(4,4-difluorobutyl)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1H6,2,5-thiadiazolidine-1,1,3-trione; 5-{6-[(ciclopropylmetil)amino]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-6-[(3-metilbutil)amino]naphthalen-2yl}-1Á6, 2,5-thiadiazolidin-1,1,3-trione; 5-{1-fluoro-3-hydroxy-6-[(3-hydroxy-3-methylbutyl)amino]naphthalen-2-yl]-1Λ6,2,5-thiadiazolidine-1,1,3trione;5-[1-fluoro-3-hydroxy-6-(3-hydroxy-3n j cnon / zznz / q / uili 917 methylbutoxy)naphthalen-2-yl]-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-(1-fluoro-3-hydroxy-6-methoxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidin-1,1,3-trione; (2-{ [5-fluoro-7-hydroxy-6-(1,1,4-trioxo-1X6, 2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}ethyl) terebutyl carbamate; 5-[6-(2-aminoethoxy)-1-fluoro-3-hydroxynaphthalen-2-yl]1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-[6-(cyclopropylmethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Α6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-6-(3-methylbutoxy)naphthalen-2-yl]1Α6, 2,5-thiadiazolidine-1,1,3-trione; 5-[6-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]—1Λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7-[(33)-3,4-dihydroxy-3-methylbutoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3-hydroxy-7-(4-hydroxy-3,3dimethylbutoxy)naphthalen-2-yl]-1Á6,2,5-thiadiazolidin-1,1,3trione;5-{7-[(3R)-3,4-dihidroxi-3-methylbutoxi]-l-fluoro-3hidroxinaftalen-2-il}-1λ6,2,5-tiadiazolidina-l,1,3-triona; 5-{l-fluoro-3-hidroxi-7-[l-(3-hidroxi-2,2dimetilpropano-l-sulfonil)-2,5-dihidro-lH-pirrol-3il]naftalen-2-il}-1λ6,2,5-tiadiazolidin-l,1,3-triona; nj cnon / zznz / q / wιλι 918 5-{7-[1-(3-aminopropano-l-sulfonil)-2,5-dihidro-lHpirrol-3-il]-1-fluoro-3-hidroxinaftalen-2-il} -1Á6, 2,5tiadiazolidin-1,1,3-triona; (3R)-5-{[8-fInoro-6-hidroxi-7-(1,1,4-trioxo-lÁ6, 2,5tiadiazolidin-2-il)naftalen-2-il]oxi]-3-hidroxi-3metilpentanonitrilo; (3S)-5-{ [8-fInoro-6-hidroxi-7-(1,1,4-trioxo-ΐλ6, 2,5tiadiazolidin-2-i1)naftalen-2-il]oxi}-3-hidroxi-3metilpentanonitrilo; 5-{7-[(5-amino-3,3-dimetilpentil)oxi]-l-fluoro-3hidroxinaftalen-2-il} -1λ6, 2,5-tiadiazolidina-l,1,3-triona; 5-(1-fluoro-3-hidroxi-7-{3-[(propan-2il)amino]propil}naftalen-2-il)-1Á6,2,5-tiadiazolidin-l,1,3triona; 5-{l-fluoro-3-hidroxi-7-[2-(oxolan-3-il)etoxi]naftalen2-il}-lÁ6,2,5-tiadiazolidin-l,1,3-triona;5-[7-(2-cyclopentylethoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1H6,2,5-thiadiazolidin-1,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Á6,2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-ciclobutiletoxi)-1-fluoro-3-hydroxynaphthalen-2yl]-1λ6,2,5-thiadiazolidin-1,1,3-trione; 5-{l-fluoro-3-hydroxy-7-[2(trifluoromethoxy)ethoxy]naphthalen-2-yl}-lÁÉ,2,5-thiadiazolidine1,1,3-trione; nj cnon / zznz / n / uili 919 5-[l-fluoro-3,6-dihydroxy-7-(3-hydroxy-3methylbutoxy)naphthalen-2-yl]-IX6, 2,5-thiadiazolidine-l,1,3-trione; 5-[7-(2-ciclopropiletoxi)-l-fluoro-3,6dihydroxynaphthalen-2-yl]-1λ6, 2,5-thiadiazolidine-l,1,3-trione; 5-(l-fluoro-3,6-dihydroxy-7-methoxynaphthalen-2-yl)IX6, 2,5-thiadiazolidine-l,1,3-trione; 5-(7-ethyl-l-fluoro-3,6-dihydroxynaphthalen-2-yl)-IX6, 2,5thiadiazolidine-1,1,3-trione; 5-[7-(3,3-dimethylbutoxy)-1-fluoro-3,6-dihydroxynaphthalen2-yl]-1X6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3,6-dihydroxy-7-[2-(oxolan-2yl)ethoxy]naphthalen-2-yl}-IX6,2,5-thiadiazolidine-1,1,3-trione;5-[l-fluoro-3,6-dihydroxy-7-(3-methylbutoxy)naphthalen-2yl]-1Λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-[7-(2-cyclobutylethoxy)-1-fluoro-3,6-dihydroxynaphthalen2-yl]-1X6,2,5-thiadiazolidine-1,1,3-trione; 5-(7-butoxy-1-fluoro-3,6-dihydroxynaphthalen-2-yl)IX6, 2,5-thiadiazolidine-1,1,3-trione; 5- [7-(2-cyclopentylethoxy)-1-fluoro-3,6dihydroxynaphthalen-2-yl]-IX6, 2,5-thiadiazolidine-1,1,3-trione; 5-[7-(4,4-difluorobutoxy)-1-fluoro-3,6dihydroxynaphthalen-2-yl]-IX6, 2,5-thiadiazolidin-1,1,3-trione; 4-{[8-fluoro-3,6-dihydroxy-7-(1,1,4-trioxo-1X6,2,5thiadiazolidin-2-yl)naphthalen-2-yl]oxy}-2,2 nt cnon / zznz / q / ml 920 dimethylbutanonitrilo; 5-{l-fluoro-3,6-dihydroxy-7-[2-(oxolan-3yl)ethoxy]naphthalen-2-yl}-lÁ6,2,5-thiadiazolidin-1,1,3-trione; 5-[1-fluoro-3,6-dihydroxy-7-(3-methoxypropoxy)naphthalen-2yl]-1,6,2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[1-(3-hydroxypropano-1,1,3-yl)-2,5-dihydro-1H-pyrrol-3-yl]naphthalen-2-yl}-1,6,2,5thiadiazolidine-1,1,3-trione;5-(7-bromo-1-fluoro-3,6-dihydroxynaphthalen-2-yl)-1λ6, 2,5thiadiazolidine-1,1,3-trione; 5-[1-fluoro-3,6-dihydroxy-7-(4-methylpentyl)naphthalen-2yl]-1Á6, 2,5-thiadiazolidine-1, 1,3-trione; 5-[7-(4,4-difluorobutoxy)-1-fluoro-3-hydroxynaphthalen-2yl]-1Λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2 - (oxetan-3-yl)ethoxy]naphthalen2-yl}-1Á6,2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[1(hydroxymethyl)cyclobutyl]ethoxy}naphthalen-2-yl)-1Á6, 2,5thiadiazolidine-1,1,3-trione; 5-{7- [ (4,4-difluoro-5-hydroxypentyl)oxy]-1-fluoro-3hydroxynaphthalen-2-yl} -1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-(7 — {2 —[3-(aminomethyl)bicyclo[1,1,1]pentan-1-yl]ethoxy}1-fluoro-3-hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidine-1,1,3-trione; nt cnon / zznz / q / yili 5-(1-fluoro-3-hydroxy-7-{ [3-(2 921 hydroxyethyl)bicyclo[1,1,l]pentan-1-yl]methoxy}naphthalen-2-yl)1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5—{7—[2—(bicyclo[1,1,l]pentan-1-yl)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Λ6, 2,5-thiadiazolidine-1,1,3-trione;5-(7-{2-[1-(aminomethyl)cyclobutyl]ethoxy}-1-fluoro-3-hydroxynaphthalen-2-yl)-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3-hydroxy-7-[2-(3-hydroxy-3-methylazetidin-1-yl)ethoxy]naphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2- [ (2S)-2(trifluoromethyl)pyrrolidin-1-yl]ethoxy}naphthalen-2-yl)-1Á6,2,5thiadiazolidine-1,1,3-trione; 5-(1-fluoro-3-hydroxy-7-{2-[(2methoxyethyl) (methyl)amino]ethoxy}naphthalen-2-i1)-1Λ6, 2,5thiadiazolidine-1,1,3-trione; 5-{7-[2-(3,3-difluoropyrrolidin-l-yl)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-1,1,3-trione; 5-{7 -[2 -(1,3-dihydro-2H-isoindol-2-yl)ethoxy]-l-fluoro-3hydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidin-1,1,3-trione; 5-{7-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-1-fluoro-3hydroxynaphthalen-2-yl}-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 5-{1-fluoro-3,6-dihydroxy-7-[2-(1methylcyclopropyl)ethoxy]naphthalen-2-yl}-1Ae,2,5-thiadiazolidine1,1,3-trione;5 —{7 — [ (3R)-3,4-dihydroxy-3-methylbutoxy]-l-fluoro-3,6dihydroxynaphthalen-2-yl}-1λ6, 2,5-thiadiazolidine-l,1,3-trione; nt cnon / zznz / q / υιλι 922 5-(7 — {2 —[ethyl(methyl)amino]ethoxy}-l-fluoro-3hydroxynaphthalen-2-yl)-1Á6, 2,5-thiadiazolidine-1,1,3-trione; 3-[(2-{[8-fluoro-6-hydroxy-7-(1,1,4-trioxo-lÁ6, 2,5thiadiazolidin-2-yl)naphthalen-2yl]oxy}ethyl)(methyl)amino]propanonitrile; 5-(l-fluoro-3-hydroxy-7-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}naphthalen-2-yl)-1A6, 2,5-thiadiazolidin-1,1,3-trione; and a pharmaceutically acceptable salt thereof.; 82. A pharmaceutically acceptable composition characterized in that it comprises a compound according to any of claims 1-81 and a pharmaceutically acceptable carrier.

83. The composition according to claim 82, characterized in that it is formulated for oral administration.

84. A method of treating cancer in a patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any of claims 1-81 in combination with an additional therapeutic agent.

85. A method of treating cancer in a patient in need, characterized in that it comprises administering to the patient an effective amount of a pharmaceutically acceptable composition according to claim 82 or 83 in combination with an additional therapeutic agent.

86. The method according to claim 84 or 85, characterized in that the additional therapeutic agent is an immunotherapeutic agent.

87. The method according to claim 86, characterized in that the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

88. A method of treating cancer in a patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any one of claims 1-81.

89. A method of treating cancer in a patient in need, characterized in that it comprises administering to the patient an effective amount of a pharmaceutically acceptable composition according to claim 82 or 83.

90. A method of treating type 2 diabetes in a patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any of claims 1-81 or the composition according to claim 82 or 83.

91. A method of treating and / or controlling obesity 924 in a patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any of claims 1-81 or the composition according to claim 82 or 83.

92. A method of inhibiting further weight gain in an overweight or obese patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any of claims 1-81 or the composition according to claim 82 or 83.

93. A method of treating a metabolic disease in a patient in need, characterized in that it comprises administering to the patient an effective amount of a compound according to any of claims 1-81 or the composition according to claim 82 nt cnon / zznz / q / υιλι u 83.